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Natural products can both challenge synthetic chemists and guide biologists.  In this work, they 
prompted the extension of oxidative methodology to new systems, inspired the systematic 
modification of the palmarumycin scaffold to produce potent thioredoxin/thioredoxin reductase 
(Trx/TrxR) inhibitors, and demanded creative synthetic solutions to the structural challenges 
Mother Nature provided.  The first pursuit was the total synthesis of parvistemonine, a 
pentacyclic azacycle isolated from Stemona plants.  These plants have been used in Chinese folk 
medicine, and the isolated Stemona alkaloids possess therapeutic uses that range from antitussive 
to antiparasitic activity.  The oxidative cyclization of tyrosine was incorporated into the 
syntheses of several natural products, and the extension of this methodology to homotyrosine for 
construction of the azacyclic core was investigated.  Ultimately, the desired cyclization was not 
optimized to give synthetically viable yields, but the competing pathways and preferred 
reactivity was elucidated.  In a separate project, a library of palmarumycin based prodrugs was 
synthesized.  The bisnaphthospiroketal functionality, which is present in palmarumycin, is a 
lucrative scaffold that potently inhibits thioredoxin/thioredoxin reductase (Trx/TrxR).  Some of 
the analogues suffered from low solubility, so various amino ester and sugar containing prodrugs 
were investigated.  A prodrug library with improved solubility and greater plasma stability was 
successfully generated.  One gram of the lead prodrug was needed for further biological testing, 
which would have been challenging with the first generation synthesis.  An alternative synthesis 
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was developed that afforded 1 g of the prodrug and decreased the total number of steps by half 
while significantly improving the overall yield.  Finally, the total synthesis of spiroxins A and B 
was pursued.  The spiroxins were isolated from an unidentified marine fungus and only spiroxin 
A was tested for biological activity.  These highly oxygenated octacyclic compounds only differ 
in their degree of chlorination.  A synthetic route was proposed that allowed access to both 
spiroxin A and B, and only diverged in the final chlorination step.  Through a series of 
oxidations and reductions, this challenging core was accessed.    
 vi 
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1.0  INTRODUCTION TO THE STEMONA ALKALOIDS 
1.1 THE STEMONA ALKALOID FAMILY 
Parvistemonine (1, Figure 1.1) is a member of the Stemona class of alkaloids.  The structural 
features of two lactones, a 4-azaazulene ring and ten stereocenters pose interesting synthetic 
challenges in a relatively compact arrangement.  This structural complexity, along with the 
diverse biological activity found among members of this class of natural products, has prompted 
synthetic interest in this compound.  Diels-Alder reactions,1 oxidative cyclization2,3 and the 
Staudinger4 reaction have all been explored in efforts to construct the 4-azaazulene ring system.  
At this time, there have been no other reports of partial or total synthetic approaches to 
parvistemonine outside of those from the Wipf group. 
 
 
Figure 1.1.  Structure of parvistemonine (1) 
 
The source of Stemona alkaloids are the Stemona plants, also known as Roxburghia.  
They are found in South Asia, Malaysia and North Australia and are classified as subshrubs, or 
  2
twining herbs, with thick and tuberous roots.5  This family can be divided into three genera: 
Stemona, Croomia, and Stichoneuron.  The Stemona genera, which contains parvistemonine, is 
the largest of the three groups and contains more than 25 species.6  This family of plants has a 
history of medicinal applications. 
Stemona and Croomia plants are used in both Japanese and Chinese folk medicine to treat 
an array of medical conditions.  The roots are boiled in water and the extracts consumed to treat 
illnesses as diverse as pulmonary bronchitis, tuberculosis and intestinal parasites.5  The roots of 
the Stemona plants are still sold for their medicinal properties.  On the internet, these roots are 
being advertised for conditions as varied as head lice, scabies, colds, and pulmonary 
tuberculosis.7  These traditional applications prompted further investigation into the source of 
this biological activity. 
There have been several reports exploring the details of the biological activities of the 
various components of the Stemona plants.  Many biological studies have focused on the roots, 
but there have also been studies on the leaf and rhizome extracts along with individually isolated 
alkaloids.8,9  Tuberostemonine, stemofoline, didehydrostemofoline and other Stemona alkaloids 
all show insecticidal activity against larvae.10  In another study, tuberostemonine was shown to 
act as a glutamate inhibitor at the neuromuscular junction of crayfish with a potency that matches 
clinically proven glutamate inhibitors.11  Neostenine and neotuberostemonine both show 
antitussive activity in guinea pigs.12      
 
  3
 
Figure 1.2.  Structure of a recently isolated Stemona alkaloid, stemocurtisine (2) 
 
Stemona alkaloids have some common structural features.  Their most distinct component 
is the 1-azabicyclo[5.3.0]-decane, or 4-azaazulene, ring system.  An exception to this 
generalization was reported in 2003.  Stemocurtisine (2, Figure 1.2) contains the [1,2-a]azepine 
core13 and exhibits larvicidal activity.14  Excluding the structural variability in some of the most 
recently isolated members, there have been several proposed ways to further subdivide this class.  
One proposal classifies the Stemona alkaloids into five groups, each named after a representative 
member: stenine, stemoamide, tuberostemospironine, stemonamine and parvistemoline (Figure 
1.3).5  These groups predominantly distinguish themselves from one another by the presence and 
arrangement of the lactone and furan moieties.    
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Figure 1.3.  Five groups of Stemona alkaloids 
1.2 STEMONA ALKALOIDS’ ISOLATION, STRUCTURE ELUCIDATION AND 
SYNTHESES 
The scientific community was first introduced to the family of Stemona alkaloids with the 
isolation of tuberostemonine (3, Figure 1.4) in 1934.15  However, its structure was not elucidated 
until 1968 by 1H NMR, mass spectrometry, X-ray studies, UV, IR and degradation studies.16  
Throughout the 1980s, Ren-Sheng Xu led an extensive investigation into the structure 
determination and isolation of new Stemona alkaloids.  Through the collective work of him and 
others, about 42 Stemona alkaloids have been described.5  In 1990, Ren-Sheng Xu and 
coworkers published the isolation and characterization of parvistemonine.  The structure was 
elucidated by 1H and 13C NMR, MS, COSY, NOESY, IR and various two dimensional 
techniques.17   
  5
 
 
Figure 1.4.  First isolated Stemona alkaloid, tuberostemonine (3) 
 
The synthetic history of Stemona alkaloids is relatively short, but well developed.  The 
first Stemona alkaloid to be synthesized was (±) croomine (Scheme 1.1).4  The Williams group 
chose to form much of the structure via a linear route and reserved the key steps of ring 
construction for the end game.  (±) Croomine (4) was constructed through treatment of 5 with 
iodine to afford both the lactone and 4-azaazulene moieties.  Intermediate 5 was obtained from a 
Staudinger reaction with azide 6.  The azide moiety in this synthesis proved to be particularly 
recalcitrant and was carried through five synthetic steps unaffected.  The early steps in the 
synthesis were devoted to functionalizing the linear components of this key intermediate starting 
from 7 and 8.  (±) Croomine (4) was synthesized in 16 steps with an overall yield of 0.02%. 
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Scheme 1.1.  Williams’ retrosynthetic analysis of (±) croomine (4) 
 
In 1993, Chen and Hart reported the first racemic synthesis of stenine (9) in 39 steps with 
a 9% overall yield using an intramolecular Diels-Alder reaction as the key step.1  In the 
retrosynthetic analysis (Scheme 1.2), the azepine in 9 was formed from substrate 10 by amide 
formation, conversion to the thioamide and reduction.  The lactone formation was accomplished 
by electrophilic cyclization of the amide in 11.  This substrate was prepared via the Claisen 
rearrangement of 12.  The hydroindole core was synthesized through hydroboration of 13, 
oxidation, conversion of the resultant alcohol to a mesylate and nucleophilic displacement.  The 
synthesis was initiated with the key intramolecular Diels-Alder reaction of substrate 15.   
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Scheme 1.2.  Chen and Hart’s retrosynthetic analysis of stenine (9) 
 
These alkaloids are an enticing target to many groups.  One of the more recent total 
syntheses of a Stemona alkaloid reported in the literature is didehydrostemofoline by Overman.18  
Total syntheses and synthetic approaches have also been reported for croomine,19,20 
stemoamide,21 stemonine,22 stemospironine,23 isostemonamide,24 isostemofoline,25 
stemonamide26 and tuberostemonine.3 
1.3  STEMONA ALKALOID SYNTHESIS IN THE WIPF GROUP 
The Wipf group first became involved in the synthetic pursuit of Stemona alkaloids in 1992, 
demonstrating that the hydroindole core 17 can be produced in good yield and excellent 
diastereoselectivity through the oxidative cyclization of tyrosine with phenyl iodoniumdiacetate 
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(Scheme 1.3).27  This reaction was performed with the amine protected either as Boc or Cbz (R = 
Cbz or Boc).  This azacycle can be envisioned as the synthetic starting point for many Stemona 
alkaloids along with other natural products.  The 6,5-system delivers three stereocenters from the 
original one and offers several sites available for further functionalization.   
 
 
Scheme 1.3.  Oxidative cyclization of tyrosine (16) 
 
Two transition states were proposed (18 and 19) that could account for the observed 
diastereoselectivity (Figure 1.5).  The diastereoselectivity was attributed to the minimization of 
allylic strain in 18 compared to 19 with respect to the placement of the ester moiety.  Other 
groups have explored the diastereoselective oxidation of phenols utilizing substrate control28 or 
organocatalysis,29 but have rarely seen the same high level of diastereoselectivity. 
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Figure 1.5.  Proposed transition states in oxidative cyclization of tyrosine 
 
The construction of this core provided access to a valuable scaffold that has been utilized 
in several natural product syntheses from the Wipf group.  The list of targets includes natural 
products outside of the Stemona family: aranorosin (21)30 and aeruginosin 298-A (22)31 (Figure 
1.6).  Other groups have also incorporated the oxidative cyclization of tyrosine and tyrosine 
derivatives into the syntheses of various alkaloids.32-36     
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Figure 1.6.  Structures of aranorosin (21) and aeruginosin 298-A (22) 
 
The oxidative cyclization shown in Scheme 1.3 has been applied to two syntheses of 
Stemona alkaloids: stenine (23) and tuberostemonine (3) and an approach towards the synthesis 
of tuberostemonone (24, Figure 1.7).  In 1995, the Wipf group reported the first asymmetric 
synthesis of stenine in 26 steps and 1.2% overall yield.2  In 1999, the possibility of combining 
the hypervalent iodine chemistry with a biomimetic approach to yield the tuberostemonone core 
was discussed.37  The postulation was that the core of tuberostemonone could come from an 
oxidative cleavage of the tuberostemonine scaffold.  These studies used PIDA and iodine for 
successful oxidative cleavage of the desired bond and construction of the core.  These Stemona 
alkaloid studies were further expanded with the asymmetric total synthesis of tuberostemonine in 
2002 (Scheme 1.4).3 
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Figure 1.7.  Structures of Stemona alkaloid synthetic targets in the Wipf group 
 
There are numerous points of interest in the total synthesis of tuberostemonine (3).  The 
first maneuver to highlight is the use of the same hydroindole core 25 that had served as the key 
scaffold in the total synthesis of stenine.  In both syntheses, 25 was readily prepared from 17 in 
three steps (Scheme 1.4).  A π-allyl palladium reaction was used to both remove the benzyl ether 
and simultaneously reduce the ring carbon with overall inversion of configuration to provide 26.  
The next key step was the ring closing metathesis with Grubbs’ catalyst 28 to afford 29.  
Following hydrogenation to 30, the core of the natural product had successfully been constructed 
and the remaining lactone moieties were the only necessary additions.  The eastern lactone in 34 
was formed from a Claisen rearrangement and selenolactonization.  The western lactone in 36 
was formed via the introduction of the orthoester, reduction and cyclization.  This synthesis 
provided the natural product in 27 steps with a 1% overall yield.    
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Scheme 1.4.  Total synthesis of tuberostemonine (3) 
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1.4 EARLY SYNTHETIC STUDIES TOWARD PARVISTEMONINE 
The synthetic studies toward parvistemonine (1) in the Wipf group commenced with the work of 
Dr. David Mareska.38  The initial goals were to extend some of the methodology that was applied 
in the total syntheses of stenine (23) and tuberostemonine (3) along with the development of 
novel methodology that could be applied to this unique core. 
 
 
Scheme 1.5.  Retrosynthetic analysis of parvistemonine (1) 
 
Among the required adjustments of the earlier methodology for 1 was the substitution of 
homotyrosine (45) for tyrosine in the PIDA mediated oxidative cyclization.  The key step in the 
initial retrosynthetic analysis of the 4-azaazulene core 38 was the reductive amination of 39 
following oxidative fragmentation of 41 (Scheme 1.5).  This substrate would have been derived 
  14
from the oxidative cyclization of 45.  Unfortunately, the synthesis of 45 proved challenging and 
there were difficulties with the oxidative cyclization.  At this point, the retrosynthetic analysis 
was modified and synthetic studies concentrated on a model system in which the carboxylic acid 
functionality was replaced with hydrogen.  A second generation model system was later explored 
that replaced the carboxylic acid functionality with benzyl ether (Scheme 1.6).   
 
 
Scheme 1.6.  Synthesis of parvistemonine model 51 
 
Although this model system would offer a substantially simplified version of the 
parvistemonine core, its primary focus was to offer a proof of concept for some of the proposed 
latter steps, in particular the oxidative fragmentation.  After testing various analogues and 
conditions, the model system was converted to the desired azaazulene core 51 (Scheme 1.6).  
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Dienone 46 was synthesized as the analogue of 44 from the original retrosynthetic analysis 
(Scheme 1.5).  Under basic conditions this substrate successfully cyclized to provide 47, which 
after several synthetic manipulations, including oxidative cleavage, afforded 49.  Reductive 
amination led to the desired azaazulene core 51.  The relative stereochemistry of 51 was not 
established.  This scheme provided answers concerning the synthetic manipulations of the 
modified azaazulene core, but an extension of this approach towards the much more highly 
substituted natural product was needed.    
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2.0  SYNTHETIC APPROACHES TO HOMOTYROSINE 
2.1 RETROSYNTHETIC ANALYSIS OF HOMOTYROSINE 
The first objective of this project was to synthesize homotyrosine.  This would permit 
investigation into some of the reactions that had been optimized on the model system (Scheme 
1.6).  In particular, the oxidative cyclization of a more functionalized intermediate could be 
explored and studies could continue toward the total synthesis of parvistemonine.   
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Scheme 2.1.  Homotyrosine retrosynthetic analysis 
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The first retrosynthetic analysis (Scheme 2.1) of homotyrosine 52 involved 
hydroalumination of phenylacetylene 55 followed by addition into imine 54, which is 
synthesized from ethyl glyoxylate (46).  This methodology is an extension of similar work 
explored in the Wipf group (Scheme 2.2).39  This earlier work had provided a methodology for 
the generation of chiral allylic amines.  Zirconium in combination with trimethylaluminum reacts 
with alkyne 57 to form reactive intermediate 58 containing the vinylic dimethyl aluminum 
moiety.  Stoichiometric water was incorporated for its ability to greatly accelerate the reaction.  
This species was then treated with chiral imine 59 to afford the final chiral allylic amine 60 in 
good yields and high diastereoselectivity.  Such adaptation of this methodology would forego the 
transmetallation from zirconium to aluminum and instead proceed by direct hydroalumination of 
the alkyne followed by immediate imine addition. 
 
 
Scheme 2.2.  Prior Wipf group work with imine additions 
2.2 ALKYNE HYDROALUMINATION AND IMINE SNTHESIS 
The first step was to synthesize phosphinamide 54.  This imine protecting group had been used 
very successfully in another Wipf group methodology that utilized hydrozirconation and zinc 
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transmetallation for the addition to imines.40  The condensation reaction never went to 
completion for the imine formation using the standard conditions with TiCl4 (Scheme 2.3).  A 
different approach was explored for formation of an imine bearing a tosyl protecting group, as in 
61.  Heating tosyl isocyanate at reflux for 36 h with 56 gave quantitative conversion to 61 
according to 1H NMR analysis of the reaction mixture.41,42  The imine possessed marginal 
stability and was susceptible to hydrolysis back to the aldehyde.  Once the imine was generated, 
it needed to be submitted directly to the hydroalumination conditions.   
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Scheme 2.3.  Imine 61 formation from ethyl glyoxylate (56) 
 
With the synthesis of 61 resolved, the hydroalumination of phenylacetylene needed to be 
resolved.  DIBALH was first examined as the aluminum source.43,44  Various conditions were 
explored for hydroalumination with varying success (Table 2.1).  Additives such as Pd or Cu 
were investigated (entries 2 and 4),45-47 but these only produced trace amounts of product.  The 
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effect of temperature on yield was also investigated (entries 1 and 3).  Ultimately, the best result 
was observed for the reaction of phenylacetylene and DIBALH in heptane at 55 °C (entry 3).   
 
Table 2.1.  Hydroalumination of phenylacetylene conditions 
Entry Additives Al source Solvent Yield [%] Temp [°C] 
1 None DIBALH (1equiv) Heptane Trace 0-55 
2 Cl2(PPh3)2Pd TIBA (1.1 equiv) CH2Cl2 Trace 23 
3 None DIBALH (1 equiv) Heptane 96 55 
4 LiCl, CuBr DIBALH (2 equiv) THF Trace 23 
 
After the successful hydroalumination of phenylacetylene, addition to the imine was 
attempted.  Tosyl imine 61, as a 6 mmol solution in toluene, was added dropwise to a solution of 
62 in heptane at −78 °C.  Unfortunately, this sequence only afforded a complex mixture (Scheme 
2.4).  The difficulties encountered prompted an investigation of a new methodology for the 
synthesis of homotyrosine. 
 
 
Scheme 2.4.  Addition of hydroaluminated phenylacetylene to tosylimine 61 
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2.3 GRIGNARD ADDITION TO IMINE 63 
An alternative approach was needed and the possibility of a Grignard addition into a protected 
imine was explored.  The stereoselectivity of similar organometallic additions has been 
documented by the Davis group using a chiral sulfonylimine generated from the condensation of 
a sulfinamide with ethyl glyoxylate 63.48,49  They reported the Grignard additions of methyl, 
ethyl and benzyl nucleophiles (59, 27, and 70% yield, respectively) (Scheme 2.5).  They initially 
investigated the p-toluenesulfonyl imine, but found that side reactions due to Grignard addition 
into the sulfoxide resulted in a low yield.  The switch to the t-butyl moiety on the sulfoxide was 
credited with providing the desired steric bulk to significantly reduce the side reactions and 
resulted in preferential imine addition.   
 
 
Scheme 2.5.  Grignard addition to imine 63 
 
  The stereoselectivity of the addition is based on the proposed transition state in Figure 
2.1.  One equivalent of BF3.OEt2 coordinates to the oxygen of the sulfoxide providing additional 
steric bias to increase the diastereoselectivity.  The second equivalent of BF3.OEt2 coordinates to 
the nitrogen of the imine and increases activation towards nucleophilic addition.   
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Figure 2.1.  Proposed conformation of BF3 complexed 63 
 
The new approach for the synthesis of homotyrosine would utilize the chemistry shown 
in Scheme 2.5 with (p-OMe)phenethyl magnesium chloride as the nucleophile.  A model study 
was first explored with phenethyl magnesium chloride as the nucleophile.  The new synthesis of 
homotyrosine first required preparation of the chiral sulfonylimine.  The synthesis of sulfinamide 
68 followed a procedure published by Ellman (Scheme 2.6).50-53    
 
S
S S S
S
NH2
O
H
N
OH
OH
VO(acac)2, CHCl3
H2O2, 66%
Li, NH3, THF
Fe(NO3)3, 89%
65 67 68
O
66  
Scheme 2.6.  Ellman’s synthesis of sulfinamide 68 
 
Sulfoxide 67 was formed through the oxidation of t-butyl disulfide with VO(acac)2 using 
methodology developed by the Ellman group.  Ammonia and dissolving metal conditions 
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afforded 68 in good yields and this product could be scaled up to gram quantities.  Sulfinamide 
68 is the identical substrate that the Davis group had used to generate their chiral sulfonylimines 
of ethyl glyoxylate.   
Of particular note is the catalytic oxidation of t-butyl disulfide with VO(acac)2 , H2O2 and 
chiral ligand 66 to provide 67 (Scheme 2.6).  The enantiomer of 66 can be readily synthesized 
and likewise allows access to the enantiomer of 67.  This procedure was both an extension and 
optimization of earlier work from the Alcudia group.  They had enantioselectively generated 68 
through the incorporation of the chiral auxiliary DAG (69).54  This had the obvious drawback of 
being stoichiometric in the chiral auxiliary (Scheme 13). 
 
 
Scheme 2.7.  Chiral auxiliary mediated enantioselective synthesis of sulfonamide 68 
 
With the chiral sulfinamide 68 in hand, imine formation proceeded smoothly by treating 
ethyl glyoxylate with 4 Å molecular sieves and 68, which afforded good yields of 63 (Scheme 
2.8).  1,2-Addition into the imine was then explored with 2 equiv of BF3.OEt2 and 2 equiv of the 
Grignard reagent. 
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Scheme 2.8.  Grignard addition into sulfonyl imine 63 
  
Various conditions were explored in hopes of improving the yield of 73 (Table 2.2).  The 
imine bearing the t-butyl sulfoxide protecting group, 63, afforded the best yields whereas the 
tosyl protecting group, 61, only afforded complex mixtures (entries 1 and 2).  This was 
analogous to the Davis group findings with the p-toluene sulfoxide protecting group.  The yield 
was influenced by the scale of the reaction.  The highest yield was 30% (entry 5) and was 
performed on the largest scale, 6 mmol.  However, the various conditions explored did not 
deliver marked improvement in the yield.       
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Table 2.2.  Grignard conditions for addition into imine 63 
Entry Imine 72 
[equiv] 
BF3.OEt2 
[equiv] 
Solvent Time Yield [%]  Scale [mmol] 
1 61 1 0 Et2O 1 h Decomp 12 
2 61 1 0 THF 8 h Decomp 7 
3 63 2 2 CH2Cl2 10 min 19 0.5 
4 63 1 1 CH2Cl2 10 min 9 2 
5 63 2 2 CH2Cl2 10 min 30 6 
6 63 2 2 CH2Cl2 10 min 26 2 
7 63 2 2 CH2Cl2 30 min Mixture 2 
 
 
The difficult scalability of the imine formation combined with the low yields of the 
Grignard addition were sizeable dilemmas for the first step in a synthesis.  In order to circumvent 
these problems, the  literature procedure for the production of homotyrosine was followed  
(Scheme 2.9).55 
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2.4 LITERATURE SYNTHESIS OF HOMOTYROSINE  
 
Scheme 2.9.  Literature synthesis of homotyrosine (79) 
 
The reported synthesis began with the protection of the nitrogen in aspartic acid (74) with methyl 
chloroformate, followed by TFA anhydride promoted dehydration of 75 to afford anhydride 76 
(Scheme 2.9).55  A Friedel-Crafts reaction with anhydride 76 and aryl 77 led to the 
functionalized homotyrosine precursor 78.  The incorporation of chlorine in 77 was important to 
improve the para-selectivity of the Friedel-Crafts reaction.  The chlorine blocks the ortho site 
next to the methoxy group and can minimize acylation at the other orthoposition via a buttressing 
effect.56  Hydrogenation of 78 at 40 p.s.i. removed both the benzylic carbonyl group and the 
aromatic chlorine to afford 79 in multigram quantities as a single isomer.    
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Several alternative approaches have been published for the enantioselective synthesis of 
homotyrosine.  Approaches have utilized the organocatalytic diastereoselective Mannich 
reaction,57 and chiral auxilariary mediated diastereoselective alkylation.58   
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3.0  OXIDATION OF HOMOTYROSINE 
3.1 OXIDATION OF HOMOTYROSINE TO DIENONE 
With 79 in hand, the hypervalent iodine chemistry could be explored (Scheme 3.1).  The one pot 
procedure of tyrosine oxidation, saponification of the lactone and aza-Michael addition has been 
reported previously.59  The goal was to apply this same sequence to homotyrosine, but the early 
studies focused first on the oxidation of homotyrosine to 80.  Saponification of 80 would afford 
dienone 44 (scheme 1.5), which would undergo conjugate addition to afford the azacyclic core 
43 (Scheme 1.5).  The oxidation was first attempted with PIDA, but the presence of the methyl 
ether prevented the cyclization from occurring, necessitating deprotection to the phenol.  The 
deprotection to phenol 81 was not trivial due to the hydrophilicity of the product, yet with careful 
workup conditions, the yield was improved to 60%.  The oxidative cyclization with hypervalent 
iodine chemistry under standard conditions with PIDA gave low yields of the desired product 80 
(Scheme 3.1).   
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Scheme 3.1.  Oxidative cyclization of homotyrosine 
 
The one side product formed was discovered to be the 5-6-spirocycle 82.  This side 
product presumably formed from initial attack of the carbamate nitrogen instead of the 
carboxylic acid oxygen after phenol 81 reacted with PIDA.  The crude 1H NMR from entry 8 
(Table 3.1) showed nearly a 3:1 ratio of 82:80.  The separation of 82 from 80 through 
chromatography proved to be surprisingly difficult, often requiring several submissions to 
column chromatography.  The most efficient method for separation of these two components 
proved to be a simple aqueous wash with sat. NaHCO3 followed by a single submission to 
standard chromatography on silica (entry 8).  Despite the efficient separation, the yield was only 
7%.   
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Table 3.1.  Oxidative cyclization of homotyrosine conditions 
Entry Reagent Solvent Yield [%] Purification 
1 PIDA TFE 9 SiO2 
2 PIDA MeOH Decomp SiO2 
3 PIDA Nitromethane 13 Fuller’s earth 
4 PIDA TFE 13 Reverse phase 
5 PIDA TFE 7 SiO2 
6 Iodosobenzene TFE Decomp - 
7 Iodosobenzene, phthalic anhydride 1:1, MeCN:CH2Cl2 8 SiO2 
8 PIFA TFE 7 SiO2 
 
 In order to improve the oxidation result, the solvent, time and workup conditions were 
modified in the hope of increasing the yield of 80 (Table 3.1).  Trifluoroethanol emerged as the 
solvent of choice due to its low nucleophilicity.  The use of methanol was accompanied with a 
small degree of methanol addition into the system (entry 2).  The choice of trifluoroethanol, 
however, did not increase the yields to a satisfactory range.  Another alternative to explore for 
reaction optimization was the use of different forms of the hypervalent iodine reagent.  Both 
iodosobenzene (entries 6 and7) and PIFA (entry 8) were tested and gave similar yields to PIDA.  
Another optimization pathway explored focused on alternative methods of purification.  PIDA is 
used in excess in the reaction and has to be removed from the reaction mixture through 
chromatography.  Fuller’s Earth and reverse phase column chromatography (entries 3 and 4) 
were tested, but, once again, no improvement in yield was observed.  None of the conditions 
explored afforded the desired yields of 80 and alternative synthetic routes needed to be explored.    
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4.0  BIRCH REDUCTION OF HOMOTYROSINE 
4.1 BIRCH REDUCTION OF HOMOTYROSINE AND ACIDIC CYCLIZATION 
A new route that would break the aromaticity of the aromatic ring with a Birch reduction 
followed by an intramolecular Michael type addition was explored.  This is a similar scheme to 
the synthesis of L-Choi (85) reported by the Bonjoch group (Scheme 4.1).  They submitted 
tyrosine (83) to the Birch reduction conditions and obtained good yields of 84.  Subsequent 
treatment of 84 in methanolic HCl provided 85. 
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Scheme 4.1.  Bonjoch’s synthesis of L-Choi (85) 
 
The Birch reduction was performed on substrate 79 to afford the desired precursor 86 in 
quantitative yield (Scheme 4.2).  The lithium salts were used in the next reaction without further 
purification.  Diene 86 was dissolved in methanolic HCl and heated for several days to initiate 
cyclization.60   
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Scheme 4.2.  Reduction and cyclization of homotyrosine  
 
Problems, however, resulted in isolating the cyclized product 87 and separation of 87 
from the multiple products obtained.  The reaction was performed in both 3.0 and 9.0 N 
methanolic HCl.  In both situations, multiple products were isolated and the desired product was 
only obtained crude and in low yields.   
4.2 BIRCH REDUCTION OF HOMOTYROSINE AND EPOXIDATION 
The problems with the cyclization to 87 prompted the question as to what other synthetic 
manipulations could be performed on 86 that could permit a more controlled reaction.  One 
option was to epoxidize both alkenes and to explore various Lewis acids and bases to afford the 
desired cyclization product.   
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Scheme 4.3.  Bisepoxidation of diene 86 
 
Modified epoxidation conditions using both a KF/mCPBA61 and NaHCO3/mCPBA62,63 
system were explored on substrate 86 (Scheme 4.3).  Both of these conditions have been 
demonstrated to be effective with the epoxidation of acid sensitive enol ethers, however there 
was no indication of formation of 88 under either of these conditions.  The lack of reactivity of 
diene 86 was attributed to the extremely low solubility of diene 86 in dichloromethane.  In an 
effort to improve the solubility of the system, a simplified analogue was devised that lacked the 
carbamate moiety (Scheme 4.4). 
4.3 MODEL STUDIES FOR BIRCH REDUCTION AND EPOXIDE CYCLIZATION 
The synthesis of the analogue 91 began with commercially available tyramine (89) (Scheme 4.4).  
Treatment of 89 with 2 equiv of methylchloroformate afforded both the carbonate, with the 
phenolic oxygen, and the carbamate, with the amine.  The carbonate was selectively removed 
with basic methanol to afford the free phenol, which was subsequently treated with methyl 
iodide to afford methyl ether 90 in good overall yield.  Intermediate 90 was subjected to Birch 
conditions and afforded diene 91 in high yields. 
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Scheme 4.4.  Preparation of diene model system 91 
 
With 91 in hand, the epoxidation conditions were explored (Scheme 4.5).  Epoxidation 
was first attempted with mCPBA.  In the presence of both KF61,64 and NaHCO3,62 5 equiv of 
mCPBA were needed for the epoxidation and the excess reagent was difficult to separate from 
the mixture apart from column chromatography.  A significant problem encountered was the 
instability of the epoxidized enol ether.  The product decomposed on alumina, silica gel, reverse 
phase and florisil columns. 
 
 
Scheme 4.5.  Bisepoxidation of 91 
 
  Alternative epoxidation conditions needed to be explored.  DMDO appeared to be a well 
suited reagent for this type of substrate because of the ease of purification (concentration under 
reduced pressure), and mild reaction conditions.65,66  
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Scheme 4.6.  Danishefsky’s conditions for glycal epoxidation 
 
The Danishefsky group has extensively investigated the epoxidation of glycals using 
DMDO (Scheme 4.6).67,68  They initially used various peroxy acids and found that once the 
epoxidized product formed, it would frequently react further with either excess acid or solvent.  
This result initiated investigation into other epoxidizing agents.  DMDO proved strong enough to 
quickly epoxidize the alkene, such as the one present in 93, while also being mild enough to not 
further react with the product.       
DMDO was prepared according to literature protocol and used immediately for reaction 
with 91 under the same reaction conditions reported by the Danishefsky group.69  Unfortunately, 
the DMDO epoxidation was still problematic.  The substrate solubility was good in both 
dichloromethane and acetone and the starting material was quickly consumed, but product 
isolation was difficult.  Different silica gel, alumina and florisil columns were utilized in an 
attempt to purify this reaction mixture, however, it was not possible to isolate 92 cleanly.  This 
was attributed to the reactivity of the epoxidized enol ether.   
 
  35
 
Scheme 4.7.  Epoxidation and acetal formation  
 
This problem was addressed by letting the bisepoxide 92 stir at room temperature in 
methanol to open the epoxide and form the α-hydroxy ketone.  The subsequent acetal opening 
occurred upon extended methanol exposure (Scheme 4.7).  The preparation of 95 on larger scale 
was often hampered by the incomplete epoxidation of both alkenes and the tedious production of 
large quantities of DMDO.  This problem was addressed by treating 91 with a slight excess of 
DMDO, which preferentially epoxidized the methyl enol ether alkene, and then stirring the 
reaction mixture overnight in MeOH.  This led to opening of the epoxide to the α-hydroxy 
ketone accompanied with partial acetal formation of the ketone.  The crude reaction mixture was 
then treated with TsOH and trimethylorthoformate for 2 h to drive the acetal formation to 
completion.  The remaining alkene was readily epoxidized with mCPBA to afford the desired 
substrate as a 1:1 mixture of inseparable diastereomers.  Both procedures afforded highly 
functionalized 95 in moderate yields.     
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Scheme 4.8.  Intramolecular epoxide opening of 95 
 
With substrate 95 in hand, conditions were sought for the cyclization to 96 (Scheme 4.8).  
A variety of Lewis acids and bases were investigated for this cyclization (Table 4.1). 
 
Table 4.1.  Acidic and basic conditions explored for cyclization to 96 
Entry Additive Solvent Temperature [°C] Yield of 96 [%] 
1 BF3OEt2 CH2Cl2 −78 Trace 
2 EtAlCl2 CH2Cl2 −78 Decomp 
3 AgClO4 CH2Cl2 25 Decomp 
4 NaOMe MeOH 0 NR 
5 NaOMe MeOH 100 0 
6 KOt-Bu t-BuOH 0-25 NR 
7 KOt-Bu t-BuOH 100 Decomp 
 
A variety of acids and bases were examined for the cyclization to 96, but delivered 
limited success (Table 4.1).  The Lewis acids explored (entries 1, 2 and 3) gave complicated 
reaction mixtures and were abandoned in favor of Brönsted bases.  The reaction with NaOMe 
was initially investigated at 0 °C, but there was no observed reaction (entry 4).  When the system 
was heated to 100 °C in the microwave (entry 5), methoxide preferentially and cleanly opened 
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the epoxide with no trace of the cyclized product.  The bulkier base KOt-Bu was tested (entry 6), 
starting at 0 °C and slowly warming to room temperature, but there was no observed reaction.  
The same base was also tested at 100 °C in t-BuOH in the microwave (entry 7).  In this example, 
starting material was consumed according to TLC, but only 5% of the mass was recovered 
following aqueous workup.  The reaction was tried one last time with the same conditions as 
entry 7 with the exception that the reaction was quenched with benzoyl chloride instead of water.  
The desired result was to protect the secondary alcohol in 95 as the carbonate and decrease the 
water solubility of the substrate.  Despite a greatly improved mass recovery following aqueous 
workup, the desired product was still not obtained.  A new approach was needed to form the ring 
system.     
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5.0  CONSTRUCTION OF BICYCLIC CORE VIA STETTER REACTION 
5.1 CATALYSTS FOR STETTER REACTION 
Nucleophilic carbenes are versatile reagents in synthesis.  These reagents offer many new 
opportunities for ring construction and condensation as highlighted in two excellent recent 
reviews.70,71  One reaction to which carbenes have been applied is the benzoin condensation.  
The mechanism (Figure 5.1) proposed in the catalytic variant of the benzoin condensation begins 
with the deprotonation of a triazolium or thiazolium salt to generate a stable carbene.  The 
mechanism is illustrated with thiazolium salt 97 in Figure 5.1.  The carbene 98 reacts with 
aldehyde 99, which converts the aldehyde into a nucleophilic species (Umpolung of activity).  
When 101 is located in proximity of another electrophile, such as 102, it can undergo an addition 
to afford 103.  After this addition, elimination of the catalyst regenerates carbene 98 and expels 
the benzoin condensation product 104.   
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Figure 5.1.  Benzoin condensation mechanism 
 
Another reaction that incorporates a carbene reactant is the Stetter reaction.  The Stetter 
group in the 1970’s developed a process for addition of an activated aldehyde into an activated 
double bond in a Michael-type fashion.  Recently, there have been several papers discussing both 
asymmetric and catalytic versions of this reaction 
Rovis has published extensively on the asymmetric and catalytic variants of the Stetter 
reaction.72,73  Heterocycles 105, 106 and 107 were developed and demonstrated high 
enantioselectivity in this reaction (Figure 5.2).  Heterocycle 105 has the distinction of 
demonstrating enantioselectivity in the formation of quartenary carbon centers through the 
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Stetter reaction.74  These carbene precursors were synthesized according to the protocol of 
Leeper.75   
 
 
Figure 5.2.  Triazolium salts utilized by Rovis group for Stetter reaction 
 
Catalyst 108 (Figure 11) had been tested by the Leeper group as a catalyst for a chiral 
benzoin condensation.75  They obtained low to moderate yields of product with good 
enantioselectivity.  The Rovis group investigated both added structural complexity on the 
triazolium salt along with alternative counter ions in order to apply this catalyst to the Stetter 
reaction and obtain high yields and enantioselectivity.  Catalyst 106 met these standards for a 
variety of substrates.   
 
 
Figure 5.3.  Catalysts investigated for Stetter reaction 
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The new goal for this project was to synthesize an aldehyde bearing enone substrate and 
explore the intramolecular Stetter reaction with a modified version of Rovis’s catalyst along with 
two commercially available carbene catalysts (109 and 110).  The triazolium salt Leeper had 
used, 108, was a convenient surrogate of 106 due to its ease of synthesis.  The first test reactions 
were intended to prove that the cyclization could occur, and, after this proof, enantioselective 
cyclization would be pursued.  Due to this ranking of priorities, the triazolium salt was 
synthesized as a racemic mixture.   
Most of the substrates that the Rovis group has investigated have been aromatic 
aldehydes, which obviously lack enolizable protons.  There are, however, a few examples of the 
asymmetric Stetter reaction being applied to readily formed 5-membered rings such as 112 
(Scheme 5.1).  The scope of reactions with aliphatic aldehydes is still limited.  Enoate 113 does 
not react to give the desired 6-membered ring.  It is necessary to further activate the enoate 
towards Michael addition with an additional ester, as in 114, to obtain the desired product 116.    
 
 
Scheme 5.1.  Aliphatic Michael acceptors in Stetter reaction 
  42
 
The synthetic route for 108 remained faithful to the Leeper process (Scheme 5.2).  
Racemic phenylalanine (117) was reduced to phenylalaninol following the published literature 
protocol.76  Phenylalaninol was treated with 118 to afford morpholinone 119.  The remaining 
steps were based on Leeper’s protocol.  Meerwein’s salt afforded the imino ether which was used 
without further purification, and carried directly into the reaction with phenylhydrazine to form 
the amidrazone chloride salt 120.  Refluxing this substrate with methylorthoformate in methanol 
afforded the triazolium catalyst.  Heterocycle 108’s structure and purity were confirmed by both 
NMR and mass spectrometry analysis and comparison to the reported spectra.  This substrate 
was used without further purification.  With catalyst 108 in hand, the next task was to synthesize 
the desired enone.   
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Scheme 5.2.  Synthesis of Stetter catalyst 108 
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5.2 STETTER REACTION WITH CYCLOHEXADIENONE 121 
Using chemistry that had been explored previously in the Wipf group, the desired 
cyclohexadieneone (121, Figure 5.4) could be envisioned being derived from 124 using PIDA or 
PIFA in methanolic solvent.   
 
 
Figure 5.4.  Target substrate for Stetter reaction 
 
The most direct route to 121 would be a simple reduction of 120 followed by oxidation to 
the aldehyde.  Initially, the synthesis was attempted without the aid of the TBS protecting group 
on the free phenol 122 (Scheme 5.3).   
 
 
Scheme 5.3.  Model system oxidation 
 
A problem arose with the oxidation of the alcohol to aldehyde 123 and the resultant low 
yields (Table 5.1).  Various conditions were explored until it was deemed more time efficient to 
simply protect the phenol as a TBS ether for the oxidation, and then remove the TBS protecting 
group prior to the PIFA conditions (Scheme 5.4). 
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Table 5.1.  Oxidation conditions to aldehyde 123 
Entry Oxidizing Agent Oxidizing Agent [equiv] Yield of  123 [%] 
1 TPAP/NMO 1.5 19 
2 PDC (0.2 M solution) 2 30 
3 PDC (0.02 M solution) 2 33 
4 PDC 18 15 
 
The commercially available acid 122 was reduced with LAH, both aliphatic and phenol 
alcohols were protected as TBS ethers, and then the aliphatic TBS ether was selectively 
deprotected with PPTS to afford 124 (Scheme 5.4).  Substrate 124 could alternatively be 
synthesized via the treatment of 122 with 2 equiv of TBSCl to form the TBS ester and the TBS 
ether from the phenol.  Subsequent treatment of this globally protected intermediate with LAH 
afforded 124.  In this synthesis, the first major cause for concern arose once the TBS group had 
been removed from 125 to afford the phenol in the presence of the aldehyde.  This is an unstable 
intermediate and can not be stored or concentrated.  Once the TBS group was removed, the 
substrate was immediately subjected to oxidative conditions.   
 
 
Scheme 5.4.  Aldehyde 121 synthesis 
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Many of the transformations carried out in the first part of the synthesis were well 
documented in the literature (Scheme 5.4).  The PIFA oxidation of a phenol in the presence of an 
unprotected aldehyde was not reported previously.  This sequence was proposed as the most 
direct route to 121.  The literature examples involved acetal-protected aldehydes under oxidative 
conditions.  The initial goal was to perform these reactions with the free aldehyde.  One potential 
side product that could result from the PIFA oxidation in the presence of the aldehyde would by 
the formation of a bicycle.  The bicycle from aldehyde participation could be opened again, or 
preferentially, an unreacted aldehyde could be subjected directly to the Stetter conditions.  
Methanol was found to preferentially add into the substrate to afford the desired 121.  As the 
reaction proceeded further, the unreacted aldehyde functionality would be converted into the 
methoxy acetal.  The formation of the acetal was minimized by keeping the reaction temperature 
at 0 °C. 
 
 
Scheme 5.5.  Stetter reaction with dieneone 121 
 
With aldehyde 121 in hand, it was possible to begin exploring the Stetter reaction 
(Scheme 5.5).  All three catalysts from Figure 11 were tested along with modifications in 
reaction conditions (Table 5.2).  Unfortunately, none of these conditions afforded any of the 
desired product 126. 
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Table 5.2.  Cyclization conditions of cyclohexadienone 121 
Entry Catalyst Base Solvent  Conditions 
1 108 KHMDS Toluene r.t., overnight 
2 109 NEt3 MeOH r.t., overnight 
3 109 NEt3 THF r.t., overnight 
4 110 NEt3 THF r.t., overnight 
 
Upon further inspection, it became clear that before the cyclization could occur, a 
fragmentation took place (Figure 5.5).  This hypothesis was tested by allowing 121 to stir with 
0.2 equiv of triethylamine in toluene at room temperature without the Stetter catalyst.  In less 
than 2 h, all of the starting material had been consumed.  The new product isolated from base 
treatment was 4-methoxy phenol 128.  The proposed complementary side product from the 
fragmentation would be the unsaturated aldehyde 129, which was never isolated.  A literature 
search did not uncover any other examples of carbon-carbon bond fragmentations on similar 
cyclohexadienone systems.  It was therefore necessary to explore a new model system substrate 
that would not be susceptible to such a fragmentation. 
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Figure 5.5.  Proposed base-induced fragmentation of cyclohexadienone 121 
5.3 STETTER REACTION WITH MODEL SYSTEM 
The new model system extended the previous model system by one methylene unit (Scheme 
5.6).  Moving the cyclohexadienone moiety one carbon away from the β−position of the enolate 
would eliminate the fragmentation side reaction.  The homologated model system was prepared 
in a route reminiscent of the synthesis of homotyrosine (Scheme 2.9).  The Friedel-Crafts 
reaction with succinic anhydride and 130 proceeded well and provided multigram quantities of 
131.  The hydrogenation to 132 and the subsequent methyl ether deprotection to 133 proceeded 
analogously to homotyrosine.  The remaining steps of reduction, TBS protection and oxidation 
employed the same conditions used in Scheme 5.4.   
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Scheme 5.6.  Synthesis of chain extended aldehyde 136 
 
After the PIFA oxidation, substrate 136 was submitted to the same basic conditions as 
121.  After 7 h of stirring at room temperature with 0.2 equiv of base, no decomposition was 
observed.  The base stability of 136 was very encouraging.  The first Stetter reaction was run on 
a 4 mg scale of substrate with 0.6 equiv of triethylamine and heated to 80 °C over 2 d.  In this 
system, no aromatic signals were observed by crude 1H NMR analysis.  These encouraging 
results prompted further investigation of the revised Stetter substrate 136.  Various Stetter 
conditions were explored (Scheme 5.7) in pursuit of enone 137. 
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Scheme 5.7.  Stetter reaction analogue 
 
On the first large scale Stetter reactions using catalyst 110, 0.4 equiv of the catalyst were 
needed.  None of the desired cyclized product was isolated.  A significant amount of the isolated 
side products were benzylated, presumably from the nucleophilic displacement of the benzyl 
moiety present in catalyst 110.  This result prompted the use of catalyst 109 which lacks the 
electrophilic benzyl group.   
The propensity for the aldehyde to enolize had been demonstrated before and hence the 
ratio of base to catalyst had to be carefully considered.  The base and catalyst were premixed and 
stirred initially for 15 min following the experimental protocol published by Rovis.  The solids 
present in the reaction mixture were a cause for concern and the mixture was subsequently 
heated to 35 °C and stirred for an additional 2 h before 136 was added.  Unfortunately, the major 
product isolated (30% yield and 50% of the recovered mass) was the result of the enolized 
aldehyde adding into the enone in a Michael fashion (138, Figure 5.6).   
 
 
Figure 5.6.  Major product isolated from Stetter reaction, 138 
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The enolization of the aldehyde proved problematic for the Stetter reaction with this 
system.  Substrate 121 was incompatible with the Stetter reaction conditions due to aldehyde 
enolization and subsequent fragmentation.  Substrate 136 was likewise incompatible with the 
Stetter reaction conditions due to enolization and enone addition.  Therefore, the Stetter reaction 
was abandoned for this project.    
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6.0  PARVISTEMONINE CONCLUSIONS 
The studies towards the total synthesis of parvistemonine have yielded some interesting results.  
The initial attempts to synthesize homotyrosine were inundated with difficulties.  Both Grignard 
reagents and hydroaluminated phenylacetylene were problematic due to low yields and the 
difficulty of producing the needed imine in large quantities.  The literature procedure for the 
synthesis of homotyrosine opened the door to testing the subsequent synthetic steps of key 
interest.  The oxidation of homotyrosine did not deliver the favorable results that the oxidation of 
tyrosine had, which prompted methodology that greatly deviated from what had been explored in 
previous work.  The Birch reduction proceeded smoothly with homotyrosine, but acidic 
cyclization did not afford the desired results. The alternative pathway of bisepoxidation, 
likewise, proved problematic.  Model studies began to further explore some of the epoxidation 
methodology.  The bisepoxidation studies demonstrated the reactivity of the enol ether and were 
extended to various epoxidizing agents.  DMDO gave especially satisfying results and 
subsequent treatment of the reaction mixture with methanol afforded the isolable acetal which 
allowed investigation of the cyclization.  The next methodology explored was the Stetter 
reaction.  This study demonstrated that the PIFA conditions can be compatible with a free 
aldehyde.  This substrate was unfortunately incompatible with the Stetter reaction conditions due 
to quick fragmentation.  The second generation Stetter reaction substrate did not suffer from the 
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earlier observed fragmentation difficulties, but conditions still need to be optimized for the 
problematic 6-membered ring formation.       
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7.0  PARVISTEMONINE EXPERIMENTAL PART 
General:  All reactions were performed in flame-dried or oven-dried glassware under a nitrogen 
atmosphere.  THF and Et2O were distilled over Na/benzophenone, while pyridine and 
triethylamine were distilled over CaH2.  Hexanes and EtOAc were distilled prior to use.  All 
other reagents and solvents were used as received unless otherwise noted.  Analytical thin layer 
chromatography was performed on pre-coated silica gel 60 F-254 plates available from Merck.  
Flash chromatography was performed using silica gel 60 (230-400 mesh) available from Baker.  
NMR spectra were recorded in CDCl3 (unless otherwise noted) at 300 MHz for 1H NMR and 75 
MHz for 13C NMR using a Bruker Avance 300 with XWIN-NMR software.  Chemical shifts (δ) 
are expressed relative to the NMR solvent peak.  IR spectra were obtained with a Nicolet Avatar 
360 FT-IR, optical rotations were measured with a Perkin-Elmer 241 polarimeter, and mass 
spectra were obtained on a double focusing instrument.  EI mass spectra were obtained with VG 
Autospec and ESI mass spectra with Q-TOF API US. 
 
 
Ethyl-N-(p-toluenesulfinyl)iminoacetate (61).48  A solution of ethyl glyoxylate (0.64 mL, 6.0 
mmol) in toluene (16 mL) was treated with 4 Å activated molecular sieves (1.0 g) and p-
toluenesulphonyl isocyanate (1.0 mL, 6.0 mmol), heated at reflux for 36 h, filtered through 
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celite, concentrated under reduced pressure and used without further purification.42  The reaction 
progress was monitored by the appearance of the signal at δ 8.3 in the crude 1H NMR 
corresponding to the imine proton.   
 
H
N
OH
OH
 
(S)-2-(N-3,5-di-tert-Butylsalicylidene)amino-3,3-dimethyl-1-butanol (66).51  A solution of 
(S)-t-leucinol (499 mg, 4.26 mmol) and 3,5-di-tert-butyl-2-hydroxybenzaldehyde (1.00 g, 4.26 
mmol) in MeOH (28 mL) was treated with Na2SO4 (3.20 g) and stirred for 4 h.  The reaction 
mixture was filtered through a pad of celite, washed with anhydrous MeOH and concentrated 
under reduced pressure to afford 1.44 g (100%) of 66 as a bright yellow solid.  The product was 
pure according to TLC and 1H NMR analysis and was used without further purification:  1H 
NMR δ 8.36 (s, 1 H), 7.41 (d, 1 H, J = 2.5 Hz), 7.14 (d, 1 H, J = 2.5 Hz), 3.93 (dd, 1 H, J = 9.7, 
2.3 Hz), 3.77 (t, 1 H, J = 9.5 Hz), 2.94 (dd, 1 H, J = 9.6, 2.7 Hz), 1.45 (s, 9 H), 1.30 (s, 9 H), 0.98 
(s, 9 H).    
 
 
S-tert-Butyl 2-methylpropane-2-sulfinothioate (67).51  An Erlenmeyer flask containing 
VO(acac)2 (333 mg, 1.25 mmol) and 66 (457 mg, 1.37 mmol) was treated with CHCl3 (56 mL) 
and stirred for 10 min.  The solution was treated with tert-butyl disulfide (26.3 mL, 141 mmol) 
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followed by a slow, steady stream of H2O2 (15.6 mL) along the sides of the flask.  The reaction 
mixture was stirred for 24 h and extracted with brine.  The organic layer was separated and the 
aqueous layer extracted with CH2Cl2.  The combined organic extracts were dried (Na2SO4), 
filtered and concentrated under reduced pressure.  Purification by column chromatography on 
SiO2 (1:19, hexanes:EtOAc) afforded 18.1 g (66%) of 67 as a colorless solid:  1H NMR δ 1.56 (s, 
9 H), 1.38 (s, 9 H). 
 
 
tert-Butylsulfinamide (68).51  A solution of 67 (2.40 g, 12.3 mmol) in THF (4.7 mL) was cooled 
to -78 °C and NH3 (13 mL) was added followed by 5 portions of Li (214 mg, 30.8 mmol) over 
0.5 h.  The reaction mixture turned deep blue, was stirred for 1 h, warmed to room temperature 
overnight and the remaining solvent was removed under reduced pressure.  The resultant solid 
was dissolved in EtOAc, washed with water, brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure.  Purification by column chromatography on SiO2 (1:19, MeOH:CH2Cl2) 
afforded 1.33 g (89%) of 68 as a colorless solid:  1H NMR δ 3.69 (bs, 2 H), 1.22 (s, 9 H).     
 
 
Ethyl (R)-(−)-N-(tert-butylsylfinyl)iminoacetate (63).48  A round bottom flask containing a 
50% solution of ethyl glyoxylate in toluene (1.2 mL, 6.7 mmol) was heated at 50 °C for 5 min 
with a heat gun, cooled to room temperature and diluted with CH2Cl2 (168 mL).  The rapidly 
stirring solution was treated with 68 (817 mg, 6.70 mmol) followed by 4 Å molecular sieves 
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(62.0 g) and stirred for 48 h.  The reaction mixture was filtered through a plug of celite, washed 
with EtOAc, dried (Na2SO4), filtered and concentrated under reduced pressure.  Purification by 
column chromatography through a short plug of SiO2 (CH2Cl2) afforded 1.20 g (87%) of 63 as a 
colorless oil:  1H NMR δ 8.01 (s, 1 H), 4.41 (q, 2 H, J = 7.1 Hz), 1.36 (t, 3 H, J = 7.1 Hz), 1.27 
(s, 9 H).   
 
 
Ethyl (RS-2-phenethyl)-(-)-N-(tert-butylsylfinylamine) ethyl ester (73).  A solution of 6348 
(102 mg, 0.500 mmol) in CH2Cl2 (10.0 ml) was cooled to -78 °C and treated with BF3.OEt2 (0.13 
mL, 1.0 mmol), and after 5 min with a 1.0 M solution of phenethyl magnesium chloride in THF 
(1.0 mL, 1.0 mmol).  The reaction mixture was quenched after 15 min with sat. NH4Cl (3.5 mL) 
and warmed to room temperature.  The aqueous layer was extracted with CH2Cl2 (2x), washed 
with brine, dried (Na2SO4), filtered and concentrated under reduced pressure.  Purification by 
column chromatography on SiO2 (2:1, hexanes:EtOAc) afforded 30 mg (19%) of 73 as a 
colorless oil:  Rf  0.2 (1:1, hexanes:EtOAc);  IR (neat) 3281, 3027, 2980, 2958, 2930, 2866, 
1735, 1497, 1474, 1455, 1389, 1366, 1299, 1200, 1176, 1075, 740, 700 cm -1;  1H NMR δ 7.29 (t, 
2 H, J = 7.1 Hz), 7.21 (d, 1 H, J = 7.2 Hz), 7.16 (d, 2 H, J = 7.2 Hz), 4.18 (q, 2 H, J = 7.1 Hz), 
3.99-3.93 (m, 1 H), 2.69 (t, 2 H, J = 8.3 Hz), 2.15-1.97 (m, 2 H), 1.28 (s, 9 H);  13C NMR δ  
173.2, 140.9, 128.7, 128.6, 126.4, 61.9, 57.0, 56.2, 35.7, 31.3, 22.8, 14.3;  MS (EI) m/z (rel 
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intensity) 312 (M+, 1), 255 (20), 181 (14), 164 (39), 134 (29), 117 (74), 91 (94), 57 (100);  
HRMS (EI) calculated for C16H26NO3S 312.1633, found 312.1640. 
 
 
(R)-N-(Methoxycarbonyl)aspartic acid(75).55  A solution of aspartic acid (10.5 g, 7.88 mmol) 
in 2.0 N NaOH (39.5 mL) was cooled to 0 °C, treated dropwise over 15 min with methyl 
chloroformate (9.9 mL, 13 mmol), warmed to room temperature and stirred for 1 h.  The reaction 
mixture was cooled to 0 °C, slowly and cautiously acidified to pH 1 with 12 N HCl, concentrated 
under reduced pressure and the solid was extracted with 60 °C EtOAc (3x).  The combined 
organic extracts were concentrated under reduced pressure to afford 10.7 g (70%) of 75 as a 
white solid:  crude 1H NMR (DMSO-d6) δ 12.61 (bs, 2 H), 7.49 (d, 1 H, J = 8.4 Hz), 4.35 (td, 1 
H, J = 8.2, 5.5 Hz), 3.57 (s, 3 H), 2.74 (dd, 1 H, J = 16.4, 5.5 Hz), 2.59 (d, 1 H, J = 8.1 Hz).       
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(R)-N-(Methoxycarbonyl)aspartic anhydride (76).55  A suspension of 75 (11.5 g, 60.5 mmol) 
in EtOAc (230 mL) was treated dropwise over 0.5 h with trifluoroacetic anhydride (12 mL, 84 
mmol), warmed to 35 °C and stirred for 1 h.  The reaction mixture was cooled to room 
temperature, concentrated to 100 mL under reduced pressure, diluted with hexanes (460 mL), 
cooled to 0 °C and stirred for 1h.  A precipitate formed and was filtered, washed with a solution 
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of hexanes:EtOAc (5:1, 3x) and dried under reduced pressure to afford 8.66 g (75%) of 76 as a 
white solid:  1H NMR (DMSO-d6) δ 8.07 (d, 2 H, J = 7.7 Hz), 4.71 (ddd, 1 H, J = 10.0, 7.7, 6.3 
Hz), 3.62 (s, 3 H), 3.28 (dd, 1 H, J = 18.5, 10.0 Hz), 2.94 (dd, 1 H, J = 18.5, J = 6.3 Hz). 
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(2R)-[(Methoxycarbonyl)amino]-4-oxo-4-(3-chloro-4-methoxyphenyl)butanoic acid (78).55  
A solution of AlCl3 (15.7 g, 118 mmol) in CH2Cl2 (100 mL) was cooled to 0 °C, treated 
dropwise over 15 min with a solution of 2-chloroanisole (4.7 mL, 37 mmol) in nitromethane (7 
mL), warmed to room temperature and treated portionwise over 0.5 h with 76 (8.91 g, 46.8 
mmol).  The reaction mixture was heated at reflux for 24 h with a vent for the HCl (g) that was 
generated, cooled to room temperature and quenched by pouring into a rapidly stirred mixture of 
ice (25 g), 2 M H3PO4 (250 mL) and EtOAc (250 mL).  The organic layer was extracted and 
washed with 2 M H3PO4, brine, filtered through celite and concentrated to 120 mL under reduced 
pressure.  The solution was diluted with hexanes (370 mL) and stirred at 0 °C for 1 h.  A 
precipitate formed and was filtered, washed with a solution of EtOAc:hexanes (3:1, 2x) and dried 
under reduced pressure to afford 11.5 g (99%) of 78 as a white solid:  1H NMR δ 7.98 (d, 2 H, J 
= 2.2 Hz), 7.86 (dd, 1 H, J = 8.7, 2.2 Hz), 6.97 (d, 1 H, J = 8.7 Hz), 5.83 (d, 2 H, J = 8.3 Hz), 
4.80-4.75 (m, 1 H), 3.97 (s, 3 H), 3.76-3.73 (m, 1 H), 3.68 (s, 3 H), 3.49 (dd, 1 H, J = 18.3, 4.4 
Hz). 
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(2R)-[(Methoxycarbonyl)amino]-4-(4-methoxyphenyl)butanoic acid (79).55  A solution of 
THF (20 mL) and water (20 mL) was added to 10% Pd/C (485 mg, 0.457 mmol) to form a 
suspension in a hydrogenation vessel.  Acid 78 (9.77 g, 30.9 mmol) was added to the suspension 
and the vessel was evacuated of air under reduced pressure and charged with H2 (2x), pressurized 
to 40 p.s.i with H2 and shaken for 24 h.  The reaction mixture was depressurized to atmospheric 
pressure and filtered through a plug of celite.  The THF was removed under reduced pressure and 
the water was extracted with 60 °C EtOAc (3 x).  The combined organic extracts were washed 
with brine and concentrated to 20 mL under reduced pressure.  Hexanes (60 mL) were added 
while the solution was rapidly stirring.  The reaction mixture was cooled to 0 °C, stirred for 1 h 
and the solid that formed was filtered, washed with hexanes:EtOAc (5:1), and dried under 
reduced pressure to afford 7.43 g (90%) of 79 as a white solid;  1H NMR (DMSO-d6) δ 12.47 
(bs, 1 H), 7.23 (d, 1 H, J = 8.0 Hz), 7.14 (d, 2 H, J = 8.6 Hz), 6.88 (d, 2 H, J = 8.6 Hz), 3.88-3.81 
(m, 1 H), 3.75 (s, 3 H), 3.65 (s, 3 H), 2.65- 2.55 (m, 2 H), 1.92-1.81 (m, 2 H).  
 
 
(2R)-[(Methoxycarbonyl)amino]-4-(4-hydroxyphenyl)butanoic acid (81).  A solution of 7955 
(1.00 g, 3.74 mmol) in CH2Cl2 (37 mL) was cooled to −78 °C and treated with a 1.0 M solution 
of BBr3 in CH2Cl2 (6.9 mL, 6.9 mmol) dropwise over 10 min.  The solution was stirred for 1 h at 
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−78 °C, 5 h at room temperature and then quenched with a mixture of CH2Cl2 (60 mL), sat. 
NH4Cl (20 mL) and ice (10 g).  The aqueous layer was extracted with EtOAc (3 x) and the 
combined organic extracts were dried (MgSO4), filtered and concentrated under reduced 
pressure.  Purification by column chromatography on SiO2 (1:9, MeOH:CH2Cl2) afforded 567 
mg (60%) of 81 as a white foam:  Rf  0.15 (10:90, MeOH:CH2Cl2);  IR (neat)  3337, 2957, 1704, 
1614, 1515, 1454, 1373, 1235, 1059 cm -1;  1H NMR (DMSO-d6) δ 12.54 (s, 1 H), 9.18 (s, 1 H), 
7.56 (d, 2 H, J = 8.0 Hz), 6.99 (d, 2 H, J = 8.2 Hz), 6.70 (d, 2 H, J = 8.2 Hz), 3.91-3.86 (m, 1 H), 
3.65 (s, 3 H), 2.58-2.50 (m, 2 H), 1.95-1.82 (m, 2 H);  13C NMR (DMSO-d6) δ 174.2, 156.7, 
155.5, 131.1, 129.2, 115.1, 53.4, 51.4, 33.2, 30.7;  MS (EI) m/z (rel intensity)   253 (M+, 14), 221 
(8), 160 (5), 147 (13), 133 (100), 121 (40), 115 (96), 107 (93), 77 (48), 59 (32);  HRMS (EI) 
calculated for C12H15NO5 253.0950, found 253.0960.   
 
 
Methyl tetrahydro-6(cyclohexa-2,5-dienone)-2-oxo-2H-pyran-3-ylcarbamate (80).  A 
solution of 81 (100 mg, 0.375 mmol) in trifluoroethanol (3.8 mL) was cooled to 0 °C, treated 
with PIFA (238 mg, 0.553 mmol) in a single portion and stirred for 1 h.  The reaction mixture 
was concentrated under reduced pressure, diluted with EtOAc, washed with sat. NaHCO3, dried 
(Na2SO4), filtered and concentrated.  Purification by column chromatography on SiO2 (1:1, 
hexanes:EtOAc) afforded 7 mg (7%) of crude 80 as a colorless oil:  Rf  0.3 (1:3, 
hexanes:EtOAc);  IR (neat)  2350, 2341, 1715, 1673, 1521, 1065, 858 cm -1;  1H NMR δ 7.27 (m, 
1 H), 6.83 (dd, 1 H, J = 3.5, 10.3 Hz), 6.26 (d, 2 H, J = 10.1 Hz), 5.54 (bs, 1 H), 4.13- 4.11 (m, 1 
H), 3.73 (s, 3 H), 2.53- 2.43 (m, 4 H);  13C NMR δ 184.0, 169.2, 146.5, 129.2, 128.9, 78.5, 52. 8, 
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51.1, 32.7, 25.3;  MS (ESI) m/z (rel intensity) 274 ([M+Na]+,100), 206 (18);  HRMS (ESI) 
calculated for C12H13NO5Na 274.0691, found 274.0730.   
 
 
Characteristic signals for 1-(methoxycarbonyl)-5-cyclohexadienone-2-carboxylic acid (82).  
Rf  0.1 (10:90, MeOH:CH2Cl2);  1H NMR (90 °C DMSO–d6) δ 13.0 (bs, 1 H), 7.19-7.02 (m, 2 
H), 6.24-6.12 (m, 2 H), 4.50 (d, 1 H, J = 7.2 Hz), 3.54 (s, 3 H), 2.25-2.25-2.00 (m, 4 H). 
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(S)-4-(4-Methoxycyclohexa-1,4-dienyl)-2-(methylcarbamate)butanoic acid (86).  A solution 
of 79 (1.00 g, 3.74 mmol) in EtOH (5.2 mL) was cooled to −78 °C and ammonia (19 mL) was 
added.  The reaction mixture was treated over 0.5 h with 5 portions of Li wire (266 mg, 38.3 
mmol) and gradually turned deep blue.  After 1 h, the -78 °C bath was removed and the reaction 
mixture was warmed to room temperature overnight with a vent for the ammonia.  The 
remaining EtOH was removed under reduced pressure and the salts were dried under high 
vacuum and used without further purification.  The diagnostic peaks in crude 1H NMR (DMSO-
d6) were the two signals at δ 5.3 (s, 1 H) and 4.7 (s, 1 H), corresponding to the alkene protons.   
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Methyl 4-hydroxyphenethylcarbamate.77  A solution of tyramine (4.00 g, 29.2 mmol) in 4.0 N 
NaOH (15 mL) was cooled to 0 °C, treated with methyl chloroformate (3.6 mL, 47 mmol) 
dropwise over 15 min and stirred for 1 h at 0 °C.  The reaction mixture was neutralized to pH 7 
with 2 N HCl, extracted with EtOAc (2x), and the combined organic extracts were washed with 
water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure.  A solution of the 
crude product in MeOH (31.3 mL) was treated with K2CO3 (0.728 g, 5.26 mmol), stirred for 12 
h, filtered and concentrated under reduced pressure.  Purification by column chromatography on 
SiO2 (2:1, hexanes:EtOAc) afforded 5.12 g (90%) of the carbamate as a white solid:  1H NMR δ 
7.03 (d, 2 H, J = 8.3 Hz), 6.77 (d, 2 H, J = 8.3 Hz), 5.53 (bs, 1 H), 4.72 (bs, 1 H), 3.66 (s, 3 H), 
3.40 (q, 2 H, J = 6.2 Hz), 2.73 (t, 2 H, J = 7.0 Hz).     
 
O
H
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Methyl 4-methoxyphenethylcarbamate (90).78  A solution of methyl 4-
hydroxyphenethylcarbamate (5.69 g, 29.2 mmol) in acetone (180 mL) was treated with K2CO3 
(10.2 g, 73.9 mmol) and methyl iodide (3.7 mL, 58 mmol) and the solution was heated at reflux 
for 24 h.  The reaction mixture was filtered and concentrated under reduced pressure.  The crude 
product was dissolved in EtOAc, washed with sat. NH4Cl, brine, dried (Na2SO4), filtered and 
concentrated under reduced pressure. Purification by column chromatography on SiO2 (3:1, 
hexanes:EtOAc) afforded 4.937 g (81%) of 90 as a colorless oil:  1H NMR δ 7.14 (d, 2 H, J = 8.6 
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Hz), 6.85 (d, 2 H, J = 8.6 Hz), 4.65 (bs, 1 H), 3.79 (s, 3 H), 3.66 (s, 3 H), 3.41 (q, 2 H, J = 6.3 
Hz), 2.75 (t, 2 H, J = 6.9 Hz).    
 
O
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Methyl 2-(4-methoxycyclohexa-1,4-dienyl)ethylcarbamate (91).  A solution of 90 (4.94 g, 
23.6 mmol) in EtOH (23 mL) was cooled to −78 °C, ammonia (75 ml) was added and the 
solution was treated over 0.5 h with 5 portions of Li (1.26 g, 182 mmol).  The reaction mixture 
turned deep blue and was stirred for 1 h, warmed to room temperature overnight and 
concentrated under reduced pressure.  The salts were dissolved in H2O and washed with EtOAc 
(2x).  The combined organic extracts were washed with brine, dried (Na2SO4), filtered and 
concentrated under reduced pressure.  Purification by column chromatography on SiO2 (3:1, 
hexanes:EtOAc) afforded 4.40 g (90%) of 91 as a colorless oil:  Rf 0.2 (75:25, hexanes:EtOAc);  
IR (neat) 3346, 2991, 2942, 2892, 2827, 1693, 1667, 1529, 1465, 1321, 1248, 1215, 1192, 1012, 
780 cm -1;  1H NMR δ 5.43 (s, 1 H), 4.70 (bs, 1 H), 4.60 (s, 1 H), 3.64 (s, 3 H), 3.53 (s, 3 H), 3.27 
(q, 2 H, J = 6.2 Hz), 2.71 (bs, 4 H), 2.18 (t, 2 H, J = 6.7 Hz);  13C NMR δ 157.0, 152.9, 132.3, 
120.0, 112.2, 90.2, 53.9, 52.0, 38.9, 36.8, 29.1;  MS (EI) m/z (rel intensity) 211 (M+, 20), 136 
(35), 123 (100);  HRMS (EI) calculated for C11H17NO3  211.1208, found 211.1203.  
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Methyl 2-(3-hydroxy-4,4-dimethoxy-7-oxa-bicyclo[4.1.0]heptan-1-yl)ethylcarbamate (95).  
A solution of 91 (350 mg, 1.66 mmol) in CH2Cl2 (33 mL) was cooled to 0 °C, treated dropwise 
over 5 min with a 0.1 M solution of DMDO in acetone (25 mL, 2.5 mmol) and stirred for 1 h.  
The reaction mixture was concentrated under reduced pressure and the highly unstable 
intermediate was immediately dissolved in MeOH (11.3 mL) and stirred at room temperature for 
12 h.  The reaction mixture was treated with trimethylorthoformate (3.3 mL, 3.3 mmol) and p-
toluenesulphonic acid (12 mg, 0.063 mmol) and stirred for 3 h at room temperature.  The 
solution was concentrated under reduced pressure, dissolved in EtOAc, washed with sat. 
NaHCO3, water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure: crude 
NMR (DMSO-d6) δ 7.0 (bs, 1 H), 5.2 (s, 1 H), 4.6 (bs, 1 H), 3.8 (bs, 1 H), 3.5 (s, 3 H), 3.2 (s, 
3H), 3.1 (s, 3 H), 3.07-3.01 (m, 4 H), 2.3 (d, 1 H, J = 17.4 Hz), 2.2 (bs, 2 H), 2.0 (t, 2 H, J = 8.9 
Hz), 1.9 (d, 1 H, J = 17.4 Hz).  A solution of the crude product in CH2Cl2 (16 mL) was cooled to 
0 °C, treated with mCPBA (343 mg, 2.00 mmol), warmed to room temperature and stirred for 2 
h.  The reaction mixture was extracted with sat. NaHCO3 and the aqueous layer was washed with 
CH2Cl2 (2x).  The combined organic extracts were washed with water, brine, dried (Na2SO4), 
filtered and concentrated under reduced pressure.  Purification by column chromatography on 
SiO2 (1:3, hexanes:EtOAc) afforded 212 mg (47%) of 95 as a colorless oil and a 1:1 mixture of 
inseparable diastereomers:  Rf  0.3 (5:95, MeOH:CH2Cl2);  IR (neat)  3348, 2948, 2834, 1705, 
1537, 1456, 1377, 1263, 1194, 1127, 1109, 1051 cm-1;  1H NMR δ 5.29 (bs, 0.5 H), 4.96 (bs, 0.5 
H), 3.80 (dd, 0.5 H, J = 5.8, 4.3 Hz), 3.78-3.73 (m, 0.5 H), 3.63 (s, 1.5 H), 3.62 (s, 1.5 H), 3.52-
3.35 (m, 2 H), 3.25 (s, 1.5 H), 3.21 (s, 1.5 H), 3.20 (s, 1.5 H), 3.16 (s, 1.5 H), 3.13-3.09 (m, 1 H), 
3.00 (t, 0.5 H, J = 2.2 Hz), 2.55 (s, 0.5 H), 2.35 (dd, 0.5 H, J = 5.4, 1.2 Hz), 2.29 (dd, 0.5 H, J = 
5.5, 1.2 Hz), 2.24-2.22 (m, 0.5 H), 2.19-2.07 (m, 3 H), 1.99 (dd, 0.5 H, J = 15.1, 6.0 Hz), 1.89-
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1.76 (m, 1.5 H), 1.69-1.61 (m, 0.5 H);  13C NMR δ 157.1, 157.0, 99.4 (2C), 67.6, 66.7, 61.1, 
57.7, 57.1, 52.2, 52.1, 49.1, 48.8, 48.1, 47.6, 37.3, 37.0, 36.7, 35.6, 31.9, 31.5, 30.1, 28.8;  MS 
(EI) m/z (rel intensity) 275 (M+, 5), 244 (13), 225 (15), 187 (100), 173 (30), 117 (43), 101 (69), 
99 (98), 88 (85);  HRMS (EI) calculated for C12H21 NO6  275.1368, found 275.1368.            
 
Typical procedure for the preparation of DMDO:  A 3-L three neck round bottom flask was 
equipped with a mechanical stirrer and thermometer for monitoring the internal temperature.  A 
solution of water (254 mL) and acetone (192 mL) was treated with NaHCO3 (58 g, 0.69 mol), 
cooled to 10 °C and treated with Oxone (120 g, 0.39 mol) in 5 portions over 15 min with rapid 
stirring.  After the addition was complete, the ice bath was removed and the thermometer 
replaced with a short path distillation head connected to a 250 mL round bottom collection flask.  
The round bottom collection flask was cooled to −78 °C and the DMDO solution was distilled 
over at ~40 torr to afford a light yellow solution (~0.1 M).  Approximately 100 mL of the 
solution was distilled over during 20 min.  The quality of the DMDO solution typically 
diminishes during longer distillation times.  The molarity was established via titration with 
thioanisole and 1H NMR analysis.  A more concentrated solution of DMDO in CH2Cl2 could be 
obtained via extraction.79  The distilled DMDO acetone solution was treated with ice cooled 
water (500 mL), transferred to a separatory funnel and extracted with CH2Cl2 (18 mL) followed 
by two smaller extractions of CH2Cl2 (9 mL, 2x).  The combined organic extracts were dried 
(Na2S2O4), filtered and stored over K2CO3 at 0 °C and used within 24 h.                                                
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5-Benzylmorpholin-3-one (119).80  A solution of phenylalinol (1.26 g, 8.35 mmol) in THF (97 
mL) was treated portionwise over 15 min with NaH (60% dispersion in mineral oil, 366 mg, 15.3 
mmol) and stirred for 0.5 h.  The reaction mixture turned deep yellow and was treated dropwise 
over 5 min with ethylchloroacetate (0.88 ml, 8.3 mmol) and heated at reflux for 3 h.  The 
solution was slowly and cautiously poured into a 1 L flask containing 1 N HCl (100 mL) and 
extracted with EtOAc (3x).  The combined organic extracts were dried (Na2SO4), filtered and 
concentrated under reduced pressure to afford 403 mg (26%) of 119 as a colorless solid:  1H 
NMR δ 7.37-7.27 (m, 3 H), 7.19 (d, 2 H, J = 6.8 Hz), 5.85 (bs, 1 H), 3.94 (dd, 1 H, J = 3.7, 11.6 
Hz), 3.82-3.72 (m, 1 H), 3.57 (dd, 1 H, J = 6.7, 11.6 Hz), 2.90 (1 H, dd, J = 5.4, 13.5 Hz), 2.69 
(dd, 1 H, J = 9.1, 13.5 Hz).   
 
 
2-(5-Benzylmorpholin-3-ylidene)-1-phenylhydrazine hydrochloride (120).  A solution of 
trimethyloxonium tetrafluoroborate (210 mg, 1.42 mmol) in CH2Cl2 (5 mL) was treated dropwise 
over 5 min with a solution of (+/-) 11980 (162 mg, 0.852 mmol) in CH2Cl2 (5 mL) and stirred for 
12 h.  The reaction mixture was diluted with CH2Cl2, washed with ice cold sat. NaHCO3 and the 
aqueous layer was extracted with CH2Cl2 (2x).  The combined organic extracts were dried 
(Na2SO4), filtered and concentrated under reduced pressure to afford 128 mg (73%) of 3-benzyl-
3,6-dihydro-5-methoxy-2H-1,4-oxazine as a colorless oil: crude 1H NMR δ 7.31-7.22 (m, 5H), 
4.02 (dd, 2 H, J = 3.9, 1.5 Hz), 3.77-3.75 (m, 1 H), 3.72 (s, 3 H), 3.60 (dd, 1 H, J = 3.8, 11.6 Hz), 
3.31 (dd, 1 H, J = 6.0, 11.6 Hz), 3.01 (dd, 1 H, J = 5.3, 13.5 Hz), 2.65 (dd, 1 H, J = 9.1, 13.5 Hz).  
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The crude product was used without further purification and carried on to the following reaction:  
A solution of  3-benzyl-3,6-dihydro-5-methoxy-2H-1,4-oxazine (148 mg, 0.721 mmol) in MeOH 
(3.5 mL) was treated with phenylhydrazine hydrochloride (104 mg, 0.721 mmol), heated at 50 
°C for 3 h, concentrated under reduced pressure and recrystallized from MeOH to afford 155 mg 
(68%) of 120 as a colorless solid:  Mp 224 °C (dec.);  IR (neat)  3565, 3321, 2946, 2830, 1471, 
1455, 1111, 1032 cm-1;  1H NMR (DMSO-d6) δ 11.60 (s, 1 H), 10.36 (s, 1 H), 8.57 (s, 1 H), 7.35-
7.28 (m, 5 H), 7.22 (d, 2 H, J = 7.3 Hz), 6.99 (d, 1 H, J = 7.4 Hz), 6.94 (2 H, J = 7.5 Hz), 4.73 (s, 
2 H), 3.88 (dd, 1 H, J = 11.3, 3.0 Hz), 3.80-3.75 (m, 1 H), 3.74-3.69 (m, 1 H), 3.10 (dd, 1 H, J = 
13.2, 3.5 Hz), 2.87 (dd, 1 H, J = 13.1, 8.9 Hz);  13C (DMSO-d6) δ 162.4, 146.1, 136.5, 129.4, 
129.1, 128.6, 126.8, 121.1, 113.8, 65.2, 61.5, 50.3, 37.7;  MS (EI) m/z (rel intensity) 282 (M+, 
100), 191 (8);  HRMS (EI) calculated for C17H20N3 282.1606, found 282.1603.       
 
 
5-Benzyl-3,5,6,8-tetrahydro-2-phenyl-2H-[1,2,4]triazolo[3,4-c][1,4]oxazium chloride (108).75  
A solution of 120 (155 mg, 0.489 mmol) in a trimethylorthoformate-methanol mixture (2:1, 0.5 
mL) was heated at 80 °C for 12 h in a sealed tube and concentrated under reduced pressure to 
afford 160 mg (quant) of 108 as a white solid:  Mp 100.3-102.2 °C (MeOH);  IR (KBr) 3399, 
3059, 2999, 2917, 2850, 2201, 1577, 1513, 1462, 1120, 1091, 762  cm-1;  1H NMR (DMSO-d6) 
11.36 (bs, 1 H), 7.98 (d, 2 H, J = 7.7 Hz), 7.74 (t, 2 H, J = 7.0 Hz), 7.67-7.72 (m, 1 H), 7.47-7.37 
(m, 5 H), 5.23 (d, 2 H, J = 8.8 Hz), 4.91-4.89 (m, 1 H), 4.00 (bs, 2 H), 3.63 (dd, 1 H, J = 13.5, 
4.4 Hz), 3.21 (dd, 1 H, J = 13.0, 10.9 Hz);  13C NMR (MeOD) δ 151.7, 136.5, 136.3, 132.1, 
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131.4, 130.7, 130.3, 128.9, 122.0, 66.7, 63.0, 58.7, 39.3;  MS (EI) m/z (rel intensity) 293 ([M+1]+ 
,60) 292 (M+, 100), 274 (8), 248 (3), 158 (10);  HRMS (EI) calculated for C18H18N3O 292.1450,  
found 292.1443.  
 
 
4-(3-Hydroxypropyl)phenol.81  A suspension of lithium aluminum hydride (2.51 g, 66.2 mmol) 
in THF (300 mL) was cooled to 0 °C, treated with 3-(4-hydroxyphenyl)propionic acid (1.87 g, 
11.2 mmol) in 3 portions over 0.5 h, stirred for 1 h and stirred at room temperature for 6 h.  The 
reaction mixture was quenched with water (700 mL), acidified to pH 6 with conc. HCl and 
extracted (2x) with CH2Cl2.  The combined organic extracts were washed with water, sat. 
NaHCO3, brine, dried (Na2SO4), filtered and concentrated under reduced pressure.  Purification 
by chromatography on SiO2 (3:1, hexanes:EtOAc) afforded 1.198 g (70%) of 3-(4-
hydroxyphenyl)propanol:  1H NMR (DMSO-d6) δ 9.14 (s, 1 H), 7.00 (d, 2 H, J = 8.3 Hz), 6.70 
(d, 2 H, J = 8.3 Hz), 3.59 (t, 2 H, J = 6.2 Hz), 2.5 (bs, 2 H), 1.7 (pent, 2 H, J = 6.6 Hz).  
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3-(4-Hydroxyphenyl)propanal (123).82  A solution of 4-(3-hydroxypropyl)phenol (430 mg, 
2.84 mmol), in EtOAc (4.8 mL) and CH2Cl2 (9.4 mL) was treated with pyridinium dichromate 
(2.19 g, 5.82 mmol) and stirred for 12 h.  The reaction mixture was filtered through a pad of 
celite and concentrated under reduced pressure.  Purification by column chromatography on SiO2 
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(3:1, EtOAc:hexanes) afforded 128 mg (30%) of 123:  1H NMR 9.80 (s, 1 H), 7.06 (d, 2 H, J = 
8.4Hz), 6.76 (d, 2 H, J = 8.5 Hz), 2.89 (t, 2 H, J = 7.2 Hz), 2.72 (t, 2 H, J = 7.2 Hz). 
 
 
3-[4-(tert-Butyldimethylsilyloxy)phenyl]propan-1-ol (124).83  A solution of 4-(3-
hydroxypropyl)phenol (186 mg, 1.22 mmol) in DMF (1.2 mL) was treated with imidazole (252 
mg, 3.70 mmol), stirred for 15 min, treated with TBSCl (452 mg, 3.01 mmol) and stirred for 8 h.  
The reaction mixture was diluted with EtOAc, washed with 1.0 N HCl and the aqueous extract 
was washed with EtOAc (3x).  The combined organic extracts were washed with water (3x), 
brine, dried (MgSO4), filtered and concentrated under reduced pressure.  The crude product was 
used without further purification and carried on to the following reaction.  A solution of the 
crude product in ethanol (16 mL) was treated with pyridinium p-toluenesulfonate (39 mg, 0.15 
mmol) and stirred at 50 °C for 3 h.  The reaction mixture was cooled to room temperature, 
concentrated, diluted with EtOAc, extracted with water (2x), brine, dried (Na2SO4), filtered and 
concentrated under reduced pressure.  Purification by column chromatography on SiO2 (9:1, 
hexanes:EtOAc) afforded 271 mg (95%) of 124:  1H NMR δ 7.04 (d, 2 H, J = 8.2 Hz), 6.76 (d, 2 
H, J = 8.3 Hz), 3.66 (t, 2 H, J = 6.4 Hz), 2.64 (appt, 2 H, J = 7.4 Hz), 1.91-1.83 (m, 2 H), 0.98 (s, 
9 H), 0.18 (s, 6 H). 
 
 
Alternative synthesis of 3-[4-(tert-butyldimethylsilyloxy)phenyl]propan-1-ol (124).83  A 
solution of 122 (3.21 g, 19.3 mmol) in DMF (7.7 mL) was treated with imidazole (3.95 g, 57.9 
mmol), cooled to 0 °C and treated with TBSCl (7.28 g, 48.3 mmol).  A precipitate formed 
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instantly and the mixture was warmed to room temperature.  The precipitate dissolved and the 
reaction mixture was stirred for 2 d, diluted with EtOAc, and washed with 1 N HCl.  The 
aqueous extract was washed with EtOAc (2x).  The combined organic extracts were washed with 
water (3x), brine, dried (Na2SO4), filtered and concentrated to afford the crude product which 
was used without further purification and carried on to the next reaction.  A suspension of LAH 
(l89 mg, 23.5 mmol) in THF (20 mL) at 0 °C was treated portionwise over 0.5 h with crude 3-(4-
tert-butyldimethylsilanyloxyphenyl)-propyl-tert-butyldimethylsilyl ether and stirred for 1 h.  The 
reaction mixture was quenched with 1 N HCl (4 mL) and diluted with water.  The aqueous layer 
was washed with EtOAc (2x).  The combined organic extracts were washed with water, brine, 
dried (Na2SO4), filtered and concentrated.  Purification by column chromatography on SiO2 (9:1, 
hexanes:EtOAc) afforded 4.40 g (75%) of 124 whose spectral and physical properties matched 
the previously synthesized material.  
 
 
3-[4-(tert-Butyldimethylsilyloxy)phenyl]propanal (125).  A solution of 124 (100 mg, 0.376 
mmol) in acetonitrile (0.43 mL) and CH2Cl2 (3.9 mL) was treated with powdered activated 4 Å 
molecular sieves (0.22 g), TPAP (7.5 mg, 0.021 mmol) and NMO (75.7 mg, 0.646 mmol) and 
stirred for 0.5 h.  The reaction mixture turned colors from dark green to black, was filtered 
through a plug of silica and concentrated under reduced pressure.  Purification by column  
chromatography on SiO2 (97:3, hexanes:EtOAc) afforded 75 mg (65%) of 125 as a colorless oil:  
Rf  0.3 (1:10, EtOAc:hexanes);  IR (neat) 3030, 2956, 2930, 2858, 2887, 2715, 1725, 1609, 
1510, 1472, 1259, 917, 840, 780 cm-1;  1H NMR δ 9.81 (t, 1 H, J = 1.5 Hz), 7.04 (d, 2 H, J = 8.5 
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Hz), 6.76 (d, 2 H, J = 8.5 Hz), 2.89 (t, 2 H, J = 7.3 Hz), 2.79-2.71 (m, 2 H), 0.97 (s, 9 H), 0.18 (s, 
6 H);  13C NMR δ 202.0, 154.2, 133.0, 129.3, 120.2, 45.6, 27.5, 25.8, 18.3, −4.3;  MS (EI) m/z 
(rel intensity) 264 (M+, 30), 207 (100), 101 (67);  HRMS (EI) calculated for C15H24O2Si 
264.1545, found 264.1547. 
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3-(4-Hydroxyphenyl)propanal (123).82  A solution of 125 (652 mg, 2.32 mmol) in THF (20 
mL) was cooled to 0 °C and treated with a 1.0 M solution of TBAF in THF (4.7 mL, 4.7 mmol).  
The reaction mixture was stirred for 3 h, concentrated under reduced pressure, diluted with 
EtOAc, washed with water and the aqueous extract was extracted with EtOAc (2x).  The 
combined organic extracts were washed with brine, dried (Na2SO4), filtered and concentrated 
under reduced pressure to afford a colorless oil.  The product slowly decomposed when 
concentrated and used immediately.   
 
 
3-(1-Methoxy-4-oxocyclohexa-2,5-dienyl)propanal (121).  A solution of crude 123 in MeOH 
(12.3 mL) and acetonitrile (4.9 mL) was cooled to 0 °C, treated with PIFA (2.47 g, 5.74 mmol) 
and stirred for 4 h.  The reaction mixture was quenched with water, diluted with EtOAc, the 
layers were separated and the aqueous layer was extracted with EtOAc (2x).  The combined 
organic extracts were washed with brine, dried (Na2SO4), filtered and concentrated under 
reduced pressure.  Purification by column chromatography on SiO2 (19:1, hexanes:EtOAc) 
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afforded 62.1 mg (18%) of crude 121 as colorless oil:  Rf  0.3 (1:1, hexanes:EtOAc);  IR (neat) 
3411, 2935, 2828, 2729, 1721, 1670, 1633, 1084, 861 cm -1;  1H NMR δ 9.73 (t, 1 H, J = 1.2 Hz), 
6.72 (d, 2 H, J = 10.3 Hz), 6.38 (d, 2 H, J = 10.3 Hz), 3.21 (s, 3 H), 2.49 (td, 2 H, J = 1.2, 7.2 
Hz), 2.07 (t, 2 H, J = 7.6 Hz);  13C NMR δ 200.3, 184.9, 150.1, 131.9, 74.8, 53.2, 38.2, 31.5;  MS 
(EI) m/z (rel intensity) 180 (M+, 25), 137 (32), 124 (40), 123 (100), 107 (37);  HRMS (EI) 
calculated for C10H12O3 180.0786, found 180.0782. 
      
   
Decomposition of 121.  A solution of 121 (10 mg, 0.056 mmol) in toluene (0.25 mL) at room 
temperature was treated with NEt3 (1.5 μL, 0.011 mmol), stirred for 1 h and concentrated under 
reduced pressure.  Crude 1H NMR analysis showed clean conversion of 121 to 4-methoxyphenol.  
 
 
4-(3-Chloro-4-methoxyphenyl)-4-oxobutanoic acid (131).  A solution of AlCl3 (7.78 g, 57.4 
mmol) in CH2Cl2 (47mL) was cooled to 0 °C, treated dropwise over 15 min with a solution of 2-
chloroanisole (5.00 g, 35.0 mmol) in nitromethane (3.2 mL), warmed to room temperature and 
treated portionwise over 0.5 h with succinic anhydride (2.34 g, 23.3 mmol).  The reaction 
mixture was heated at reflux for 8 h with a vent for the HCl (g) that was generated, cooled to 
room temperature and quenched by pouring into a rapidly stirred mixture of ice (25 g), 2N 
H3PO4 (250 mL) and CH2Cl2 (250 mL).  A precipitate formed, the suspension was stirred for 6 h, 
the precipitate dissolved, and the aqueous mixture was extracted with CH2Cl2, washed with 
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water, brine, dried (MgSO4), filtered and concentrated under reduced pressure.  Purification by 
column chromatography on SiO2 (1:19, MeOH:CH2Cl2) afforded 5.27g (93%) of 131 as a white 
solid:  Rf  0.27 (10:90, MeOH:CH2Cl2);  Mp 184 °C (CH2Cl2);  IR (neat) 3063, 2658, 2589, 
1694, 1674, 1594, 1258, 1203, 1173, 823 cm-1;  1H NMR δ 8.03 (d, 1 H, J = 1.7 Hz), 7.93 (dd, 1 
H, J = 8.7, 1.7 Hz), 6.99 (d, 1 H, J = 8.7 Hz), 3.98 (s, 3 H), 3.26 (t, 2 H, J = 6.5 Hz), 2.81 (t, 2 H, 
J = 6.4 Hz);  13C NMR δ 196.3, 174.0, 158.0, 130.0, 129.5, 129.0, 121.6, 112.4, 56.6, 32.9, 28.0;  
MS (EI) m/z (rel. intensity) 242 (M+, 39), 171 (75), 169 (100);  HRMS (EI) calculated for 
C11H11O4Cl  242.03459, found 242.0343.  
     
 
4-(4-Methoxyphenyl)butanoic acid (132).84  A hydrogenator vessel containing 3% Pd/C (983 
mg, 0.278 mmol) was treated with a mixture of THF (5 mL) and water (5 mL) to form a 
suspension.  Acid 131 (5.27 g, 22 mmol) was added to the suspension and the vessel evacuated 
of air, charged with H2 (2x), pressurized with H2 to 40 p.s.i and shaken for 24 h.  The reaction 
mixture was depressurized, filtered through a plug of celite, diluted with EtOAc (50 mL), 
washed with water, brine, dried (Na2SO4), filtered and concentrated under reduced pressure.  
Purification by column chromatography on SiO2 (1:19, MeOH:CH2Cl2) afforded 3.20 g (76%) of 
132:  1H NMR δ 7.07 (d, 2 H, J = 8.5 Hz), 6.84 (d, 2 H, J = 8.6 Hz), 3.79 (s, 3 H), 2.63 (t, 2 H, J 
= 7.4 Hz), 2.37 (t, 2 H, J = 7.4 Hz), 1.92 (p, 2 H, J = 7.3 Hz). 
 
HO
O
OH
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4-(4-Hydroxyphenyl)butanoic acid (133).85  A solution of 132 (2.55 g, 13.1 mmol) in CH2Cl2 
(187 mL) was cooled to −78 °C and treated dropwise over 10 min with a 1.0 M solution of BBr3 
in CH2Cl2 (59 mL, 59 mmol), stirred for 3 h at −78 °C and at room temperature for 2 h.  The 
reaction mixture was poured into a mixture of ice, sat. NH4Cl and CH2Cl2, stirred for 0.5 h and 
extracted with CH2Cl2 (2x).  The combined organic extracts were washed with brine, dried 
(MgSO4), filtered and concentrated under reduced pressure.  Purification by column 
chromatography on SiO2 (1:3, hexanes:EtOAc) afforded 1.89 g (80%) of 133 as a white solid:  
1H NMR δ 7.05 (d, 2 H, J = 8.5 Hz), 6.76 (d, 2 H, J = 8.5 Hz), 2.61 (t, 2 H, J = 7.7 Hz), 2.36 (t, 2 
H, J = 7.5 Hz), 1.93 (pentet, 2 H, J = 7.5 Hz).   
 
 
4-(4-Hydroxybutyl)phenol.  A suspension of LAH (505 mg, 2.80 mmol) in THF (40 mL) was 
cooled to 0 °C, treated dropwise over 5 min with a solution of 133 (0.505 g, 23.2 mmol) in THF 
(5 mL) and stirred at 0 °C for 1 h.  The reaction mixture was warmed to room temperature, 
stirred for 8 h, cooled to 0 °C and slowly and cautiously quenched by dropwise addition of water.  
The color of the suspension turned from grey to white.  The reaction mixture was warmed to 
room temperature and acidified to pH 7 with 1 N HCl.  It was diluted with EtOAc, washed with 
water, brine, dried (MgSO4), filtered and concentrated.  Purification by column chromatography 
on SiO2 (1:1, hexanes:EtOAc) afforded 300 mg (65%) of the alcohol:  1H NMR (DMSO-d6)  δ 
9.14 (s, 1 H), 6.99 (d, 2 H, J = 8.2 Hz), 6.68 (d, 2 H, J = 8.1 Hz), 4.37 (t, 1 H, J = 5.2 Hz), 3.42 
(q, 2 H, J = 6.3 Hz), 2.48 ( t, 2 H, J = 7.2 Hz), 1.55 (m, 2 H), 1.41-1.21 (m, 2 H).  
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4-[4-(tert-Butyldimethylsilyloxy)phenyl]-1-butanol (134).86  A solution of 4-(4-
hydroxyphenyl)-1-butanol (300 mg, 1.81 mmol) in DMF (0.3 mL) was treated with imidazole 
(379 mg, 5.57 mmol), stirred for 15 min, treated with TBSCl (666 mg, 4.42 mmol) and stirred 
for 8 h.  The reaction mixture was diluted with EtOAc, washed with 2 N HCl and the aqueous 
layer was washed with EtOAc (3x).  The combined organic extracts were washed with water (3 
x), brine, dried (Na2SO4), filtered and concentrated under reduced pressure.  A solution of the 
crude product in ethanol (17 mL) was treated with PPTS (43 mg, 0.17 mmol) and heated at 50 
°C for 3 h.  The reaction mixture was concentrated under reduced pressure, diluted with EtOAc, 
washed with 2 N HCl, water, brine, dried (Na2SO4), filtered and concentrated under reduced 
pressure.  Purification by column chromatography on SiO2 (9:1, hexanes:EtOAc) afforded 420 
mg (88%) of 134:  1H NMR δ 7.03 (d, 2 H, J = 8.4 Hz), 6.75 (d, 2 H, J = 8.4 Hz), 3.66 (t, 2 H, J 
= 6.3 Hz), 2.58 (t, 2 H, J = 7.0 Hz), 1.63 (m, 4 H), 1.39 (s, 1 H), 0.98 (s, 9 H), 0.19 (s, 6 H).  
 
 
4-[4-(tert-Butyldimethylsilyloxy)phenyl]butanal (135).  A solution of 134 (420 mg, 1.50 
mmol) in MeCN (1.68 mL) and CH2Cl2 (17.0 mL) was treated with powdered activated 4 Å 
molecular sieves (0.83 g), TPAP (30.0 mg, 0.0853 mmol) and NMO (279 mg, 2.38 mmol), and 
stirred for 0.5 h.  The reaction mixture turned from dark green to black and was filtered through a 
plug of silica and concentrated under reduced pressure.  Purification by column chromatography 
on SiO2 (97:3, hexanes:EtOAc) afforded 284 mg (68%) of 135 as a colorless oil:  Rf  0.38 (10:1, 
hexanes:EtOAc);  IR (neat) 2955, 2930, 2858, 1726, 1510, 1256, 917, 840, 781 cm -1;  1H NMR 
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δ 9.74 (s, 1H), 7.01 (d, 2 H, J = 8.3 Hz), 6.8 (d, 2 H, J = 8.3 Hz), 2.58 (t, 2 H, J = 7.4 Hz), 2.56-
2.40 (m, 2 H), 1.95-1.89 (m, 2 H), 1.0 (s, 9 H), 0.2 (s, 5 H);  13C NMR δ 202.3, 154.0, 134.0, 
129.4, 120.1, 43.2, 34.0, 25.9, 23. 9, 18.3, −4.4;  MS (EI) m/z (rel intensity) 278 (M+, 51), 221 
(85), 165 (71), 151 (100), 73 (75). 
 
 
4-(1-Methoxy-4-oxocyclohexa-2,5-dienyl)butanal (136).  A solution of 135 (283 mg, 1.02 
mmol) in THF (10 mL) was cooled to 0 °C, treated with a 1.0 M solution of TBAF in THF (2.1 
mL, 2.1 mmol) and stirred for 1 h at 0 °C.  The reaction mixture was concentrated under reduced 
pressure, diluted with EtOAc, washed with water and the aqueous layer was extracted with 
EtOAc (2x).  The combined organic extracts were washed with brine, dried (Na2SO4), filtered 
and concentrated under reduced pressure.  The product slowly decomposed when concentrated 
and was immediately carried on to the following reaction conditions.  A solution of the crude 
product in MeOH (0.78 mL) and acetonitrile (0.30 mL) was cooled to 0 °C, treated with PIFA 
(140 mg, 0.326 mmol) and stirred for 1h.  The reaction mixture was concentrated under reduced 
pressure, diluted with EtOAc, washed with water and the aqueous layer was extracted with 
EtOAc (2x).  The combined organic extracts were washed with brine, dried (Na2SO4), filtered 
and concentrated under reduced pressure.  Purification by column chromatography on SiO2 (1:1, 
hexanes:EtOAc) afforded 75 mg (40%) of 136 as a colorless oil:  Rf  0.3 (1:1, hexanes:EtOAc);  
IR (neat) 3429, 2935, 2827, 1721, 1670, 1633, 1459, 1393, 1272, 1167, 1093, 862, 703 cm -1;  1H 
NMR δ 9.74 (t, 1 H, J = 1.3 Hz), 6.75 (d, 2 H, J = 10.1 Hz), 6.38 (d, 2 H, J = 10.3 Hz), 3.21 (s, 3 
H), 2.46 (td, 2 H, J = 1.3, 7.0 Hz), 1.67-1.66 (m, 2 H), 1.66- 1.57 (m, 2 H);  13C NMR δ 201.5, 
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185.4, 150.7, 131.9, 75.5, 53.2, 43.7, 38.9, 16.3;  MS (EI) m/z (rel intensity) 194 (M+, 3), 192 (1), 
150 (23), 149 (15), 124 (43), 123 (100);  HRMS (EI) calculated for C11H14O3 194.0943, found 
194.0945.   
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8.0  BISNAPHTHOSPIROKETALS 
8.1 INTRODUCTION 
A variety of structurally intricate and biologically active bisnaphthospiroketals are found in 
nature.87  The Wipf group has a history of exploring this substance class and utilizing the 
generated biological data to guide further synthetic investigations (Figure 8.1).  Of particular 
interest to us are the naphthoquinone bisnaphthospiroketals, such as the palmarumycins (139).  
This scaffold has been the starting point for a library of analogues and prodrugs that were tested 
as Trx/TrxR inhibitors with potential applications in cancer therapy.  Initial in vitro results 
prompted the exploration of an expedited route for the prodrug synthesis to provide multi-gram 
quantities for biological testing.  Bisnaphthospiroketals functionalized as an 
epoxynaphthoquinone, such as the spiroxins, are also structurally and strategically alluring to us.  
The total syntheses of spiroxin A and B (140) were pursued utilizing some key oxidative 
transformations to gain access to the core of these natural products.   
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Figure 8.1.  Palmarumycin (139) and spiroxin B (140) 
8.2 BISNAPHTHOSPIROKETAL CLASSIFICATION 
Chemists immediately noted and appreciated the synthetic challenges of the 
bisnaphthospiroketal’s compact architecture.  The first member of this class was isolated in the 
early 1990’s, and more recent additions88 include spiro-mamakone A89 and the decaspirones 
isolated from Helicoma viridis.90,91  Structurally, bisnaphthospiroketals can be divided into types 
I, II and III; all members have a compact and highly oxygenated ring system and a spiroketal 
linking two naphthalenes or naphthoquinones.92  These types differ primarily in the connectivity 
between the upper and lower rings.   
8.2.1 Type I bisnaphthospiroketals 
Type I bisnaphthospiroketals are characterized by a spiroketal moiety between a naphthoquinone 
and a dihydroxynaphthalene.  MK 3018 was first isolated in 1989,93 and since that report this 
class has grown to include many new members that primarily differ in their degree and sites of 
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oxidation.94-97  A series of particularly noteworthy representatives is the palmarumycin CP 
family (Figure 8.2).   
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Figure 8.2.  Palmarumycins CP1-CP4 (139, 141-143) 
 
Palmarumycins CP1-CP4 (Figure 8.2) were first isolated in 1994 from the endophytic 
fungus Coniothurium palmarum and numbered according to their polarities, with palmarumycin 
CP1 (139) being the least polar and palmarumycin CP4 (133) being the most polar.94  Their 
structures were elucidated by 1H NMR, 13C NMR, DEPT, C-H COSY, H-H COSY, IR, MS and 
X-ray crystallography.  The initial report identified the anti-fungal activity and later reports 
described the antibacterial activity of these compounds.98  Members of this family subject to total 
synthesis include palmarumycins CP1 (139),99-101 CP2 (141),100,101 C2 (144),100 C11,102 diepoxin σ 
(145),103-105 CJ 12371,100,101,106 CJ 12372106 and others (Figure 8.3).107,108   
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Figure 8.3.  Palmarumycin CP1 (139), C2 (144) and diepoxin σ (145) 
 
The initial report inspired further explorations of the biological activity of other type I 
bisnaphthospiroketals.  Schering-Plough researchers isolated a number of bisnaphthospiroketals 
from the fungus Nattrassia mangiferae in pursuit of anti-tumor and phospholipase D activity.109-
113  Merck isolated several palmarumycins and preussomerins from the unidentified fungus C. 
elomycetes114  which exhibited DNA gyrase115 and ras farnesyl transferase inhibition.116-118  As a 
testament to the versatility of this pharmacophore, unnatural type I analogues have been 
synthesized by the Wipf group and identified as thioredoxin/thioredoxin reductase (Trx/TrxR) 
inhibitors.119,120  
The synthetic routes for type I bisnaphthospiroketals can typically be divided into two 
categories: acid catalyzed spiroketalizations and biaryl ether oxidative cyclizations.  The 
Barrett101 and Taylor100 groups both utilized the former approach (Scheme 8.1).  The Taylor 
group synthesized spiroketal 148 via an acid catalyzed spiroketalization of 5-methoxytetralone 
(146) and dinaphthol 147. 
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Scheme 8.1.  Taylor's acid catalyzed spiroketalization 
 
An alternative synthetic approach to this architecture is the oxidative cyclization of biaryl 
ethers.  The Wipf group synthesized spiroketal 150 in good yield via a reduction of biaryl ether 
149 and treatment with PIDA (Scheme 8.2).99   The primary advantage of the PIFA or PIDA 
mediated spiroketalization is the milder reaction conditions. 
  
 
Scheme 8.2.  Oxidative cyclization to spiroketal 150 
8.2.2 Type II bisnaphthospiroketals 
The preussomerins are examples of type II bisnaphthospiroketals and are characterized by three 
oxygen bridges between the dihydronaphthoquinones (Figure 8.4).  These antifungal metabolites 
were isolated from Preussia isomera in 1990 by the Gloer group.121  Their structures were 
  83
elucidated via HREIMS, 13C NMR, 1H NMR, INEPT 1H-13C, X-ray crystal diffraction and CD 
calculations.122,123   
 
 
Figure 8.4.  Preussomerin A (151), preussomerin C (152) and preussomerin H (153) 
 
The isolation of type I and type II bisnapthospiroketals from a common source sparked 
some interesting biosynthetic proposals.114  One hypothesis was that the preussomerins could be 
derived from the oxidation of type I bisnaphthospiroketals.  There have been no reports to 
substantiate these hypotheses in vivo, but organic chemists have demonstrated that this 
transformation is chemically possible.  The first reported preussomerin synthesis was from the 
Heathcock group in 1999.  They calculated that the preussomerin framework 155 was 
energetically favored by 5 kcal/mol to the type I spiroketal 154 (Figure 8.5)124  Treatment of 154 
with LiOH afforded 155 in 97% yield.  The Barrett group likewise demonstrated a similar 
interconversion, except with the aid of Pb(OAc)4.125  
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Figure 8.5.  Interconversion between 154 and 155 
8.2.3 Type III bisnaphthospiroketals 
A third type of bisnaphthospiroketal is represented by the spiroxins (Figure 8.6).  This group 
consists of five members characterized by a spiroketal and a biaryl bond between two 
naphthoquinone derivatives.  The spiroxins were isolated in 1999 from coral fungal strain LL-
37H248 off the coast of Vancouver Island.126-128  Only spiroxin A (156) was tested for biological 
effects and displayed anti-tumor and antibacterial activity against gram positive bacteria.  
Spiroxin A (156) induced single strand cleavage of double stranded DNA in the presence of 
thiols, which could account for its anti-tumor activity.  The absolute configuration was 
determined through exciton coupled CD spectroscopy.129   
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Figure 8.6.  Type III bisnaphthospiroketals 
 
The only reported total synthesis of a spiroxin was published in 1999 by the Imanishi 
group (Scheme 8.3).130  The synthesis of spiroxin C (157) commenced with standard oxidative 
conditions to afford hemiacetal 161 from 160.  Bromoetherification followed by epoxidation 
delivered bromide 163.  The epoxidation of bromide 163 occurred stereoselectively on the 
convex face.  Protecting group manipulation, enone formation and a final stereoselective 
epoxidation delivered spiroxin C (157) in 15 steps and 0.6% overall yield.   
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Scheme 8.3.  Imanishi's spiroxin C (157) synthesis 
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9.0  THIOREDOXIN/THIOREDOXIN REDUCTASE 
9.1 TRX/TRXR BACKGROUND 
The thioredoxin-thioredoxin reductase (Trx/TrxR) complex is a homodimeric flavoprotein 
present in both eukaryotic and prokaryotic cells.131  The complex was first studied in E. coli and 
differences between the bacterial and human Trx/TrxR were discovered shortly afterwards.132-139  
In humans, thioredoxin is one of over 25 selenocysteine containing proteins known.140  In other 
species, the Trx/TrxR selenocysteine is replaced with the more common cysteine residue.141-143  
These proteins regulate a variety of essential enzymes and processes through a series of 
oxidations and reductions.   
Trx/TrxR is essential for cell function and survival and hence an attractive medicinal 
target.144  This complex relies on thioredoxin, thioredoxin-reductase, FAD and NADPH to 
initiate the flow of electrons (Figure 9.1).141  TrxR reduces the Trx dithiane to a thiol.  In the 
reduced state, Trx activates a plethora of different enzymes.145  Examples include the initiation of 
DNA synthesis through activation of ribonucleotide reductase,141,146 the regulation of gene 
transcription factor binding to DNA,147,148 and the growth factor properties of Trx/TrxR.131  
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Figure 9.1.  Trx/TrxR redox cycle 
 
A crystal structure increases the appeal of an enzyme as a target for the medicinal 
chemist.149  Human TrxR-1 has been crystallized in 2.8 Å resolution with bound NADP+ (blue) 
and FAD (yellow) (Figure 9.2).150  The active site in thioredoxin contains a conserved Cys-Gly-
Pro-Cys-Lys sequence located on the flexible solvent exposed side arm of the protein.131  The N- 
and C- terminal active redox centers are displayed in green and marked as NR and CR 
respectively.  This orientation permits access for potential inhibitors.  The active site was 
compared to glutathione reductase, another common and important cellular anti-oxidant protein 
involved in the synthesis of proteins, catalysis, metabolism and transport.151  Binding site 
comparisons revealed unique binding pockets available to Trx inhibitors and could assist in the 
systematic development of selective inhibitors.  
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Figure 9.2.  Crystal structure of hTrx homodimer150 
9.2 TRX/TRXR AS THERAPEUTIC TARGET 
Trx/TrxR is increasingly considered a drug target because it is involved in many crucial 
biological pathways.150,152-159  It has implication in cancer, HIV-AIDS, rheumatoid arthritis and 
other medical conditions.160,161  There are two isoforms of thioredoxin: Trx-1 is found in the 
cytoplasm and the nucleus of cancer cells, and Trx-2 is found in the mitochondria.141,162  Trx-1 
and Trx-2 differ in size, 105 and 166 amino acids, respectively, and each have distinct TrxR’s 
associated with them.   
The dichotomy of thioredoxin’s role in cancer proliferation is noteworthy.  Trx/TrxR 
protects against cancer by disabling DNA damaging oxidizers, activating gene transcription for 
antioxidative proteins and activating p53.163  P53 is a crucial transcription factor that acts as a 
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guardian for the genome via cell cycle regulation and tumor suppression.  P53 is critical to the 
cell’s anticancer measures because it signals DNA repair proteins, pauses the cell cycle at the 
G1/S regulation point for DNA damage repair and initiates apoptosis.164,165  After tumor 
formation, Trx/TrxR’s role shifts from protector to bad actor.  The complex acts as a tumor 
growth factor, becomes responsible for supplying deoxyribonucleotides for tumor growth and 
protects the tumor against NK lysin tumor necrosis factor166 and the immune system.167  The 
expression of Trx-1 is 10 fold higher in cancer cells than in normal cells, making this system a 
natural target to combat the growing tumor.168-170   
A myriad of Trx/TrxR inhibitors have been developed for cancer therapy (Figure 9.3).  
One series of Au (I) and Au (III) compounds inhibits Trx/TrxR in the low μM range.171-173  A 
well known example is auronafin (166), which traditionally has been used in arthritis 
therapy.174,175  Palmarumycin CP1 (139),176,177 BCNU,178 organotellerium 167179 curcumin,180 a 
wide assortment of quinones and naphthoquinones,181-183 quinol 168184,185 and many other 
examples186-191 have been shown to inhibit the Trx/TrxR complex.   
  
 
Figure 9.3.  Trx/TrxR inhibitors 
 
Quinol 168 is one member from a library of heteroaromatic substituted quinols 
synthesized in pursuit of anticancer activity from the laboratory of Dr. Malcolm Stevens (Figure 
9.3).185  Phenols are susceptible to first pass metabolism and there are numerous in vivo 
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processes that can modify the phenol moiety such as methylation, oxidation, glucuridination or 
acetylation.192-194  These phenolic modifications can be the source of inconsistencies between in 
vivo and in vitro data or a short plasma half life.195,196  However, in some systems these cellular 
modifications of the phenol are the true source of biological activity.  There are reports where the 
biological activity is dependent on phenol oxidation to a quinine or quinol.197,198  The Stevens 
group investigated the phenol oxidation to the quinine or quinol of a series of biologically active 
phenols in pursuit of enhanced biological activity.185  Quinol 168 was one of the synthesized 
compounds and found to have a very good antiproliferative and cytotoxic profile with a mean 
GI50 of 0.23 μM and a mean LC50 of 3.39 μM.  This work highlights how small molecule 
quinones or quinols can be very potent anticancer agents.   
A diverse set of in vitro Trx/TrxR inhibitors has been developed, but in vivo data are 
scarce.  Selectivity, solubility, potency and ease of synthetic availability are obstacles that need 
to be overcome to produce a viable drug.  The therapeutic potential of this target combined with 
as of yet unmet clinical applications inspired the Wipf group to become involved in this area of 
research.  
9.3 EARLY WIPF GROUP WORK WITH TRX/TRXR INHIBITORS 
The Wipf group previously reported that the type I bisnaphthospiroketal pharmacophore leads to 
promising biological activity.176  In 2001, deoxypreussomerin A, palmarumycin CP1 (139) and a 
library of palmarumycin analogues were synthesized and tested against two human breast cancer 
cell lines.177  Several analogues were more cytotoxic and as potent as pleurotin (169, Figure 9.4) 
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at inhibiting Trx/TrxR.176,177  Pleurotin was the most potent Trx/TrxR inhibitor known at the time 
with an IC50 of 0.17 μM.176,199,200   
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Figure 9.4.  Pleurotin, a potent Trx/TrxR inhibitor 
 
The Wipf group recently reported a new series of palmarumycin CP1 analogues.  The 
compound identification number from the published paper is shown in parentheses (Figure 
9.5).119  The double bond of the enone was functionalized with substituents such as bromine 
(171), 2-furyl (172) and pyridyl (173).  The lower naphthalene moiety was functionalized with a 
methyl ether (170-174), benzyl ether (175) and a free hydroxyl group (176 and 177).  The 
synthesized compounds were submitted to the laboratory of Dr. Garth Powis for biological 
testing.   
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Figure 9.5.  Early palmarumycin analogues 
 
The palmarumycin CP1 (139) analogues were similarly potent inhibitors, but the two 
most potent analogues were 176 and 177 (Table 9.1).  Although 176 and 177 shared a similar 
biological profile, the limited solubility of 177 raised questions concerning its actual activity and 
prevented efficacy in mouse models.  A library of prodrugs of 177 was synthesized to address 
the issue of low water solubility.201 
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Table 9.1.  IC50 (μM) values for Trx-1/TrxR inhibition and cell growth inhibition 
Entry Compound  Trx/TrxR MCF-7 
1 Pleurotin 0.17 4.1 
2 Palmarumycin CP1 0.35 1.0 
3 170 3.2 9.2 
4 171 3.1 2.6 
5 172 6.4 6.0 
6 173 5.0 1.6 
7 174 1.0 14.0 
8 175 5.2 14.2 
9 176 0.34 2.8 
10 177 0.2 2.6 
 
9.4 SYNTHESIS OF PALMARUMYCIN PRODRUGS 
9.4.1 Introduction and history of prodrugs 
A variety of factors can hinder the application of a potential drug.202,203  Among these factors are 
low aqueous solubility,204 poor absorption and distribution,205 low patient acceptability and 
formulation problems.206,207  Additional attributes that hurt a potential drug are lack of selectivity 
for the target tissue, taste and odor or volatility.208  A way to bypass several of these pitfalls is 
via the synthesis of prodrugs.   
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The term prodrug was first coined in 1958 by Albert209 and defined as a 
pharmacologically inactive, or less active, compound that is converted into a biologically active 
drug via a metabolic biotransformation by, for example, cytochrome P 450,210 antibodies211,212 
esterases,213,214 or a non-enzymatic process, such as hydrolysis.206  Prodrugs can be designed to 
improve physiochemical properties, increase oral absorption,215 increase site specificity by only 
being unmasked by enzymes located at the target site216-218 and attenuate the desired dose 
through slow release of the active compound.219-221   
A plethora of groups have been used to convert drugs into prodrugs such as phosphonate 
or phosphate esters,222,223 amino acid esters,224 phenolic acetates225-228 and others.229,230  There are 
many prodrugs on the market (Figure 9.6).202,231  Merck’s ACE inhibitor enalapril (178)232 and 
Glaxo Smith Klein’s anti-viral valaciclovir (179)233 are both converted to their active form by 
esterases for improved oral bioavailability and activity, respectively.   The anti-Parkinson’s drug 
levodopa (180) is converted to dopamine by DOPA decarboxylase234  after crossing the blood-
brain barrier.235,236  The anti-microbial chloramphenicol (181) succinate ester has improved water 
solubility over the active compound, chloramphenicol (181).237  Codeine (182) is demethylated 
by the liver enzyme CYP2D6 to give morphine.238,239  These are only a few examples where a 
prodrug improves the properties and pharmacological profile of a drug.  
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Figure 9.6.  Commercially available prodrugs 
 
In order to increase the in vivo activity of these promising, yet very hydrophobic, 
spiroketal agents, these compounds were functionalized with charged moieties at the phenol 
oxygen for improved water solubility.240  The palmarumycin core 177 was first synthesized 
according to the reported protocol.119 
9.4.2 Synthesis of spiroketal 177 
The synthesis of 177 followed the previously reported synthetic route (Scheme 9.1).119  
Bromofluorobenzaldehyde 183 was reduced, brominated and treated with allyl magnesium 
bromide to afford the alkene.  Hydroboration of the introduced alkene and Jones oxidation 
afforded acid 184.  Cyclodehydration with PPA, α-bromination and subsequent elimination 
afforded naphthol 185.  MOM protection of the naphthol followed by formylation readily 
delivered naphthaldehyde 186 in 10 steps and 31% overall yield.   
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Scheme 9.1.  Synthesis of naphthyl fluoride 186 
 
The second etherification component, 191, was rapidly synthesized starting with 1,5- 
dihydroxynaphthalene (187) (Scheme 9.2).  Methylation, Vilsmeier-Haack formylation and 
deprotection of 187 afforded the needed naphthaldehyde 190.  This compound was selectively 
MOM protected to deliver naphthol 191 in four steps and 47% overall yield.   
 
  98
 
Scheme 9.2.  Synthesis of naphthaldehyde 191 
 
Using both substrates, the SNAr biaryl ether synthesis was performed (Scheme 9.3).  The 
etherification of 191 and 186 proceeded smoothly with Barton’s base to deliver 192 in 54% 
yield.241  A Dakin reaction delivered naphthol 193 which was oxidized with PIFA to afford 
spiroketal 194.  One MOM group was lost during the cyclization, which can be attributed to trace 
amounts of water and the acidity of the PIFA conditions.  Treatment of 194 with TMSBr 
followed by TBAF deprotected the MOM group and delivered the target structure 177. 
 
  99
 
Scheme 9.3.  Synthesis of palmarumycin analogue 177 
 
The PIFA or PIDA mediated oxidative cyclization has been used in many Wipf group 
publications.59,242-244  The proposed mechanism for the formation of 194 is that an attack of the 
naphthol oxygen on PIFA (196) affords the reactive O-I bonded intermediate 197 (Figure 9.7).245  
The naphthol oxygen on the lower ring in 197 then attacks para to the O-I bond generating 
naphthoquinone 195.  As stated earlier, the MOM group on the naphthoquinone is acid sensitive 
and is hydrolyzed under standard PIFA conditions to afford 194.  
 
  100
HO
I
PhCF3CO2
O2CCF3
O
I
O2CCF3
Ph O
O O
OHO OHO
Ph
I
CF3CO2
CF3CO2
MOMO MOMO MOMO
193
196
197 195
OMOM OMOM
OMOM
 
Figure 9.7.  PIFA mediated oxidative cyclization of 193245 
 
PIFA is an environmentally benign, commercially available and relatively non-toxic 
oxidant, but the reaction conditions are sometimes difficult to optimize.246  The major side 
product isolated was juglone (198, Figure 9.8), presumably from oxidation and fragmentation of 
193.  Quinones are ubiquitous building blocks in synthesis and a wide variety of preparations are 
available.247  Various oxidants, solvents, bases and temperatures were screened with hopes of 
improving the yield (Table 9.2).  PIFA (entries 1-9), Ag2O (entry 10),248 DDQ (entry 11),249 
benzoquinone (entry 12),125,250 Pb(OAc)4 (entry 13)251 and LiClO4 (entry 14)252 were 
investigated.  Water could mediate at least one decomposition pathway.  If water reacted with 
197 preferential to the naphthol, the resultant hemiketal would hydrolyze to the quinone during 
the reaction workup.  If this was the primary decomposition pathway, addition of a dehydrating 
agent, such as 4 Å molecular sieves, should improve the reaction efficiency.  The yield did not 
greatly improve with 4Å molecular sieves, and the primary difference was the isolation of both 
195 and 194 (entry 15).     
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Figure 9.8.  Oxidation side product, juglone (198) 
 
Table 9.2.  Oxidative cyclization of 193 
Entry Conditions Yield of 194 [%]/Result 
1 PIFA (3 equiv), Cs2CO3, CH3CN, −20 °C 28 
2 PIFA (3 equiv), Cs2CO3 (6 equiv), CH3CN, 0 °C 32 
3 PIFA (3 equiv), K2CO3 (6 equiv), CH3CN, 0 °C 21 
4 PIFA (5 equiv), K2CO3 (10 equiv), CH3CN, 0 °C 15 
5 PIFA (1.3 equiv), K2CO3 (2.6 equiv), CH3CN, 0 °C 15 
6 PIFA (2 equiv), CH3CN, THF, H2O (1:4:4) Juglone (198) 
7 PIFA (2 equiv), TEMPO (0.5 equiv), CH3CN, rt Decomp 
8 TBS protected phenol, PIFA (2 equiv) NR 
9 PIFA (1 equiv), TMSOTf, CH3CN Decomp 
10 Ag2O NR 
11 DDQ Decomp 
12 Benzoquinone NR 
13 Pb(OAc)4 No desired product 
14 CH3CN, H2O, LiClO4, 1.5 V NR 
15 PIFA, CH3CN, 4Å mol sieves 26 
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Despite the extensive search for alternative conditions, the yields could not be increased 
nor could the major side reaction to juglone (198) be avoided.  The equivalents of PIFA in the 
presence of either K2CO3 or Cs2CO3 were varied.  The other oxidants screened either resulted in 
decomposition or no reaction (entries 10-14).  The original PIFA conditions were used for the 
synthesis 177.  Using these conditions, the synthesis was completed to produce 100 mg of 177.   
9.4.3 Generation I prodrugs 
Selective functionalization of spiroketals 176 and 177 at the phenol moiety with various Boc-
protected amino acids was desired.119,253  The esterification occurred selectively at the non-
hydrogen bonded naphthol even when two hydroxyl groups were present.  This selectivity was 
due to the attenuated nucleophilicity of the phenol hydrogen bonded to the carbonyl, which is a 
trend witnessed in other similarly functionalized scaffolds.254-256  This methodology was 
followed to functionalize both 176 and 177 with glycine, valine and morpholine side chains.  In 
Scheme 9.4, the first number in parentheses correlates to the numbers of the compounds in the 
published paper and the SML number correlates to the sample numbers the compounds were 
given prior to biological testing.201  Following esterification, 20% TFA in CH2Cl2 was used to 
remove the BOC group and afford the prodrug as the TFA salt.  These salts were pure according 
to 1H and 13C NMR spectral analysis and submitted directly to the biological assays.      
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Scheme 9.4.  Synthesis of 177 prodrugs 
 
In addition to amino esters, the introduction of a tertiary amine in the form of a 
morpholine was likewise pursued (Scheme 9.4).  Once again, monoetherification at the hydroxyl 
group distal from the carbonyl was observed.  Unlike the amino esters, the ether linkage is not 
readily cleaved to release the parent compound.  The morpholine moiety was selected to improve 
water solubility and decrease plasma protein binding.257  Previous SAR studies indicated that the 
naphthalene diol substructure is primarily solvent exposed and can tolerate modifications without 
adversely affecting the biological activity.119,176,177  Hence, it was believed that the role of the 
morpholine moiety would be solely to improve the water solubility.   
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All prodrugs were submitted to the laboratory of Dr. Garth Powis for biological testing.  
The tests were performed with an estrogen positive, p53 positive human breast cancer cell 
line.258  The cells were seeded at 4,000 cells/well in 96 well titer plates and allowed to attach 
overnight.  After the cells were exposed to the prodrugs for 72 h, the viable cells were stained 
with 3-[4,5]-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT).  When MTT is 
reduced by the mitochondria, it forms non-water soluble violet crystals in the cell.259,260  The 
plates were incubated for three h in the dark and the reduced MTT in the cells was measured 
spectrophotometrically at 540 nm.261  All compounds were cytotoxic against the MCF-7 cell line 
with activities in the low μM range with compounds 200 and 202 being the most active (Table 
9.3).   
The Trx/TrxR inhibition of the prodrugs was also measured.  All of the Trx/TrxR 
activities were measured in microtiter plate calorimetric assays using purified human placenta 
Trx and recombinant human Trx.262  In these assays, dithionitrobenzoic acid (DTNB), also 
known as Ellman’s reagent,263 is reduced via the enzyme mediated transfer of electrons from 
NADPH.  The reduction of DTNB correlates to the increase of absorbance at 405 nm and 
indicates TrxR activity.  Trx activity was measured via the Trx dependent reduction of insulin in 
the presence of TrxR and NADPH.  DTNB reduction at the end of incubation was used to detect 
Trx activity.  The in vitro tests of the prodrugs generated greater variability (Table 9.3).  The in 
vitro results of 201 were equipotent with 177, but many of the other prodrugs did not match the 
activity of 177.   
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Table 9.3.  IC50 values (μM) for TrxR and human breast cancer growth inhibition 
Entry Compound TrxR inhibitory activity 
(±SEM) 
MCF-7 Growth Inhibition (±SEM) 
1 177 0.20 ± 0.01 2.6 ± 0.1 
2 199 (SML-152) 1.8 ± 0.1 2.4 ± 0.1 
3 200 (SML-154) 0.62 ± 0.06 2.2 ± 0.1 
4 201 (SML-16) 0.28 ± 0.04 3.1 ± 0.3 
5 202 (SML-135) 1.6 ± 0.1 1.2 ± 0.3 
6 203 (SML-230) 4.2 ± 0.3 2.6 ± 0.6 
SEM = the standard error of the mean from three separate experiments 
 
The spontaneous hydrolysis of 201 during the enzyme assays was likely the source of 
some of the released active drug.  The t1/2 of 201 in water at room temperature with different pHs 
was measured.119  At pH 4 and 7 the t1/2 was 37 h and <1 h respectively.  The t1/2 in mouse 
plasma was <2 min.  The short t1/2 at pH 7 does not present a problem clinically because a 
formulation of 201 at pH 4 can be administered to patients.  It was established according to 
HPLC analysis that the consumed prodrug was releasing 177, as opposed to proceeding via an 
unproductive pathway or decomposing.  The water solubility of 201 and 177 was measured to be 
0.7 and <0.1 mg/mL, respectively.  The improved water solubility of 201 validated the 
hypothesis that incorporation of amino esters can deliver prodrugs of greater water solubility 
than 177.  The excellent water solubility and promising in vitro results led to the selection of 201 
for further biological testing in vivo against A-673 rhabdomyosarcoma in beige nude mice.    
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9.5 SEPARATION OF ENANTIOMERS OF 177 
All chiral spiroketals were submitted for biological testing as racemic mixtures.  Separation of 
the enantiomers of spirocycle 177 and testing of their individual biological activity was of 
interest.  The most direct approach was a separation by chiral column HPLC.  A Chiralcel AD-H 
column separated the enantiomers of 177 with retention times of 8.5 and 11.24 min.  However, a 
preparative separation was limited by the low solubility of 177 of 1 mg/1.5 mL in a 15% i-PrOH/ 
hexanes solution.  The low solubility that plagued the biological testing likewise hampered 
efforts towards chiral separation on quantities larger than several milligrams.  A series of related 
analogues was therefore synthesized with the goal of improved solubility and good separation on 
the chiral column. 
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Scheme 9.5.  Mono and bis-acetylated 177 
 
The mono- and bis-acetylation of 177 was first synthesized for improved solubility and 
ultimate separation of the enantiomers during chiral chromatography (Scheme 9.5).  The mono- 
acetate 205 was readily synthesized in 2 h by treating 177 with Ac2O in pyridine.  The assigned 
regioselectivity was based upon the chemical shifts of the phenol protons in 1H NMR.  The 
phenol hydrogen bonded to the carbonyl in 177 is at δ 12.18 whereas the non-hydrogen bonded 
phenol is at δ 8.99 in the 1H NMR.  The only phenol signal in the 1H NMR spectra of 205 is at δ 
12.15 which correlates to the hydrogen bonded phenol and hence the non-hydrogen bonded 
phenol is presumably acetylated.  The bis-acetate 204 required 12 h for the less reactive phenol 
to be acetylated.  Chiral HPLC conditions were screened with varying concentrations of i-PrOH 
in hexanes, but separation was not achieved.  Bis-acetate 204 eluted in 10% i-PrOH in hexanes at 
  108
31.2 min as a single peak.  Mono-acetate 205 eluted in 10% i-PrOH in hexanes as 2 unresolved 
peaks at 17.0 and 17.5 min.  Other groups tethered to the 177 core were also explored.  Mono-
MOM protected 194 possessed a prohibitively long retention time for the separation of 
enantiomers, 35.8 min in 0.5% i-PrOH in hexanes.  The free-based glycine prodrug 201 was 
unsuitable for chiral separation due to decomposition on the column.  Ultimately, the best option 
was to separate 177 in small batches until 1 mg of each enantiomer was collected.  The back up 
option would have been to esterify 177 with a chiral resolving agent, such as Mosher’s ester.264  
Isolation of 0.5 mg of each 177 enantiomer was achieved on the Daicel AD-H analytical column, 
and in vitro biological testing established that both enantiomers demonstrated comparable 
activity.  This supports the earlier stated hypothesis that the naphthalene diol does not participate 
in active site bonding or engage in any interactions critical for efficacy.119             
In conclusion, a library of palmarumycin CP1 analogues was synthesized in a rapid and 
efficient manner.  The biological activity of the members was tested, and many members had 
improved solubility compared to spirocycle 177 while maintaining good to moderate biological 
activity in the inhibition of thioredoxin-thioredoxin reductase system.  As a follow up to earlier 
studies, the enantiomers of 177 were separated and shown to exhibit similar biological activity. 
9.6 GENERATION II PRODRUGS 
9.6.1 Amino acid containing prodrugs 
The biological results from the first batch of prodrugs shown in Table 9.3 led to the pursuit of the 
synthesis of a series of prodrugs that was more resistant to metabolic cleavage.201  The primary 
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reason was to address the inconsistencies between the Trx inhibitory action and the MCF-7 
growth inhibition.  The rapid degradation of amino acids by peptidases can account the 
inconsistencies.  For greater stability against proteolytic enzymes, there is a history of 
incorporating nonproteinogenic amino acids into the prodrug scaffold.265,266  Clinically, sterically 
hindered amino esters can assist the prodrug in withstanding the acidic environment of the 
stomach and alkaline conditions of the intestines, and result in the absorption of the intact 
prodrug into the plasma.267  For greater stability in aqueous buffer, sterically hindered amino 
acids have been utilized to increase the half life of the prodrug to clinically viable times needed 
for administration to a patient.268  The goal was to synthesize a second generation library of 
prodrugs of 177 to overcome the low water solubility of 177 and produce an even stronger 
inhibitor of Trx/TrxR in both in vitro and in vivo assays.  
As an extension of the prodrug studies, a second generation series of esters of 177 with 
phenylglycine (206) and α-aminoisobutyric acid (AIB, 207) was synthesized.  Both substituents, 
in particular the AIB residue, add to the steric hindrance near the ester functionality and decrease 
the rate of hydrolytic cleavage.267  The amino esters were prepared using a similar protocol as for 
the generation I prodrugs.  BOC-protection of both amino acids afforded 207 and 209 in good 
yields (Scheme 9.6). 
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Scheme 9.6.  BOC-protection of AIB (208) and phenylalanine (206) 
 
DCC was the coupling reagent of choice for the esterification between the amino esters 
and 177 due to its previous success.  Protected phenylalanine (207) was esterified in good yield 
and the more hindered AIB analogue was obtained in moderate, but acceptable yield (Scheme 
9.7).  Once again, selective coupling occurred at the phenol that was not deactivated.  20% TFA 
in CH2Cl2 removed the Boc group and concentration under reduced pressure delivered the salts 
210 and 211.  These salts were pure according to 1H and 13C NMR analysis and submitted 
directly to the biological assays without further purification. 
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Scheme 9.7.  Prodrugs containing amino acids 207 and 209 
 
9.6.2 Carbohydrate linked prodrugs 
Prodrugs that were not based on amino ester substituents were also considered, such as 
glycosides.  A carbon-linked C-glycoside was of particular interest.269  This modification would 
introduce a very polar, non-cleavable group.  There are numerous approaches for C-glycoside 
synthesis, including the Stille coupling between tin glycals and sulfonyl chlorides270 or a cross 
metathesis between two olefins.271  The Wipf group has a history of C-glycoside synthesis and a 
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recent example involves the allyl silane addition into sugar 212 to afford C-glycoside 213 
(Scheme 9.8).272   
 
 
Scheme 9.8.  Synthesis of C-glycoside 213  
 
Glycosylated palmarumycin prodrugs are interesting for several reasons.  A variety of 
sugar containing cancer inhibitors has been reported in the literature, and the anti-cancer activity 
of N-acetyl-D-mannosamine n-butyrate esters was found to be dependent on the glycosyl residue 
(214, Figure 9.9).273  Carbohydrates have been used as prodrugs for a variety of applications 
including, but not limited to, improving solubility,274,275 biological site specificity,276 tumor 
therapy,277 GLUT-1 assisted transport across the blood brain barrier,278 and colon specific 
targeting.279  The improved water solubility of sugar-based prodrugs was of greatest interest.280 
 
 
Figure 9.9.  Sugar based cancer inhibitor 
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The phenol moiety was taken advantage of for glycosylation (Scheme 9.9).  Acidic 
conditions can be used to catalyze a sugar migration from the phenolic oxygen to the aromatic 
carbon.281  These protocols commenced with phenol glycosylation with glycosyl phosphates282 
fluorides283 or chloroimidates followed by acid promoted migration.284-286  The synthesis of C-
glycosides utilizing various sugars287 such as O-benzyl glucals,288 the 2-deoxy variants,289-291 and 
tetra-protected glucose were considered.  Ultimately, the most direct, readily modified and 
commercially available D-glucose was selected to glycosylate 177. 
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Scheme 9.9.  Proposed path to C-glycosylated 177 
 
The synthesis began with benzyl protected glucose 217 (Scheme 9.10).282  Treatment of 
217 with Ac2O and pyridine provided the anomeric acetate 218.  The glycosylation of 177 in the 
presence of BF3.OEt2,292 Sc(OTf)3293 and various drying agents294 failed to deliver the desired 
pyran migration.  O-glycosylated 215 could still provide the desired solubilizing effect and hence 
the removal of the benzyl protecting groups to generate the final prodrug was explored. 
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Scheme 9.10.  Glycosylation of 177  
 
Problems were encountered with the hydrogenation of the benzylic ethers.295  Palladium 
on carbon296 and Wilkinson’s catalyst297 were screened, but the starting material either remained 
or there was poor mass recovery.  The possibility of reducing the enone was a concern which 
could be addressed by transiently protecting the double bond with methanol123 or thiophenol.298  
However, these modifications were also unsuccessful.   
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Scheme 9.11.  Synthesis of acetylated imidate 223 
 
D-Glucose can be protected with acetyl groups and converted to the anomeric 
chloroimidate, fluoride287 or bromide299 in preparation for coupling.  Acetate 220 was 
synthesized by treating D-glucose (219) with acetic anhydride in pyridine (Scheme 9.11), but did 
not glycosylate 177.  The bromo derivative 221 was synthesized in good yield by treatment of 
220 with HBr in AcOH, but this compound also did not glycosylate 177.300  Acetate 220 was 
mono-deprotected with benzyl amine to give 222, and subsequently treated with 
trichloroacetonitrile to deliver the chloroimidate 223 in modest yield.   
Chloroimidate 223 was used to glycosylate 177 under standard Schmidt glycosylation 
conditions (Scheme 9.12).301  Instead of the desired O-C migration, only the O-glycosylated 
product was isolated.  The limitation of this migration with acetylated sugars has previously been 
noted in the literature and attributed  to the electron withdrawing nature of the acetates.302  When 
the acetates were exchanged to benzyl protecting groups, the migration proceeded.  O-
Glycosylated 224 was also a suitably soluble prodrug, and the acetate groups were removed with 
base.  There are some very mild methods for acetate removal.  It is possible to deprotect the 
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acetates from a sugar in the presence of sensitive moieties, such as a β-lactam, with NEt3, H2O 
and MeOH.303,304  NaOMe is also a common base used for the removal of acetate groups on a 
sugar.305,306  The deprotection was performed with NaOMe and a Dowex 50 x 8 quench to afford 
224, which was found to be soluble in water at a concentration of 1.4 mg/mL.   
 
 
Scheme 9.12.  Glycosylation of 177 and deprotection 
9.6.3 Biological data for generation II prodrugs 
The second generation prodrugs were submitted to the laboratory of Dr. Garth Powis for 
biological testing.  The relative metabolic stabilities of the new prodrugs were compared to the 
first generation glycine prodrug 201 (Table 9.4).  The entry numbers in parentheses in the table 
correspond to the code names given to the compounds prior to biological testing.  The prodrugs 
were incubated at 33 °C at a concentration of 1 mg/mL in ES1 mouse and human plasma and 
their stability was measured by calculating the formation of the parent drug over the first 20 min 
of incubation.  HPLC analyses of the mixture and comparison of the relative areas under the 
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generated peaks for the parent compound and starting prodrug provided information about the 
rate of hydrolysis.  The unit of “area/20 min” in the table refers to the area under the peak in the 
HPLC trace corresponding to parent compound 177 relative to the area under the peak in the 
HPLC trace corresponding to the prodrug after 20 min of incubation.  Therefore, a large area/20 
min value correlates to lower metabolic stability.  The two most promising new prodrugs were 
carbohydrate 224 and the AIB derivative 211.  Both agents were more stable in plasma than the 
lead compound 177 and were therefore selected for further biological testing.  The phenylalanine 
prodrug 210 had low water solubility and was not studied in mouse plasma.   
 
Table 9.4.  Relative plasma stabilities of prodrugs (in area/20 min) 
Entry Mouse plasma  
(area/20 min) 
ES1 mouse plasma 
(area/20 min) 
Human plasma 
(area/20 min) 
201 (3-SML-16) 350 210 135 
224 (EEE-86-III) 20 17 70 
211 (EEE-263-II) 42 82 81 
210 (EEE-273-II) 19 n.a. n.a 
 
In addition to the biological studies, the logP values of the prodrugs were calculated.  The 
LogP value predicts the water solubility of a molecule.  The logP is a partition coefficient for the 
concentration of a given compound between octanol and water.  Most optimally soluble drugs 
fall into the logP range of 0-3,215 and the Lipinski rules state that the logP of a viable drug 
candidate should be less than 5.307  One method to calculate logP is based on work by Cates and 
evaluates the hydrophobic and hydrophilic properties of each functional group.308  There are also 
various computer programs available for the calculation of log P such as ALOGPs at the Virtual 
Computational Chemistry Lab (www.vcclab.org).  This program was developed with 12908 
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molecules from the PHYSPROP database using 75 E-state indices.  Sixtyfour neural networks 
were trained using 50% of molecules selected by chance from the whole set.309-311  The logP 
values for 201, 211, 210 and 224 were calculated to be 1.90 ± 1.49, 2.53 ± 1.53, 3.64 ± 1.73 and 
2.24 ± 0.89.  A low level calculation of log P using ChemBioDraw Ultra 11.0 predicted the logP 
values of 201, 211, 210 and 224 to be 1.74, 2.14, 3.13 and 1.95 respectively.  Both programs 
predicted that the phenylalanine prodrug 210 would be the least soluble in water, which is an 
attribute that was observed experimentally (Table 9.5).  
The water solubilities of the AIB 211, sugar 224 and phenylalanine 210 prodrugs were 
experimentally determined and compared to the solubility of the glycine prodrug 201 (Table 
9.5).119  Compound 177 and generation I prodrug 201 have a water solubility of <0.1 mg/mL and 
0.7 mg/mL, respectively.  The water solubilities of the generation II prodrugs 211, 224 and 210 
were 4.5, 1.4 and <0.1 mg/ mL, respectively.  Prodrug 210 had a low water solubility, a property 
that hampered biological testing, of <0.1 mg/mL.  Gratifyingly, the other prodrugs had improved 
water solubility.  
 
Table 9.5.  Water solubility of prodrugs 
Compound Solubility (mg/mL) 
201 0.7 
211 4.5 
224 1.4 
210 <0.1 
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10.0  SYNTHESIS OF 177 & PRODRUGS EXPERIMENTAL PART 
General:  All moisture sensitive reactions were performed in flame-dried or oven-dried 
glassware under a nitrogen atmosphere.  THF and Et2O were distilled over Na/benzophenone, 
while pyridine and triethylamine were distilled over CaH2.  Hexanes and ethyl acetate were 
distilled prior to use.  All other reagents and solvents were used as received unless otherwise 
noted.  Analytical thin layer chromatography was performed on pre-coated silica gel 60 F-254 
plates available from Merck.  Flash chromatography was performed using silica gel (230-400 
mesh) available from Baker.  NMR spectra were recorded in CDCl3 (unless otherwise noted) at 
300 MHz for 1H NMR and 75 MHz for 13C NMR using a Bruker Avance 300 with XWIN-NMR 
software.  Chemical shifts (δ) are expressed relative to the NMR solvent peak.  IR spectra were 
obtained with a Nicolet Aviator 360 FT-IR, ATR-IR spectra were measured with a Smiths 
IdentifyIR, optical rotations were measured with a Perkin-Elmer 241 polarimeter and mass 
spectra were obtained on a double focusing instrument.  EI mass spectra were obtained with VG 
Autospec and ESI mass spectra with Q-TOF API US. 
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(5-Bromo-2-fluorophenyl)methanol.312  A solution of 5-bromo-2-fluorobenzaldehyde (183) (25 
g, 0.12 mol) in MeOH (310 mL) was cooled to 0 °C and treated with NaBH4 (6.1 g, 0.16 mol) in 
4 batches over 10 min.  The reaction mixture was stirred for 20 min, quenched with 1.0 M HCl 
and extracted with Et2O (2x).  The combined organic extracts were dried (MgSO4), filtered and 
concentrated under reduced pressure to afford the benzyl alcohol 183 as a light yellow oil which 
was used without further purification:  Rf 0.1 (19:1, hexanes:EtOAc);  1H NMR δ  7.59 (dd, 1 H, 
J = 6.6, 2.4 Hz), 7.41-7.36 (m, 1 H), 6.93 (t, 1 H, J = 9.0 Hz), 4.96 (bs, 1 H), 2.02 (bs, 2H). 
   
Br
F
Br
 
4-Bromo-2-(bromomethyl)-1-fluorobenzene.312  A solution of (5-bromo-2-
fluorophenyl)methanol (25.0 g, 0.123 mol) in THF (245 mL) was cooled to 10 °C and treated 
with PPh3 (33.1 g, 0.126 mol) followed by NBS (21.5 g, 0.121 mol).  The reaction mixture was 
warmed to room temperature, stirred for 30 min, concentrated under reduced pressure and 
purified by column chromatography on SiO2 (19:1, hexanes:EtOAc) to afford 22.8 g (68%) of 
the benzyl bromide as an orange oil:  Rf 0.7 (19:1, hexanes:EtOAc);  1H NMR δ 7.52 (dd, 1H, J 
= 6.6, 2.5 Hz), 7.41 (dd, 1 H, J = 9.0, 6.6, 2.5 Hz), 6.96 (t, 1 H, J = 9.0 Hz), 4.44 (s, 2H).   
 
Br
F  
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4-Bromo-2-(but-3-enyl)-1-fluorobenzene.  A solution of 4-bromo-2-(bromomethyl)-1-
fluorobenzene (22.8 g, 83.8 mmol) in THF (95 mL) was cooled to 0 °C, treated with a 1.0 M 
solution of allyl magnesium bromide in THF (125.4 mL, 0.1254 mol), warmed to room 
temperature and stirred for 1 h.  The reaction mixture was cooled to 0 °C, quenched with sat. 
NH4Cl, diluted with H2O, and extracted with Et2O (2x).  The combined organic extracts were 
dried (MgSO4), filtered and concentrated under reduced pressure to afford 19.2 g (quant.) of the 
olefin as a clear oil which was used without further purification.  An analytically pure sample 
was obtained by column chromatography on SiO2 (9:1, hexanes:EtOAc):  Rf 0.8 (9:1, 
hexanes:EtOAc);  1H NMR δ 7.32-7.25 (m, 2H), 6.89 (t, 1H, J = 9.0 Hz), 5.89-5.73 (m, 1 H), 
5.11-4.96 (m, 2 H), 2.70 (t, 2 H, J = 7.7 Hz), 2.38-2.25 (m, 2 H);  MS (EI) m/z (rel intensity) 228 
(M+,6), 189 (70), 187 (73), 108 (100), 107 (80);  HRMS (EI) calculated for C10H10BrF 227.9950, 
found 227.9948. 
 
 
4-(5-Bromo-2-fluorophenyl)butan-1-ol.  A solution of 4-bromo-2-(but-3-enyl)-1-fluorobenzene 
(19.20 g, 84.21 mmol) in THF (76 mL) was slowly transferred to a 2.0 M solution of BH3.DMS 
in THF (82.9 mL, 0.166 mol) at 0 °C.  The reaction mixture was warmed to room temperature, 
stirred for 2 h, cooled to 0 °C and quenched with 2.0 N NaOH (136.9 mL), which resulted in a 
large amount of gas evolution.  The reaction mixture was treated with 30% H2O2 (91.24 mL), 
stirred at room temperature for 12 h, diluted with H2O and extracted with Et2O (2x).  The 
combined organic extracts were washed with sat. NH4Cl , H2O and brine, dried (MgSO4), filtered 
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and concentrated under reduced pressure to afford the alcohol as a clear oil which was used 
without further purification:  Rf 0.4 (7:3, hexanes:EtOAc);  1H NMR δ 7.32-7.23 (m, 2 H), 6.88 
(t, 1 H, J = 9.0 Hz), 3.66 (t, 2 H, J = 6.2 Hz), 2.63 (t, 2 H, J = 7.1 Hz), 1.70-1.55 (m, 4 H);  MS 
(EI) m/z (rel intensity) 246 (M+, 22), 200 (85), 187 (54), 149 (53), 134 (35), 109 (58), 108 (90), 
107 (100);  HRMS (EI) calculated for C10H12BrFO 246.0056, found 246.0464.    
 
 
4-(5-Bromo-2-fluorophenyl)butanoic acid (184).  A solution of CrO3 (16.72 g, 0.1672 mol) in 
H2O (60.8 mL) was cooled to 0 °C and treated with concentrated H2SO4 (15.2 mL).  A solution 
of 4-(5-bromo-2-fluorophenyl)butan-1-ol (84.21mmol) in acetone (380 mL) was cooled to 0 °C, 
treated with the chromium solution dropwise via addition funnel, stirred for 1 h, warmed to room 
temperature and stirred for 1 h.  The reaction mixture was cooled back to 0 °C and quenched 
dropwise with i-PrOH until the precipitation of dark green solids ceased.  The reaction mixture 
was filtered through celite, washed with acetone and concentrated under reduced pressure.  The 
filtrate was dissolved in Et2O and extracted with 10% NaOH.  The aqueous extract was washed 
with Et2O, acidified to pH 2 with HCl (conc.) and extracted with Et2O (2x).  The combined 
acidified organic extracts were dried (MgSO4), filtered and concentrated.  Recrystallization 
(hexanes) of the crude product afforded 6.9 g (36%) of acid 184 as a white solid:  Rf 0.3 (7:3, 
hexanes:EtOAc); 1H NMR δ 7.33-7.27 (m, 2 H), 6.91 (t, 1 H, J = 9.0 Hz), 2.68 (t, 2 H, J = 7.6 
Hz), 2.40 (t, 2H, J = 7.5 Hz) 1.95 (app pent, 2 H, J = 7.5 Hz);  MS (EI) m/z (rel intensity) 260 
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(M+, 25), 201 (71), 200 (72), 189 (52), 187 (54), 108 (87), 107 (100);  HRMS (EI) calculated for 
C10H10BrFO2 259.9848, found 259.9852.  
 
 
8-Bromo-5-fluoro-3,4-dihydronaphthalen-1(2H)-one.  H3PO4 (sat, 30.8 mL) was treated with 
P2O5 (69.3 g, 0.488 mol) with continuous stirring to afford a thick solution of PPA.  Acid 184 
(3.84 g, 14.8 mmol) was added to the freshly prepared PPA solution, heated to 120 °C for 1.5 h, 
cooled to room temperature and poured into an ice/H2O mixture.  The suspension was agitated 
until all the solids dissolved and extracted with Et2O (2x).  The combined organic extracts were 
washed with 5% NaOH, dried (MgSO4), filtered and concentrated under reduced pressure to 
afford 2.281 g (64%) of the product as an orange solid which was used without further 
purification.  An analytically pure sample was attained by column chromatography on SiO2 (4:1, 
hexanes:EtOAc):  Rf = 0.6 (7:3, hexanes:EtOAc);  1H NMR δ 7.54 (dd, 1H, J = 8.7, 5.1 Hz), 
7.05 (t, 1 H, J = 8.7 Hz), 2.97 (t, 2H, J = 6.2 Hz), 2.71 (t, 2 H, J = 6.2 Hz), 2.14 (pent, 2 H, J = 
6.2 Hz);  MS (EI) m/z (rel intensity) 242 (M+, 37), 227 (5), 216 (46), 214 (49), 186 (24), 133 
(35), 107 (100), 81 (39);  HRMS (EI) calculated for C10H8BrFO 241.9743, found 241.9733.      
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8-Bromo-5-fluoronaphthalen-1-ol (185).  A solution of 8-bromo-5-fluoro-3,4-
dihydronaphthalen-1(2H)-one (2.28 g, 9.43 mmol) in THF (42 mL) was treated with 
trimethylphenylammonium tribromide (3.52 g, 9.37 mmol) and white solids precipitated out of 
solution.  The reaction mixture was stirred for 30 min, quenched with H2O and extracted with 
EtOAc (2x).  The combined organic extracts were washed with H2O, dried (MgSO4), filtered and 
concentrated under reduced pressure.  A solution of the crude product in DMF (42 mL) was 
treated with LiBr (1.70 g, 19.6 mmol) and Li2CO3 (2.22 g, 30.0 mmol), and heated to 130 °C for 
1 h.  The reaction mixture was cooled to room temperature, filtered and washed with EtOAc (80 
mL, 3x).  The EtOAc filtrate was washed with H2O (80 mL, 3x), dried (MgSO4), filtered and 
concentrated under reduced pressure to afford 0.850 g (40%) of the naphthol as an off white 
solid:  Rf 0.4 (4:1, hexanes:EtOAc);  1H NMR δ 8.10 (s, 1 H), 7.73 (d, 1 H, J = 8.3 Hz), 7.56 (dd, 
1H, J = 8.3, 5.8 Hz), 7.48 (t, 1 H, J = 8.1 Hz), 7.15 (d, 1 H, J = 8.1 Hz), 6.97 (dd, 1 H, J = 9.6, 
8.3 Hz).        
 
 
4-Bromo-1-fluoro-5-(methoxymethoxy)naphthalene.  A solution of naphthol 185 (0.850 g, 
3.73 mmol) in DMF (17.8 mL) was cooled to 0 °C, treated with NaH (60% dispersion in mineral 
oil, 0.14 g, 3.6 mmol) warmed to room temperature, stirred for 30 min and cooled back to 0 °C.  
The reaction mixture was treated with MOMCl (0.38 mL, 5.0 mmol), warmed to room 
temperature, stirred for 30 min, cooled to 0 °C and quenched with H2O.  It was extracted with 
EtOAc (3x), dried (MgSO4), filtered and concentrated under reduced pressure.  Purification by 
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column chromatography on SiO2 (9:1, hexanes:EtOAc) afforded 0.709 g (67%) of the 
naphthalene as a yellow solid:  Rf  0.6 (9:1, hexanes:EtOAc);  1H NMR δ 7.79 (dt, 1 H, J = 8.4, 
1.0 Hz), 7.69 (dd, 1 H, J = 8.3, 5.4 Hz), 7.47 (t, 1 H, J = 8.1 Hz), 7.26 (bd, 1 H, J = 7.7 Hz), 6.97 
(dd, 1 H, J = 9.6, 8.3 Hz), 5.34 (s, 2 H), 3.60 (s, 3 H). 
 
 
4-Fluoro-8-(methoxymethoxy)naphthalene-1-carbaldehyde (186).  A solution of 4-bromo-1-
fluoro-5-(methoxymethoxy)naphthalene (4.589 g, 1.616 mmol) in Et2O (92 mL) was cooled to 
−78 °C and treated with a 1.7 M solution of t-BuLi in pentane (20.7 mL, 35.2 mmol) dropwise.  
The reaction mixture was stirred for 15 min, treated with DMF (3.68 mL, 53.3 mmol), warmed 
to room temperature and stirred for 1 h.  The reaction mixture was quenched with H2O, extracted 
with EtOAc (2x), dried (MgSO4), filtered and concentrated under reduced pressure.  Purification 
by column chromatography on SiO2 (7:3, hexanes:EtOAc) afforded 3.0 g (79%) of 186 as a 
yellow solid:  Rf 0.3 (7:3, hexanes:EtOAc); 1H NMR δ 11.08 (s, 1 H), 7.99 (dd, 1 H, J = 8.4, 5.7 
Hz), 7.85 (d, 1 H, J = 8.4 Hz), 7.53 (t, 1 H, J = 8.1 Hz), 7.37 (d, 1 H, J = 7.5 Hz), 7.22 (d, 1 H, J 
= 8.4 Hz), 5.40 (s, 2 H), 3.54 (s, 3 H);  MS (EI) m/z (rel intensity) 234 (M+, 4), 189 (24), 133 
(100), 81 (39);  HRMS (EI) calculated for C13H11O3F 234.0692, found 234.0698. 
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1,5-Dimethoxynaphthalene (188).313  A dark purple solution of 1,5-dihydroxynaphthalene (187)  
(100 g, 0.63 moles) in 2.0 N NaOH (125 mL) at 0 °C was slowly treated with dimethyl sulfate 
(120 mL, 1.26 moles) in two 60 mL batches over 10 minutes.  The addition was very exothermic 
and light beige solids precipitated out of solution.  Additional H2O (100 mL) was added to the 
thick suspension.  The reaction mixture was stirred for 2 h, quenched with 2.0 M NaOH (120 
mL), diluted with water and extracted with CH2Cl2 (2x).  The combined organic extracts were 
dried (MgSO4), filtered, concentrated under reduced pressure and purified by chromatography on 
SiO2 (CH2Cl2) to afford 64 g (55%) of 188 as a beige solid:  Rf  0.6 (7:3, hexanes:EtOAc);  1H 
NMR δ 7.83 (d, 2 H, J = 8.4 Hz), 7.38 (t, 2 H, J = 8.1 Hz), 6.79 (d, 2 H, J = 8.1 Hz), 4.00 (s, 6 
H);  MS (EI) m/z (rel intensity) 188 (M+, 100), 173 (65), 115 (46); HRMS (EI) calculated for 
C12H12O2 188.0837, found 188.0833. 
 
 
4,8-Dimethoxynaphthalene-1-carbaldehyde (189).314  A suspension of naphthaldehyde 188 
(9.70 g, 50.6 mmol) in toluene (9.83 mL) and DMF (5.93 mL, 6.36 mmol) was cooled to 0 °C 
and treated with POCl3 (5.89 mL, 63.2 mol) dropwise.  The reaction mixture was stirred at 0 °C 
for 30 min, heated to reflux for 12 h, cooled to room temperature, poured into 2.0 N NaOH and 
extracted with EtOAc.  The combined organic extracts were washed with 1.0 N HCl, H2O and 
brine, dried (MgSO4), filtered and concentrated under reduced pressure to afford 9.26 g (83%) of 
189 as a light yellow solid:  Rf 0.4 (7:3, hexanes:EtOAc);  1H NMR δ 11.06 (s, 1 H), 8.08 (d, 1 
H, J = 8.4 Hz), 7.96 (dd, 1 H, J = 8.4, 0.9 Hz), 7.45 (t, 1 H, J = 8.1 Hz), 7.04 (d, 1 H, J = 7.8 Hz), 
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6.92 (d, 1 H, J = 8.4 Hz), 4.06 (s, 3 H), 4.02 (s, 3 H);  MS (EI) m/z (rel intensity) 216 (M+, 100), 
201 (31), 185 (26), 173 (25), 115 (80), 102 (34);  HRMS (EI) calculated for C13H12O3 216.0786, 
found 216.0785. 
 
 
4,8-Dihydroxynaphthalene-1-carbaldehyde (190).  A solution of naphthaldehyde 189 (9.26 g, 
42.9 mmol) in tetrachloroethane (89 mL) was treated with AlCl3 (26.88 g, 0.2013 mol) and 
heated to 75 °C for 1 h.  The reaction mixture was cooled to room temperature, poured into an 
ice and 1.0 M HCl mixture and stirred while dark green solids precipitated out of solution.  The 
solids were filtered, washed with H2O and dried under high vacuum to afford 7.784 g (91%) of 
carbaldehyde 190 as an off white solid:  1H NMR (DMSO-d6) δ 11.51 (s, 1 H), 11.38 (s, 1 H), 
10.51 (s, 1 H), 8.05 (d, 1 H, J = 8.1 Hz), 7.78 (d, 1 H, J = 8.1 Hz), 7.43 (t, 1 H, J = 8.0 Hz), 7.11 
(d, 1 H, J = 7.5 Hz), 7.02 (d, 1 H, J = 8.1 Hz);  MS (EI) m/z (rel intensity) 188 (M+, 44), 187 
(34), 117 (100), 115 (69), 91 (51);  HRMS (EI) calculated for C11H8O3 188.0473, found 
188.0469. 
 
 
8-Hydroxy-4-(methoxymethoxy)naphthalene-1-carbaldehyde (191).119  A solution of 
naphthaldehyde 190 (5.00 g, 26.7 mmol) in acetone (125 mL) was treated with K2CO3 (8.82 g, 
88.8 mmol) followed by MOMCl (2.6 mL, 0.034 mol) and stirred for 1.5 h.  The reaction 
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mixture was quenched with H2O, extracted with CH2Cl2, dried (MgSO4), filtered, concentrated 
under reduced pressure and purified by column chromatography through a 3 cm plug of SiO2 
(CH2Cl2) to afford 3.78 g (62%) of 191 as a yellow solid:  Rf  0.3 (7:3, hexanes:EtOAc);  1H 
NMR δ 12.12 (d, 1 H, J = 0.9 Hz), 9.67 (d, 1H, J = 0.9 Hz), 8.00 (d, 1 H, J = 8.2 Hz), 7.90 (dd, 1 
H, J = 8.3, 1.2 Hz), 7.51 (t, 1H, J = 8.0 Hz), 7.20 (dd, 1 H, J = 7.8, 1.2 Hz), 7.16 (d, 1H, J = 8.2 
Hz), 5.50 (s, 2 H), 3.57 (s, 3H);  MS (EI) m/z (relative intensity) 232 (M+, 100), 202 (37), 131 
(77), 115 (65), 102 (56), 77 (62);  HRMS (EI) calculated for C13H12O4 232.0736, found 
232.0741.  
 
 
4-(1-(Methoxymethoxy)-4-formylnaphthalen-5-yloxy)-8-(methoxymethoxy)naphthalene-1-
carbaldehyde (192).119  A solution of fluoride 186 (2.00 g, 8.54 mmol) and naphthol 191 (3.00 
g, 12.9 mmol) in CH3CN (30 mL) was treated with Barton’s Base (2.63 mL, 13.2 mmol) and the 
solution turned dark brown.  The reaction mixture was stirred at 80 °C for 5 h, cooled to room 
temperature, poured into 1.0 M HCl and extracted with CH2Cl2 (2x).  The combined organic 
extracts were washed with H2O, dried (MgSO4), filtered, concentrated under reduced pressure 
and purified by column chromatography on SiO2 (7:3, hexanes:EtOAc) to afford 2.849 g (74%) 
of 192 as a light yellow solid:  Rf 0.4 (3:2, EtOAc:hexanes); 1H NMR δ 11.09 (s, 1H), 10.94 (s, 
1H), 8.31 (dd, 1H, J = 8.4, 1.1 Hz), 8.17 (d, 1H, J = 8.3 Hz), 8.11 (dd, 1H, J = 8.3, 1.1 Hz), 7.89 
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(d, 1 H, J = 8.1 Hz), 7.53 (t, 1H, J = 8.4 Hz), 7.50 (t, 1H, J = 7.8 Hz), 7.41 (dd, 1H, J = 7.8, 1.1 
Hz), 7.25 (d, 1H, J = 8.3 Hz), 7.21 (dd, 1H, J = 7.7, 1.0 Hz), 6.81 (d, 1H, J = 8.1 Hz), 5.51 (s, 
2H), 5.44 (s, 2H), 3.59 (s, 3H), 3.56 (s, 3H);  MS (EI) m/z (rel intensity) 446 (M+, 82), 402 (76), 
401 (100), 171 (54), 117 (92), 115 (96);  HRMS (EI) calculated for C26H22O7 446.1366, found 
446.1351. 
 
 
4-(1-Hydroxy-4-(methoxymethoxy)naphthalen-8-yloxy)-8-(methoxymethoxy)naphthalen-1-
ol (193).119  A solution of aldehyde 192 (2.849 g, 6.386 mmol) in CH2Cl2 (133 mL) was treated 
with mCPBA (2.85 g, 16.5 mmol), stirred for 15 h, treated with 10% Na2S2O3 (133 mL) and 
stirred for 1 h.  The reaction mixture was diluted (CH2Cl2), washed with sat. NaHCO3, dried 
(MgSO4), filtered and concentrated under reduced pressure.  The reaction mixture was purified 
by column chromatography on SiO2 (3:2, hexanes:EtOAc) to afford 1.857 g (61%) of the 
formate as a yellow foam:  Rf 0.6 (3:2, EtOAc:hexanes); 1H NMR δ 8.38 (s, 1H), 8.16 (d, 1H, J 
= 8.4 Hz), 8.08 (s, 1H), 7.97 (d, 1H, J = 8.4 Hz), 7.46 (t, 1 H, J = 8.0 Hz), 7.42 (t, 1H, J = 8.0 
Hz), 7.25 (d, 1H, masked), 7.16 (d, 1H, J = 8.4 Hz), 7.06 (d, 1H, J = 8.4 Hz), 7.00 (d, 1H, J = 8.0 
Hz), 6.68 (d, 1H, J = 8.0 Hz), 5.36 (s, 2H), 5.32 (s, 2 H), 3.57 (s, 3 H), 3.55 (s, 3 H);  MS (ESI-
Q-TOF) m/z (relative intensity) 501 ([M+Na]+, 100);  HRMS (ESI-Q-TOF) calculated for 
C26H22O9Na 501.1162, found 501.1164.   
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A crude solution of the formate (1.875 g, 39.23 mmol) in MeOH (44.5 mL) and THF (44.5 mL) 
was cooled to 0 °C and treated with NaBH4 (0.339 g, 9.00 mmol).  The reaction mixture was 
stirred at 0 °C for 3 h, quenched with H2O, extracted with EtOAc (2x), dried (MgSO4), filtered 
and concentrated under reduced pressure.  The crude product was immediately subjected to 
column chromatography on SiO2 (3:2, hexanes:EtOAc) to afford 1.186 g (72%) of 193 as a white 
foam:  Rf 0.5 (3:2, hexanes:EtOAc);  1H NMR δ 9.36 (s, 1 H), 8.99 (s, 1 H), 7.89 (dd, 1 H, J = 
8.5, 1.0 Hz), 7.62 (dd, 1 H, J = 8.5, 1.0 Hz), 7.30 (t, 1 H, J = 8.2 Hz), 7.25 (d, 1 H, J = 8.3 Hz), 
7.17-7.12 (m, 2 H), 6.91 (d, 1 H, J = 8.3 Hz), 6.90 (d, 1 H, J = 8.3 Hz), 6.46 (dd, 1 H, J = 7.7, 0.9 
Hz), 5.49 (s, 2 H), 5.32 (s, 2 H), 3.62 (s, 3 H), 3.56 (s, 3 H);  MS (EI) m/z (rel intensity) 422 (M+, 
15), 149 (100), 117 (77), 75 (42);  HRMS (EI) calculated for C24H22O7 422.1366, found 
422.1362. 
 
O O
OOH
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5-Hydroxy-6'-(methoxymethoxy)-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxin]-4-
one (194).119  A solution of 193 (0.600 g, 1.42 mmol) in CH3CN (22 mL) was treated with 
activated 4 Å molecular sieves (1.3 g), cooled to 0 °C and treated with PIFA (0.733 g, 1.70 
mmol).  The reaction mixture was stirred at 0 °C for 30 minutes, filtered through celite and 
washed with EtOAc.  The organic extracts were washed with H2O, dried (MgSO4), filtered, 
concentrated under reduced pressure and purified by column chromatography on SiO2 (7:3, 
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hexanes:EtOAc) to afford 0.682 g (37%) of 194 as a yellow oil:  Rf  0.6 (7:3, hexanes:EtOAc); 
1H NMR δ 12.17 (s, 1 H), 7.90 (dd, 1 H, J = 8.5, 0.7 Hz), 7.66 (t, 1 H, J = 8.1 Hz), 7.48 (dd, 1 H, 
J = 8.6, 7.7 Hz), 7.46 (dd, 1 H, J =7.7, 1.1 Hz), 7.13 (dd, 1 H, J = 8.7, 1.2 Hz), 7.11 (d, 1 H, J = 
8.1 Hz), 7.02 (dd, 1 H, J = 7.2, 0.6 Hz), 7.01 (d, 1 H, J = 10.5 Hz), 6.89 (d, 1 H, J = 8.4), 5.36 (s, 
2 H), 3.57 (s, 3 H);  MS (EI) m/z (relative intensity) 376 (M+, 60), 331 (56), 121 (100), 69 (66);  
 
 
5,6'-Dihydroxy-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxin]-4-one (177).119  A 
solution of 194 (0.681 g, 1.81 mmol) in CH2Cl2 (27 mL) was treated with 4 Å molecular sieves 
(1.70 g), cooled to 0 °C and treated with TMSBr (0.88 mL, 6.7 mmol) dropwise.  The reaction 
mixture was stirred at 0 °C for 1 h, warmed to room temperature, stirred 12 h, filtered through 
celite, washed (CH2Cl2) and concentrated under reduced pressure.  A solution of the crude 
product in THF (40.5 mL) was treated with a 1.0 M solution of TBAF in THF (1.62 mL, 1.62 
mmol) and stirred at room temperature for 15 min.  The reaction was quenched with H2O and 
extracted with EtOAc.  The combined organic extracts were dried (MgSO4), filtered and 
concentrated under reduced pressure.  Purification by column chromatography on SiO2 (CH2Cl2) 
afforded 0.366 g (68%) of 177 as a yellow solid:  Rf 0.3 (7:3, hexanes:EtOAc); 1H NMR δ 12.18 
(s, 1 H), 8.99 (s, 1 H), 7.88 (dd, 1 H, J = 8.5, 0.9 Hz), 7.78 (t, 1 H, J = 7.9 Hz), 7.52-7.47 (m, 2 
H), 7.18 (d, 1 H, J = 10.5 Hz), 7.16 (dd, 1 H, J = 8.5, 1.1 Hz), 7.03 (dd, 1 H, J = 7.5, 0.9 Hz), 
6.93 (d, 1 H, J = 8.2 Hz), 6.85 (d, 1 H, J = 8.1 Hz), 6.44 (d, 1 H, J = 10.5 Hz);  MS (EI) 332 (M+, 
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82), 256 (13), 167 (33), 121 (72), 69 (100); HRMS (EI) calculated for C20H12O5 332.0685, found 
332.0685.  
 
 
4-Oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-5,6'-diyl diacetate (204).  A 
solution of spiroketal 177 (6.25 mg, 0.0188 mmol) in pyridine (0.12 mL) was treated with Ac2O 
(0.04 mL, 0.4 mmol) and diluted with CH2Cl2 (0.12 mL).  The reaction mixture was stirred for 3 
h, treated with additional Ac2O (0.04 mL, 0.4 mmol) and stirred for an additional 12 h.  It was 
diluted with CH2Cl2, extracted with sat. NaHCO3, dried (MgSO4), filtered and concentrated 
under reduced pressure.  Purification by column chromatography on SiO2 (7:3, hexanes:EtOAc) 
afforded 3.8 mg (77%) of bis-acetate 177 as an orange oil:  Rf 0.24 (7:3, hexanes:EtOAc);  IR 
(ATR) 2917, 1765, 1674, 1640, 1606, 1323, 1265, 1193, 1111, 1032 cm -1;  1H NMR δ 7.89 (dd, 
1 H, J = 7.9, 1.1 Hz), 7.77 (t, 1 H, J = 7.9 Hz), 7.52 (d, 2 H, J = 7.9 Hz), 7.27 (dd, 1 H, J = 7.9, 
1.1 Hz), 7.23 (d, 1 H, J = 8.2 Hz), 7.04-7.01 (m, 1 H), 6.96 (d, 1 H, J = 8.2 Hz), 6.95 (d, 1 H, J = 
10.5 Hz), 6.27 (d, 1 H, J = 10.5 Hz), 2.47 (s, 3 H), 2.45 (s, 3 H);  13C NMR δ 182.0, 169.7, 169.6, 
149.7, 147.5, 145.0, 141.2, 140.4, 136.6, 134.6, 131.3, 128.3, 127.3, 126.3, 125.9, 122.1, 119.9, 
115.5, 113.5, 110.7, 109.5, 93.1, 21.1, 20.9;  MS (EI) m/z (rel intensity) 416 (M+, 21), 376 (4), 
375 (6), 374 (94), 334 (40), 332 (100), 231 (14), 117 (49);  HRMS (EI) calculated for C24H16O7 
416.0896, found 416.0897.    
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5-Hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-6'-yl acetate 
(205).  A solution of spiroketal 177 (6.25 mg, 0.0194 mmol) in pyridine (0.12 mL) was treated 
with Ac2O (0.5 mL, 0.5 mmol) and stirred at room temperature for 2 h.  The reaction mixture 
was diluted with CH2Cl2 (3 mL), washed with sat. NaHCO3 (0.5 mL), dried (MgSO4), filtered 
and concentrated under reduced pressure.  Purification by column chromatography on SiO2 (7:3, 
hexanes:EtOAc) afforded 3.9 mg (88%) of mono-acetate 205 as a bright yellow oil:  Rf 0.4 (7:3, 
hexanes:EtOAc);  IR (ATR) 3054, 2920, 1761, 1661, 1606, 1418, 1346, 1265, 1195, 1073 cm -1;  
1H NMR δ 12.15 (s, 1 H), 7.67 (t, 1 H, J = 7.8 Hz), 7.52-7.43 (m, 3 H), 7.23 (d, 1 H, J = 8.1 Hz), 
7.15 (d, 1 H, J = 8.6 Hz), 7.05-6.95 (m, 3 H), 6.38 (d, 1 H, J = 10.6 Hz), 2.47 (s, 3 H);  13C NMR 
δ 188.7, 169.6, 161.9, 147.4, 144.9, 141.3, 139.4, 138.6, 136.6, 129.9, 128.3, 127.3, 119.9, 119.8, 
119.3, 115.6, 113.8, 113.4, 110.7, 109.5, 93.1, 20.9;  MS (EI) m/z (rel intensity) 374 (M+, 20), 
333 (24), 332 (100), 231 (7), 117 (31);  HRMS (EI) calculated for C22H14O6 374.0790, found 
374.0790.  
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(R)-2-(tert-Butoxycarbonylamino)-3-phenylpropanoic acid (207).315  A solution of D-phenyl 
alanine (0.50 g, 3.0 mmol) in 2.0 N NaOH (3 mL) was cooled to 0 °C, treated with Boc2O (0.990 
g, 4.54 mmol) and warmed to room temperature.  The Boc2O was insoluble at 0 °C, but 
dissolved as the reaction mixture was warmed to room temperature.  The reaction mixture was 
stirred for 3 h, cooled to 0 °C, acidified to pH 2 with 1.0 N HCl and extracted with EtOAc (2x).  
The combined organic extracts were dried (MgSO4), filtered and concentrated under reduced 
pressure to afford 207 as a white solid which was used without further purification:  1H NMR 
(DMSO-d6) δ 12.60 (s, 1 H), 7.30-7.19 (m, 4 H), 7.12 (d, 1 H, J = 7.8 Hz), 4.08 (ddd, 1 H, J = 
13.8, 10.5, 4.5 Hz), 3.01 (dd, 1 H, J = 13.8, 4.5 Hz), 2.81 (dd, 1 H, J = 13.8, 10.5 Hz), 2.50 (t, 1 
H, J = 1.8 Hz), 1.31 (s, 9 H);  MS (EI) m/z (rel intensity) 265 (M+, 28), 237 (12), 220 (14), 176 
(58), 164 (33), 148 (31), 120 (54), 91 (51), 57 (100);  HRMS (EI) calculated for C14H19NO4 
265.1314, found 265.1324. 
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(2R)-5-Hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-6'-yl 2-(tert-
butoxycarbonylamino)-3-phenylpropanoate.  The bright orange suspension of 177 (18 mg, 
0.054 mmol) in CH2Cl2 (0.7 mL) was treated with N-Boc phenyl alanine (207) (10.34 mg, 
0.03900 mmol) followed by DCC (0.0087 g, 0.042 mmol) and DMAP (1 mg, 0.008 mmol) and 
stirred for 30 min at room temperature.  The reaction mixture was treated with additional N-Boc 
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phenylalanine (10.34 mg, 0.03900 mmol), DCC (0.0087 g, 0.42 mol) and DMAP (1 mg, 0.008 
mmol) and stirred 5 min.  It was filtered, concentrated under reduced pressure and purified by 
column chromatography on SiO2 (7:3, hexanes:EtOAc) to afford 17.3 mg (90%) of the amino 
ester as a yellow foam:  Rf  0.5 (7:3, hexanes:EtOAc);  IR (ATR) 3388 (bs), 2973, 2926, 2855, 
1763, 1707, 1662, 1606, 1390, 1377, 1347, 1263, 1155, 1129 cm-1;  1H NMR δ 12.11 (s, 1H), 
7.73 (t, 1 H, J = 8.1 Hz), 7.48-7.42 (m, 2 H), 7.40-7.31 (m, 2 H), 7.27-7.17 (m, 1 H), 7.15 (d, 1 
H, J = 8.4 Hz), 7.07 (dd, 1 H, J = 8.1, 3.6 Hz), 7.01 (d, 1 H, J = 10.5 Hz), 7.01 (d, 1 H, J = 7.5 
Hz), 6.92 (d, 1 H, J = 8.1 Hz), 6.38 (d, 1 H, J = 10.5 Hz), 5.11 (d, 1 H, J = 8.4 Hz), 4.99-4.95 (m, 
1 H), 3.33 (d, 2 H, J = 6.3 Hz), 1.42 (s, 9 H);  13C NMR δ 188.6, 171.1, 161.8, 155.3, 147.2, 
145.0, 141.0, 139.3, 138.5, 136.6, 135.6, 129.9, 129.5, 128.9, 128.3, 127.4, 119.7, 119.5, 119.5, 
119.3, 115.8, 113.7, 113.3, 110.7, 109.3, 93.1, 80.4, 54.9, 38.2, 28.2;  MS (EI) m/z (rel. intensity) 
506 ([M-Ot-Bu]+,1), 333 (22), 332 (100), 271 (20), 120 (83), 91 (72);  HRMS (EI) calculated for 
C30H20NO7 506.1240, found 506.1239  
 
 
(2R)-1-(5-Hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-6'-
yloxy)-1-oxo-3-phenylpropan-2-aminium 2,2,2-trifluoroacetate (210).  A solution of the N-
BOC protected phenylalanine ester of 177 (17.3 mg, 0.0489 mmol) in CH2Cl2 (0.6 mL) was 
treated with TFA (0.15 mL, 2.0 mmol), stirred at room temperature for 30 min, concentrated 
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under reduced pressure and further dried under high vacuum to afford 210 as a yellow solid in 
quantitative yield:  Mp 80.7-81.2 °C (CH2Cl2);  IR (ATR) 2956 (bs), 1653, 1606, 1437, 1264, 
1204, 1148, 1073, 1046 cm-1;  1H NMR (CD3CN) δ 12.10 (s, 1 H), 7.73 (t, 1 H, J = 8.1 Hz), 7.56 
(t, 1 H, J = 8.0 Hz), 7.49-7.39 (m, 6 H), 7.29 (dd, 1 H, J = 8.4, 2.4 Hz), 7.16 (dd, 1 H, J = 8.6, 0.8 
Hz), 7.09 (d, 1 H, J = 8.7 Hz), 7.08 (d, 1 H, J = 10.5 Hz), 7.01 (d, 1 H, J = 8.4 Hz), 6.39 (dd, 1 H, 
J = 10.5, 1.2 Hz), 4.82 (bs, 1 H), 3.55 (bs, 2 H);  13C NMR (CD3CN) δ 189.9, 168.9, 162.7, 
148.4, 146.6, 141.3, 140.3, 139.7, 137.9, 135.0, 130.9, 130.8, 130.7, 130.5, 130.3, 129.9, 129.7, 
129.1, 127.8, 120.9, 120.6, 118.4, 116.4, 114.7, 111.9, 110.4, 94.3, 55.7, 37.0;  MS (ESI-Q-TOF) 
m/z (relative intensity) 480 (M+, 42), 120 (100);  HRMS (ESI-Q-TOF) calculated for C28H18NO7 
480.1082, found 480.1083.  
  
 
2-(tert-Butoxycarbonylamino)-2-methylpropanoic acid (209).316,317  A solution of 2-
aminoisobutyric acid (208) (2.06 g, 20.0 mmol) 1.0 M NaOH (20 mL), H2O (40 mL), and 
dioxane (40 mL), cooled to 0 °C was treated with Boc2O (4.8 g, 22 mmol) and stirred at room 
temperature for 3 h.  The reaction mixture was partially concentrated under reduced pressure, 
acidified to pH 2.0 with 1.0 M NaHSO4, extracted with EtOAc, dried (MgSO4), filtered and 
concentrated under reduced pressure to afford 4.0 g (99%) of 209 as a white solid.  1H NMR 
(DMSO-d6) δ 5.27 (bs, 1 H), 1.53 (s, 6 H), 1.44 (s, 9 H); MS (ESI-Q-TOF) m/z (rel intensity) 226 
(M+, 29), 191 (90), 170 (100);  HRMS (ESI-Q-TOF) calculated for C9H17NO4Na 226.1055, 
found 226.1048.  
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5-Hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-6'-yl 2-(tert-
butoxycarbonylamino)-2-methylpropanoate.  A suspension of spiroketal 177 (4.7 mg, 0.014 
mmol) in CH2Cl2 (1.27 mL) was treated with N-Boc aminoisobutyric acid 209 (4.80 mg, 0.0237 
mmol), DCC (4.7 mg, 0.023 mmol) and DMAP (0.47 mg, 0.0039 mmol), and stirred for 1.5 h.  
The reaction mixture was treated with additional N-Boc aminoisobutyric acid 209 (4.7 mg, 0.014 
mmol) and DCC (4.0 mg, 0.019 mmol), stirred for 30 min, filtered, concentrated under reduced 
pressure and purified by column chromatography on SiO2 (7:3, hexanes:EtOAc) to afford 5 mg 
(68%) of the AIB ester of 177 as a bright yellow foam:  Rf 0.4 (7:3, hexanes:EtOAc);  IR (neat) 
3500 (bs), 1764, 1708, 1664, 1610, 1506, 1457, 1419, 1380, 1348, 1265, 1239, 1159, 1114, 
1075, 956 cm-1;  1H NMR δ 12.16 (s, 1 H), 7.69-7.62 (m, 2 H), 7.51 (d, 1 H, J = 7.6 Hz), 7.45 
(dd, 1 H, J = 7.6, 1.0 Hz), 7.23 (d, 1 H, J = 8.2 Hz), 7.14 (dd, 1 H, J = 8.4, 1.3 Hz), 7.03 (d, 1 H, 
J = 10.5 Hz), 7.01 (d, 1 H, J = 6.9 Hz), 6.95 (d, 1 H, J = 8.2 Hz), 6.38 (d, 1 H, J = 10.5 Hz), 5.15 
(s, 1 H), 1.76 (s, 6 H), 1.49 (s, 9 H);  13C NMR δ 188.7, 161.8, 154.8, 147.2, 144.8, 141.7, 138.6, 
136.6, 129.8, 128.2, 127.5, 119.7, 119.6, 119.3, 113.7, 113.3, 110.6, 93.0, 56.4, 28.4, 25.7;  MS 
(EI) m/z (rel intensity) 517 (M+, 24), 458 (11), 444 (20), 443 (5), 417 (30), 401 (6), 373 (18), 334 
(22), 332 (81), 58 (100);  HRMS (EI) calculated for C29H27NO8 517.1737, found 517.1758.   
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1-(5-Hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-6'-yloxy)-2-
methyl-1-oxopropan-2-aminium 2,2,2-trifluoroacetate (211).  A solution of the N-Boc AIB 
prodrug of 177 (5.0 mg, 0.0096 mmol) in CH2Cl2 (0.42 mL) was treated with TFA (0.10 mL, 1.4 
mmol), stirred for 30 min at room temperature, concentrated under reduced pressure and dried 
further under high vacuum to afford  221 in quantitative yield as a light yellow powder:  Mp 
137.7-138.1 °C (CH2Cl2);  IR (neat) 2936.1 (bs), 2860.0, 1768.2, 1666.3, 1610.5, 1456.3, 1420.0, 
1378.7, 1347.4, 1267.6, 1236.9, 1166.4, 112.6 cm -1;  1H NMR (CD3CN) δ 12.07 (bs, 1 H), 8.16 
(bs, 3 H), 7.69 (t, 1 H, J = 8.0 Hz), 7.61-7.53 (m, 2 H), 7.45 (d, 1 H, J = 7.5 Hz), 7.35 (d, 1 H, J = 
8.3 Hz), 7.13 (d, 1 H, J = 8.3Hz), 7.08-7.04 (m, 2 H), 7.00 (d, 1 H, J = 8.2 Hz), 6.35 (d, 1 H, J = 
10.5 Hz), 1.89 (s, 6 H);  13C NMR (Acetone-d6) δ 189.8, 171.6, 162.6, 148.5, 146.6, 141.4, 
140.5, 139.7, 137.8, 130.9, 130.1, 127.9, 121.0, 120.5, 120.4, 116.1, 114.7, 114.3, 111.9, 110.4, 
94.3, 59.1, 24.3;  MS (ESI) m/z (rel intensity) 441 ([M+Na]+, 32), 191 (42), 146 (87), 135 (100);  
HRMS (ESI) calculated for C24H20NO6Na 441.1179, found 441.1188. 
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(3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-((benzyloxy)methyl)-tetrahydro-2H-pyran-2-yl 
acetate (218).318  A solution of 2,3,4,6 tetra-O-benzyl-D-glucopyranose (0.15 g, 0.35 mmol) in 
pyridine (2.5 mL) was cooled to 0 °C, treated with Ac2O (0.5 mL, 6 mmol), warmed to room 
temperature and stirred for 20 h.  The reaction mixture was cooled to 0 °C, quenched with 
MeOH (0.5 mL), stirred for 1h.  It was diluted with EtOAc, washed with sat. NaHCO3, H2O, sat. 
CuSO4, brine, dried (Na2SO4), filtered and concentrated under reduced pressure to afford 0.064 g 
(31%) of 218 as a colorless oil which was used without further purification:  1H NMR δ 7.49-
7.24 (m, 20 H), 7.14-7.12 (m, 2 H), 6.35 (d, 1 H, J = 3.6 Hz), 4.95 (d, 1 H, J = 5.7 Hz), 4.84 (d, 1 
H, J = 6.0), 4.81 (d, 1 H, J = 6.3 Hz), 4.70 (d, 1 H, J = 11.4 Hz), 4.64 (d, 1 H, J = 7.5 Hz), 4.60 
(d, 1 H, J = 8.1 Hz), 4.50 (d, 1 H, J = 4.2 Hz), 4.46 (d, 1 H, J = 5.7 Hz), 3.94 (t, 1 H, J = 9.3 Hz), 
3.90 (appd, 1 H, J = 9.0 Hz), 3.76-3.62 (m, 6 H); MS (EI) m/z (rel intensity) 491 ([M-Bn]+, 2), 
431 (5), 325 (4), 253 (5), 91 (100); HRMS calculated for C29H31O7 [M-Bn] 491.2070, found 
491.2070. 
 
 
(3R,4S,5R,6R)-6-(Acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate (220).319  
A solution of pyridine (7.5 mL) and acetic anhydride (5.0 mL, 0.053 mol) was cooled to 0 °C 
and treated with D-glucose (1.00 g, 5.55 mmol).  The suspension was stirred at 0 °C until all of 
the solids dissolved (1.5 h), warmed to room temperature and stirred for 16 h.  The reaction 
mixture was poured into ice water (20 mL) and white solids immediately precipitated out of 
solution.  The solids were filtered through a coarse sintered glass filter, washed (H2O) and dried 
under high vacuum to afford 2.003 g (93%) of 220 as a white solid and 1:1 anomeric mixture:  
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Rf 0.6 (4:1, hexanes:EtOAc);  1H NMR δ 6.33 (d, 1 H, J = 3.66 Hz), 5.47 (t, 1 H, J = 9.6 Hz), 
5.16 (d, 1 H, J = 9.7 Hz), 5.10 (dd, 1 H, J = 10.3, 3.7 Hz), 4.30-4.24 (m, 1 H), 4.15-4.06 (m, 2 
H), 2.18 (s, 3 H), 2.10 (s, 3 H), 2.04 (s, 3 H), 2.03 (s, 3 H), 2.02 (s, 3 H);  MS (ESI-Q-TOF) m/z 
(rel intensity)  413 ([M+Na]+, 100);  HRMS (ESI-Q-TOF) calculated for C16H22O11Na 412.1060, 
found 413.1027. 
 
 
(2R,3R,4S,5R)-2-(Acetoxymethyl)-6-bromotetrahydro-2H-pyran-3,4,5-triyl triacetate 
(221).320  A 30% solution of HBr in AcOH (1.05 mL) was cooled to 0 °C and treated with 10 
portions of acetylated D-glucose 220 (0.600 g, 1.54 mmol) over the course of 10 min.  The ice 
bath was removed and the sugar slowly dissolved to afford a light yellow solution.  The reaction 
mixture was stirred for 45 min, quenched with ice cold H2O (25 mL), extracted with CH2Cl2 
(2x), dried (MgSO4), filtered and concentrated under reduced pressure to afford 0.607 g (96%) of 
221 as a clear oil which was clean according to 1H NMR analysis and used without further 
purification:  Rf 0.8 (4:1, hexanes:EtOAc);  1H NMR δ 6.60 (d, 1 H, J = 3.9 Hz), 5.6 (t, 1 H, J = 
5.7 Hz), 5.15 (t, 1 H, J = 9.9 Hz), 4.83 (dd, 1 H, J = 10.0, 4.1 Hz), 4.26-4.04 (m, 2 H), 4.14-4.10 
(m, 1 H), 2.10 (s, 3 H), 2.09 (s, 3 H), 2.05 (s, 3 H), 2.03 (s, 3 H). 
 
 
(2R,3R,4S,5R)-2-(Acetoxymethyl)-6-hydroxytetrahydro-2H-pyran-3,4,5-triyl triacetate 
(222).321  A solution of penta-acetylated D-glucose 220 (0.290 g, 0.743 mmol) in THF (3 mL) 
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was treated with benzylamine (0.22 mL, 2.0 mmol) dropwise at room temperature, stirred for 6 
h, diluted with EtOAc and H2O and extracted.  The organic extract was washed with H2O (2x), 
1.0 N HCl, and a final wash with H2O.  The combined organic extracts were dried (MgSO4), 
filtered, concentrated under reduced pressure and purified by column chromatography on SiO2 
(4:1, hexanes:EtOAc) to afford 0.173 g (68%) of deprotected glucose 222 as a white foam:  Rf  
0.5 (4:1, hexanes:EtOAc);  1H NMR δ 7.26 (s, 1 H), 5.55 (t, 1 H, J = 4.3 Hz), 5.50 (d, 1 H, J = 
3.4 Hz), 5.09 (t, 1 H, J = 9.5 Hz), 4.91 (dd, 1 H, J = 10.2, 3.5 Hz), 4.31-4.21 (m, 2 H), 4.15-4.08 
(m, 1 H), 2.10 (s, 3 H), 2.09 (s, 3 H), 2.04 (s, 3 H), 2.02 (s, 3 H);  MS (ESI-Q-TOF) m/z (rel 
intensity) 371 ([M+Na]+, 100), 229 (8), 198 (12), 169 (20), 127 (23);  HRMS (ESI-Q-TOF) 
calculated for C14H20O10Na 371.0954, found 371.0918. 
 
 
(2R,3R,4S,5R)-2-(Acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-pyran-
3,4,5-triyl triacetate (223).322  A solution of 222 (0.301 g, 0.864 mmol) in CH2Cl2 (2.95 mL) 
was treated with DBU (0.26 mL, 1.7 mmol) followed by trichloroacetonitrile (0.87 mL, 6.9 
mmol), stirred at room temperature for 4 h and concentrated under reduced pressure.  The crude 
product was immediately purified by column chromatography on SiO2 (1:1, EtOAc:hexanes) to 
afford 0.196 g (48%) of chloroimidate 223 as a 1:3 mixture of α and β anomers.  Rf  0.4 (1:1, 
EtOAc:hexanes);  1H NMR δ 8.69 (s, 1 H), 8.57 (s, 0.3 H), 6.64 (d, 0.3 H, J = 3.6 H), 6.56 (d, 1 
H, J = 3.6 Hz), 5.66 (t, 0.3 H, J = 3.6 Hz), 5.57 (t, 1 H, J = 9.8 Hz), 5.19 (t, 1.3 H, J = 9.8 Hz), 
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5.13 (dd, 1.3 H, J = 10.2, 3.7 Hz), 4.31-4.11 (m, 3.9 H), 2.15 (s, 1 H), 2.10 (s, 1 H), 2.08 (s, 3 H), 
2.05 (s, 4 H), 2.04 (s, 3 H), 2.02 (s, 3 H), 2.00 (s, 1 H). 
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(2R,3R,4S,5R)-2-(Acetoxymethyl)-6-(5-hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-
naphtho[1,8-de][1,3]dioxine]-6'-yloxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate.  A 
suspension of 177 (42.4 mg, 0.128 mmol) in CH2Cl2 (9.3 mL) was treated with chloroimidate 
223 (90.7 mg, 0.190 mmol) and cooled to 0 °C.  The reaction mixture was treated with BF3OEt2 
(0.03 mL, 0.2 mmol) and the light yellow solution instantly turned to a deep red color.  The 
reaction mixture was stirred for 20 min at 0 °C and quenched with H2O which caused the color 
of the solution to return to light yellow.  It was diluted with CH2Cl2, washed with H2O (2x), 
dried (Na2SO4), filtered, concentrated under reduced pressure and purified by column 
chromatography on SiO2 (3:2, hexanes:EtOAc) to afford 0.069 g (82%) of the desired O-
glycosylated product as a yellow oil and 1:1 anomeric mixture:  Rf 0.5 (3:2, hexanes:EtOAc);  IR 
(ATR) 2939 (bs), 1744, 1661, 1608, 1456, 1418, 1346, 1211, 1113, 1064, 1032, 729 cm -1;  1H 
NMR δ 12.16 (s, 0.5 H), 12.14 (s, 0.5 H), 7.73 (d, 1 H, J = 8.2 Hz), 7.67 (t, 0.5 H, J = 7.6 Hz), 
7.66 (t, 0.5 H, J = 7.6 Hz), 7.5 (d, 0.5 H, J = 7.6 Hz), 7.47 (d, 0.5 H, J = 7.6 Hz), 7.47 (t, 0.5 H, J 
= 7.6 Hz), 7.44 (t, 0.5 H, J = 7.6 Hz), 7.14 (d, 0.5 H, J = 8.4 Hz), 7.14 (d, 0.5 H, J = 8.4 Hz), 
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7.07 (d, 0.5 H, J = 8.3 Hz), 7.07 (d, 0.5 H, J = 8.3 z), 7.03 (d, 0.5 H, J = 7.5 Hz), 7.03 (d, 0.5 H, J 
= 7.5 Hz), 6.98 (d, 0.5 H, J = 10.5 Hz), 6.98 (d, 0.5 H, J = 10.5 Hz), 6.88 (d, 0.5 H, J = 8.3 Hz), 
6.87 (d, 0.5 H, J = 8.3 Hz), 6.37 (d, 0.5 H, J = 10.5 Hz), 6.35 (d, 0.5 H, J = 10.5 Hz), 5.49 (dd, 
0.5 H, J = 7.9, 1.3 Hz), 5.47 (dd, 0,5 H, J = 7.9, 1.3 Hz), 5.38 (0.5 H, d, J = 9.5 Hz), 5.35 (d, 0.5 
H, J = 9.5 Hz), 5.25 (app d, 1 H, J = 9.3 Hz), 5.19 (d, 0.5 H, J = 7.8 Hz), 5.18 (d, 0.5 H, J = 7.8 
Hz), 4.38-4.31 (m, 1 H), 4.21 (dd, 0.5 H, J = 12.4, 2.7 Hz), 4.20 (dd, 0.5 H, J = 12.4, 2.7 Hz), 
2.10 (s, 3 H), 2.08 (s, 3 H), 2.08 (s, 1.5 H), 2.07 (s, 1.5 H), 2.07 (s, 1.5 H), 2.05 (s, 1.5 H);  13C 
NMR δ 188.6, 170.4, 170.1, 170.1, 169.4, 169.4, 161.7, 147.8, 147.7, 147.1, 147.0, 142.7, 142.6, 
139.4, 139.4, 138.6, 138.6, 136.6, 136.5, 129.7, 129.7, 127.7, 126.2, 119.6, 119.3, 119.1, 115.9, 
115,9, 113.7, 113.6, 113.3, 113.3, 111.4, 111.1, 110.9, 109.2, 109.1, 100.0, 99.8, 92.9, 92.8, 72.4, 
72.1, 71.0, 71.0, 68.3, 61.8, 60.3, 21.0, 20.7, 20.6, 20.6, 20.5, 14.1;  MS (ESI-Q-TOF) m/z (rel. 
intensity) 685 ([M+Na]+, 100), 617 (10), 415 (10);  HRMS (ESI-Q-TOF) calculated for 
C34H30O14Na 685.1533, found 685.1542.  
   
 
5-Hydroxy-6'-((3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yloxy)-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxin]-4-one (224).  A solution of O-
glycosylated 177 (53.0 mg, 0.16 mmol) in MeOH (1.5 mL) and THF (1.5 mL) was treated with a 
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solution of NaOMe (25 mg, 0.46 mmol) in MeOH (2.5 mL) dropwise.  The light yellow solution 
turned to a light orange color, was stirred for 45 min and quenched with DOWEX 50 W beads 
until the pH = 6.0.  The reaction mixture was filtered and concentrated under reduced pressure to 
afford 224 as a bright yellow solid and 1:1 mixture of anomers:  Rf 0.25 (9:1, CH2Cl2:MeOH); 
Mp (toluene) 189.5 (dec.);  IR (ATR) 3378 (bs), 1592, 1415, 1265, 1224, 1068, 1036, 1014 cm-1;  
1H NMR (DMSO-d6) δ  12.22 (s, 1 H), 8.05-7.98 (m, 0.5 H), 7.97-7.944 (m, 0.5 H), 7.78 (t, 0.5 
H, J =  8.1 Hz), 7.71 (t, 0.5 H, J = 8.1 Hz), 7.59 (d, 0.5 H, J = 7.8 Hz), 7.54 (d, 0.5 H, J = 7.8 
Hz), 7.49-7.44 (m, 1 H), 7.39 (d, 1 H, J = 7.8 Hz), 7.28-7.22 (m, 2 H), 7.03 (dd, 1 H, J = 8.4, 7.8 
Hz) ,6.96 (d, 0.5 H, J = 8.3 Hz), 6.96 (d, 0.5 H, J = 8.3 Hz), 6.46 (d, 0.5 H, J = 10.5 Hz), 6.46 (d, 
0.5 H, J = 10.5 Hz), 5.53-5.50 (m, 1 H), 5.16-5.15 (m, 1 H), 5.07 (d, 1 H, J = 4.8 Hz), 4.97-4.88 
(m, 2 H), 4.65-4.58 (m, 1 H) 4.10 (bs, 1 H), 3.78-3.72 (m, 2 H), 3.41-3.38 (m, 2 H);  13C NMR δ 
201.9, 188.4, 161.0, 150.4, 148.5, 148.2, 148.1, 147.9, 146.8, 146.6, 141.3, 141.1, 140.9, 138.7, 
138.4, 137.5, 137.1, 129.8, 127.4, 127.2, 125.9, 125.7, 121.7, 119.2, 117.5, 116.2, 115.0, 113.2, 
113.1, 112.7, 111.2, 110.6, 109.6, 108.9, 102.0, 98.4, 98.3, 77.2, 76.5, 75.0, 73.4, 69.8, 60.8, 
59.8, 58.7, 45.7, 20.8, 14.1; MS (EI) m/z (rel intensity) 526 (M+, 2), 494 (2), 332 (100), 190 (38), 
160 (25);  HRMS (EI) calculated for C26H22O10 494.1213, found 494.1228. 
 
General Procedure for determination of prodrug water solubility: 
A suspension of the prodrug in H2O was agitated, allowed to sit for 15 min and filtered.  The 
filtrate was concentrated under reduced pressure and further dried under high vacuum.  The mass 
of both the collected filtrate and the solids were recorded to confirm that there was neither loss of 
sample nor a falsely high value due to residual water.  The value for water solubility was 
determined by: mass (mg of prodrug isolated from the filtrate)/total volume of H2O. 
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Phenylalanine prodrug (210):  1.9 mg of 210 was treated with H2O (0.5 mL).  Because very 
little of the prodrug went into solution, it was treated with additional H2O (0.5 mL) to make the 
total volume of H2O = 1.0 mL.  0.06 Mg of 210 was isolated from the filtrate.  Water solubility 
of 210 = 0.06 mg/mL (<0.1 mg/mL). 
 AIB prodrug (211):  3.76 mg of 211 was treated with H2O (0.5 mL).  2.26 mg of prodrug 211 
was isolated from the filtrate.  Water solubility of 211 = 4.5 mg/mL 
Sugar prodrug (224):  2.1 mg of 224 was treated with H2O (0.5 mL).  0.7 mg of prodrug 224 
was isolated from the filtrate.  Water solubility of 224 = 1.4 mg/ mL 
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11.0  PRODRUG SCALE-UP 
11.1 REVISED RETROSYNTHETIC ANALYSIS OF PRODRUG 211 
The promising biological results with 177 inspired the prodrug project.  Spirocycle 177 had a 
Trx/TrxR inhibition of 0.20 ± 0.01 μM and MCF-7 growth inhibition of 2.6 ± 0.1 μM.  
Unfortunately, the low solubility limited more extensive biological studies.  The undesirable 
physical properties of 177 inspired the investigation of prodrugs of 177.  After measuring the 
water solubilities of the synthesized prodrugs, it was found that prodrug 211 had significantly 
improved water solubility (4.5 mg/mL vs. <0.1 mg/mL for 177).  Since it improved on the poor 
plasma stability of the other prodrugs and poor water solubility of the parent compound, prodrug 
211 was selected as a suitable candidate for animal studies.  The biologists needed at least one 
gram of the prodrug for their proposed animal tests.323  With any new anticancer drug, one of the 
most important questions is what type of tumor will respond best.  Each tumor has a “standard of 
care” for treatment.324  Examples are the treatment of breast cancer with doxorubicin325 or 
Taxol,326 and the treatment of lung cancer with platinum containing drugs327 or imatinib.328  
Biologists not only test the efficacy of the synthesized drug, but they need to test the drug with a 
combination of the “standard of care” for each of the standard tumors.  There are 8-10 mice per 
group for each tumor tested.  The number of tests that need to be performed necessitates the 
delivery of 1 g of material. 
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It was exciting that prodrug 211 was viable for animal tests, but this also raised concerns 
about the best synthetic route to prepare 1 g of compound.  At best, the current route allowed for 
the synthesis of 100 mg of 177.  An alternative route was needed, and therefore the synthetic 
plan had to be optimized to allow for the preparation of gram quantities.   
The bottlenecks in the original synthesis were evaluated.  Fluoride 186 was synthesized 
in 10 steps and 31% overall yield and naphthol 191 was obtained in four steps and 54% overall 
yield.  The segment condensation and the last six steps, with an overall yield of 7%, were clearly 
a major problem.  Primarily responsible for the mediocre efficiency was the PIFA mediated 
oxidation of 193.  Unfortunately, earlier attempts to optimize this oxidation were unsuccessful 
(Table 9.1).  The retrosynthetic analysis was changed to more efficiently arrive at 177. 
The first modified retrosynthetic analysis (Scheme 11.1) investigated the incorporation of 
the AIB ester earlier in the synthesis (Scheme 9.3).  Prodrug 211 would be synthesized from 226 
following Dakin conversion of the naphthaldehydes to naphthols and subsequent oxidative 
cyclization.  The yields of hypervalent iodine mediated oxidative cyclizations can be sensitive to 
the electronic nature of the aromatic substituents.329  It would be interesting to see the effect on 
yield during the oxidative cyclization that the amino ester substituent would exert compared to 
the MOM ether substituent in 193.  Biaryl ether 226 would be synthesized from an SNAr 
condensation between naphthyl fluoride 186 and naphthol 225.  Naphthyl fluoride 186 was the 
same etherification partner used in the original synthesis of 177 (Scheme 9.1).  Naphthol 225 
could be readily synthesized via esterification between N-Boc-AIB (209) and the previously 
synthesized naphthaldehyde 190 (Scheme 9.2).  The primary advantage of this synthesis would 
be the removal of one of the MOM protections early in the synthesis, and the removal of the late 
stage MOM deprotection and esterification.  The other advantage of this revised retrosynthetic 
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analysis was that the majority of the proposed chemistry mirrors transformations applied in the 
original synthesis of 177.  Ideally, this would expedite the process of reaction optimization 
(Scheme 11.1).   
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Scheme 11.1.  Modified retrosynthetic analysis of 211 
    
The revised synthesis commenced with the esterification between 209 and 190 (Scheme 
11.2).  The esterification proceeded in excellent yield utilizing the standard DCC conditions to 
afford 225.  Unfortunately, problems were rapidly encountered with this route.  The amino ester 
did not survive the standard SNAr conditions and no 226 was isolated.  Amino ester 225 rapidly 
decomposed during these conditions.  This necessitated the development of a completely revised 
retrosynthetic plan.  
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Scheme 11.2.  Failed synthesis of 226 
11.2 ATTEMPTED SYNTHESIS OF 227 
In the new retrosynthetic analysis, the oxidative cyclization (Scheme 9.3) was replaced with a 
spiroketalization between naphthalene diol 229 and ketone 228 (Scheme 11.3).  Other syntheses 
that performed a spiroketalization required a late stage introduction of the enone, but it would be 
advantageous to introduce the enone earlier in the synthesis.125  Conveniently, both mono ketal 
228 and naphthol 229 can be synthesized from benzyl protected juglone 230 (Scheme 11.3).   
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Scheme 11.3.  Modified retrosynthetic analysis of 227 
 
The synthesis of acetate 229 commenced with the benzyl protection of juglone (231, 
Scheme 11.4).  The initial benzylation in CHCl3 afforded 230 in 30% yield, but a solvent 
switch to CH2Cl2 increased the yield to 80%.330  Naphthoquinone 230 was reduced with 
Na2S2O4 in Et2O and one of the phenol groups was acetylated with AcCl.  The benzyl ether 
blocked the acetylation of the proximal phenol to give 232 selectively.331  Debenzylation 
proceeded cleanly in 15 min with 10% Pd/C to afford diol 229 in excellent yield.   
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Scheme 11.4.  Synthesis of acetate 229  
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Spiroketalization ketone component 228 was also synthesized starting from 230 (Scheme 
11.5).  The naphthoquinone was reduced with Na2S2O4 and monoprotected with dimethyl 
sulphate to afford 233.  Monomethylated 233 was oxidized with DDQ332-334  to afford 
monoacetal 228 as a single observed regioisomer in good yield.  
    
 
Scheme 11.5.  Selective monoketalization 
 
The spiroketalization between 228 and 229 with catalytic TsOH was attempted (Scheme 
11.6).  Both starting materials were consumed, but the spiroketal was not observed according to 
1H NMR analysis of the crude reaction mixture.  The conjugate addition of the naphthol to the 
enone was presumably the preferred pathway to afford either 234 or 235 based on 1H NMR and 
MS analysis.  A series of conditions were screened, but the enone was not preserved.  
Accordingly, the introduction of the enone needed to be performed after the spiroketalization. 
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Scheme 11.6.  Conjugate addition of naphthol 229 to 228 
11.3 REVISED RETROSYNTHETIC ANALYSIS II 
The new revised retrosynthetic analysis of 236 postponed the enone introduction until after the 
spiroketalization between 5-methoxytetralone (146) and naphthol 238 (Scheme 11.7).101,124,125  
The enone could be introduced in a two step protocol.  First, benzylic oxidation to the ketone 
could be performed with chromium, MnO4,335 NBS and AIBN with subsequent DMSO and 
NaHCO3 treatment,130,336,337 or DDQ.125  Secondly, the alkene could be introduced by further 
DDQ treatment124,338 or the Saegusa reaction.  5-Methoxytetralone (146) is commercially 
available and 1,2,5-trihydroxynaphthalene (238) can be synthesized via the reduction of juglone 
(231).  If 238 needed to be protected, the earlier developed methodology for monoprotection 
could be readily employed (Scheme 11.4).   
 
  153
O O
O OH
OR
O O
OH
OR
O
OMe
OH OH
OH
+
236 237
146
238  
Scheme 11.7.  Revised retrosynthetic analysis II 
11.4 PROTECTING GROUP FREE SYNTHESIS OF BUILDING BLOCKS 
The unprotected naphthol 238 was synthesized by reduction of juglone (231) with Na2S2O4 
(Scheme 11.8).  This electron rich aromatic ring would likely be susceptible to air oxidation and 
was rapidly subjected to the spiroketalization conditions with tetralone 146.339  The 
disappearance of triol 238 was observed in the 1H NMR analysis of the crude reaction mixture, 
but 146 remained unreacted.  5-Hydroxytetralone (240) was synthesized by a simple 
demethylation of 146 with AlCl3.  The yield of the demethylation step was improved to 90% via 
treatment with 10% AcOH in HBr.  However, 238 decomposed during the spiroketalization with 
TsOH in toluene, and tetralone 240 was recovered quantitatively.  The TLC of the 
spiroketalization reaction showed one spot corresponding to the tetralone, disappearance of 238 
and baseline material.  The polar decomposition product was never isolated, but the likely 
decomposition pathway can be speculated on.  There are numerous examples of air oxidation of 
electron rich naphthols to the corresponding quinones.339,340  Juglone (231) would be expected if 
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this was the lone mode for consumption of 238, but it was not isolated.   A possible explanation 
is that the oxidation to 231 is followed by additional reactions such as the dimerization of 231 or 
condensation between 231 and 238.341  The homocoupling of electron rich aromatics to afford 
various biaryl compounds has been reported and could also account for the decomposition of 
238.342-344  Although the side product was never isolated, precedence from the literature indicates 
that some form of dimerization most likely accounted for the consumption of 238.   
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Scheme 11.8.  Attempted protecting group free spiroketalization 
 
Variants of tetralone 146 were synthesized to facilitate the desired spiroketalization.  
Methyl enol ether 242 was synthesized via treatment of tetralone 146 with catalytic TsOH and 
trimethylorthoformate (Scheme 11.9).345-347 Triol 238 rapidly decomposed during the 
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spiroketalization conditions.  The pyrolidine enamine 244348 and morpholine enamine 243 were 
also synthesized from 146 with TiCl4 and used without further purification for the 
spiroketalization reaction (Scheme 11.10).349,350  The same rapid decomposition of naphthol 238 
was observed during the spiroketalization reaction with the enamines as had occurred with 
methyl enol ether 242.  In these trials, the lability of the triol was not overcome, and a suitable 
protecting group needed to be introduced.   
 
 
Scheme 11.9.  Spiroketalization with enol ether 242 
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Scheme 11.10.  Morpholine and pyrrolidine enamines of tetralone 146 
11.5 SYNTHESIS AND PROTECTION OF NAPHTHOL 238 
The literature protocols to synthesize trihydroxynaphthalene 238 either proceed in low yield351 or 
require the reduction of relatively expensive juglone 231 (Scheme 11.4).352,353  A cheap starting 
material and a concise synthesis of the monoprotected naphthol were desired with minimal 
protecting group manipulations. 
11.5.1 Naphthosultone starting material 
Commercially available and cheap naphthosultone 245 is a synthetic equivalent of 1,8-
dihydroxynaphthalene, which is not commercially available (Scheme 11.11).125 Conversion of 
naphthosultone 245 to 1,8-dihydroxynaphthalene requires forceful conditions with strong base 
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and temperatures around 200 °C.354,355  It was predicted that the acetylation of 245 to afford 246 
would provide a robust enough group to withstand these conditions and also a handle to deliver 
acetate 229 after conversion to the diol and after Baeyer-Villiger oxidation.    
 
 
Scheme 11.11.  Synthesis of 229 from naphthosultone 245 
 
Conditions for the Friedel-Crafts acylation of 245 were first screened (Scheme 11.12).356    
The solution in CH2Cl2 could not be heated high enough to promote acylation, but even at 100 
°C in MeNO2 no reaction was observed.  This lack of conversion was attributed to the 
evaporation of AcCl.  Lowering the temperature to 60 °C led to the successful formation of 246 
in 85% yield.   
 
 
Scheme 11.12.  Attempted naphthosultone conversion to 247 
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A series of basic conditions were screened for the conversion of 246 to 247 (Scheme 
11.12).356  A one step conversion to 247 was most desirable, but there are examples in the 
literature where the major isolated product was naphthol 248.357,358  A solution of naphthosultone 
246 in either aqueous KOH or NaOH was stirred at room temperature, as well as at 100 °C under 
conventional heating or microwave conditions, but no 247 was detected (Table 11.1).  The mass 
recovery for these reactions was poor and the low solubility of the isolated material made 
characterization and scale-up difficult.   
 
Table 11.1.  Deprotection conditions of naphthosultone 246 
Entry Conditions 
1 EtOH, KOH, r.t. to 70 °C 
2 KOH, CH2Cl2, H2O, rt 
3 KOH, H2O, 100 °C, 12 h 
4 KOH,  H2O, 120 °C, 12 h 
5 KOH, H2O, 120 °C, μW 
 
11.5.2 Acetonide protection of 238 
An alternative route to monoprotected 229 was the selective deprotection of 249 (Scheme 
11.13).342  The acetonide of 238 is a known compound and could be readily acetylated.352  
Conditions needed to be developed for selective acetonide deprotection of 229. 
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Scheme 11.13.  Planned synthesis of 229 via the acetonide 
 
Juglone (231) was reduced to triol 238 and subjected directly to acetonide protection by 
treatment with H2SO4 in acetone to afford 250 in good yield (Scheme 11.14).  The acetylation of 
250 with acetic anhydride afforded bis-protected 249.   
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Scheme 11.14.  Protection of naphthalene triol 238 
 
Selectivity problems were encountered with the deprotection of 249 (Table 11.2).  10% 
TFA in CH2Cl2, 50% TFA, neat TFA, and TFA in THF and H2O only led to recovered starting 
material 249 (entries 1-4).359  Treatment with BCl3 rapidly decomposed 249 (entry 5).360  The 
acetate was lost when 249 was treated with TsOH in MeOH to afford 250 (entry 6).  The lability 
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of the acetate was too great and selective deprotection of the acetonide in the presence of this 
functionality was not achieved.   
 
Table 11.2.  Conditions explored for deprotection of 249 
Entry Conditions Results 
1 TFA, THF, H2O, r.t. Starting material 
2 TFA, overnight Starting material 
3 TFA, CH2Cl2, reflux Starting material 
4 TFA, CH2Cl2, 2 days Starting material 
5 BCl3, CH2Cl2, 0 °C Decomposition 
6 TsOH, MeOH Deacetylation (250) 
7 HCl, THF Deacetylation (250) 
 
 A solution to the undesired preferential cleavage of the acetate in 249 could be identified 
by the synthesis of diphenylacetal 252.361,362  Protection of the 1,8-diol as the diphenyl acetonide 
and acetylation would afford 253, a similar scaffold as in Scheme 11.14.363,364,365   The advantage 
of this sequence would be the diphenyl acetonide removal via hydrogenation which should not 
impact the acetate.366  Unfortunately, 252 could not be synthesized (Scheme 11.15).   
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Scheme 11.15.  Failed protection of 238 with benzophenone acetal 
 
A bridging silicon ether can be synthesized from silyl chlorides,367 triflates367 or chlorides 
in the presence of additives.368  The attempted silylation of 238 with dichlorodimethylsilane, 
HOBt and NEt3 resulted in juglone (231) as the major product. (Scheme 11.16)369  The electron 
rich naphthalene triol 238 was a perpetually difficult substrate to handle because of its low 
solubility and tendency to decompose.  Benzyl protected juglone 230 was returned to as the 
starting point in the synthesis.  
 
 
Scheme 11.16.  Failed protection of 238 with bridging silane 
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11.5.3 Spiroketalization with protected 238 
The spiroketalization between tetralone 146 and acetate 229 was investigated.  The earlier failed 
spiroketalization attempts with 146 and 238 were attributed to the decomposition of 238.  A 
rapid synthesis of 229 was sought starting from cheap starting materials, as previously discussed, 
but ultimately the previously optimized synthesis of 229 was utilized (Scheme 11.4).  Acetate 
229 was synthesized (Scheme 11.4) and subjected to the spiroketalization conditions with 5-
methoxytetralone (146) in toluene with catalytic TsOH (Scheme 11.17).  Once again, tetralone 
146 was cleanly recovered and 229 decomposed.  This is presumably due to the loss of the 
acetate protecting group during the reaction conditions.  This process would unmask 238 which 
could proceed to decompose.  A less labile group, such as a silyl protecting group, was needed to 
protect 238.   
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Scheme 11.17.  Acetate protected naphthol 229 in spiroketalization 
   
The synthesis for the silyl protection of 238 followed an analogous route to acetate 229 
starting from 231 (Scheme 11.4).  The TBDPS ether was first explored as a protecting group of 
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reduced 230, but the reaction with TBDPSCl resulted in many side products that were difficult to 
characterize.  The silylation of reduced 230 with TBSCl proceeded well.  Reduction of 
naphthoquinone 230 with Na2S2O4 and TBS protection afforded 256 in 98% yield.  The benzyl 
group was cleaved and diol 257 was initially recovered in 31% yield when the hydrogenation 
was performed with hydrogen gas and 10% Pd/C in EtOAc and AcOH.  A hydrogen transfer 
reaction with Pd/C (10%) and cyclohexadiene in EtOH improved the yield to 92%.  As long as 
the debenzylation was performed in EtOH in the absence of acid, cyclohexadiene could be 
replaced by hydrogen gas to afford 257 in 91% yield (Scheme 11.18).   
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Scheme 11.18.  Silylation and debenzylation of naphthoquinone 230 
11.6 COMPLETION OF THE SYNTHESIS OF 211 
With mono protected naphthol 257 in hand, the enol ether of 5-methoxytetralone (242) was 
prepared via the previously described treatment of 146 with trimethyl orthoformate and TsOH in 
MeOH (Scheme 11.9).  The initial attempts for the spiroketalization between 242 and 257 were 
plagued with either low yields or a coeluting impurity.  After much optimization, the impurity 
could be eliminated and the yield improved by swapping the solvent from MeOH to toluene prior 
to introduction of diol 257.  The crude solution of 242 was treated with a toluene solution of diol 
  164
257 to afford the desired spiroketal 258 in 77%.  The spiroketal was subjected to benzylic 
oxidation with PDC and TBHP to afford 259 in 61% yield (Scheme 11.19).  
 
 
Scheme 11.19.  Spiroketalization and enone formation 
 
Many conditions were screened for the synthesis of spiroketal 258 (Table 11.3).  The 
hypothesis was that the coeluting side product could be derived from the methylation of 257 with 
the residual trimethylorthoformate.  Isolating 242 prior to spiroketalization removed the residual 
trimethyl orthoformate, but resulted in a slower reaction presumably due to partial hydrolysis of 
the enol ether (entry 2).  Various Lewis acids and temperatures were screened, but these variants 
proceeded in low yield.  The best yield and product purity was obtained by performing the 
solvent swap from methanol to toluene prior to the addition of 257 (entry 9).  This modification 
eliminated the undesired side product and delivered clean spiroketal 259.   
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Table 11.3.  Spiroketalization to 258 conditions 
Entry Reagents Conditions Yield of 
258 [%] 
1 257, 146, MgSO4  Toluene, r.t., 12 h N.R. 
2 257, 242, TsOH 242 isolated prior to spiroketalization, 
toluene, r.t. 
Trace 
3 257, 146, TMSOTf -78 °C- r.t. 15 
4 257, 242, BF3.OEt2 Toluene, r.t. to reflux Decomp. 
5 257, 146, TESOTf, BF3.OEt2 Toluene, r.t to reflux Decomp. 
6 257, 242, toluene Solvent swap (from MeOH to toluene) 
after 12 h 
8 
7 257, 146, TESOTf Benzene Decomp. 
8 257, 242, toluene Solvent swap (from MeOH to toluene) 
after addition of 257 
40 
9 257, 242, toluene Solvent swap (from MeOH to toluene) 
prior to addition of 257 
77 
10 257, 146, TsOH, toluene Dean-Stark N.R. 
 
Many conditions were also screened for the benzylic oxidation of 258 to 259 (Table 
11.4).  The early trials with PCC (entry 1), PDC (entries 2 and 3) and 
bipyridiniumchlorochromate (entry 8) with TBHP afforded clean product, albeit in low yield.  
Oxidation with mCPBA (entry 5), and NBS followed by basic DMSO (entry 6) only resulted in 
decomposition.  DDQ and SiO2 hydrolyzed 258 to 5-methoxytetralone (146), and there was no 
reaction with FeCl3 and TBHP.  Ultimately, PDC and TBHP at room temperature were selected 
due to the higher yield and the scalability of these conditions (entry 11).  
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Table 11.4.  Benzylic oxidation optimization for conversion of 258 to 259 
Entry Conditions Yield [%] 
1 PCC, TBHP, benzene 10 
2 PDC, TBHP, benzene, 60 °C – reflux 19 
3 PDC, TBHP, benzene, reflux 26 
4 FeCl3, TBHP, pyridine n.r. 
5 mCPBA, air, CH2Cl2 Decomp. 
6 NBS then DMSO, Na2CO3 Decomp. 
7 DDQ, SiO2 Hydrolysis to 
146 
8 Bipyridiniumchlorochromate, TBHP, celite, benzene 10 
9 PDC (batchwise), TBHP (batchwise), celite, benzene 44 
10 Bipyridiniumchlorochromate, TBHP (slow addition), celite, benzene 50 
11 PDC, TBHP, celite, benzene  61 
 
Conditions were also screened for the enone synthesis (Table 11.5).  DDQ consistently 
provided low yields (entries 1-2).  The Saegusa reaction has been successfully employed on 
similarly functionalized substrates.123,370  1.2 Equiv of Pd(OAc)2 delivered 50% of the product 
with some remaining starting material that closely eluted with the desired product.  Lowering the 
catalyst loading to 0.5 equiv of Pd(OAc)2 with 0.5 equiv of benzoquinone resulted in no desired 
product (entry 4).338  Excess lutidine inhibited the oxidation and when the TMS enol ether was 
purified through a short SiO2 plug, the reaction proceeded much more efficiently (entry 5).  
Ultimately, the best conditions were to azeotrope the enol ether with toluene prior to introduction 
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of Pd(OAc)2 (entry 6).   Presumably, this procedure removed the lutidine and also minimized any 
potential hydrolysis of the enol ether by removing residual water. 
 
 
 
Table 11.5.  Optimization of oxidation of 259 to enone 260 
Entry Conditions Yield [%] of 260 
1 DDQ, benzene, room temperature n.r. 
2 DDQ, reflux inconsistent 
3 TMSOTf, then Pd(OAc)2 (1.2 equiv), CH3CN 50 
4 TMSOTF, then Pd(OAc)2 (0.5 equiv), benzoquinone (0.5 equiv), 
CH3CN 
n.r. 
5 TMSOTf, isolate enol ether, then Pd(OAc)2 (1.2 equiv), CH3CN 44 
6 TMSOTf, azeotrope with toluene, then Pd(OAc)2, CH3CN 93 
 
With enone 260 in hand, the methyl and TBS ethers needed to be removed (Scheme 
11.20).  It was predicted that the TBS group would likely be deprotected under many of the 
Lewis acidic conditions commonly used for demethylation, but found instead that the TBS group 
was quite resilient.  The first reagent tried was BBr3 (entry 6).100  On small scale, both 177 and 
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TBS protected 177 were isolated according to 1H NMR analysis of the crude reaction mixture.  
Treating the reaction mixture with TBAF for 10 min afforded 18% of 177 whose mass and 1H 
NMR matched the previously synthesized material.  Other conditions for this deprotection were 
screened (Table 11.6).  For example, BCl3 (entry 1),371,372 B-bromocatechol (entry 7) and B-I-9-
BBN (entry 3)373 were tested, but none of the yields were suitable for scale-up.  Methyl 
deprotection with BCl3 with Bu4NI improved the yield ,374 but there was some decomposition 
during the TBAF deprotection.  Treatment of the reaction mixture with TBAF followed by 
AcOH did not greatly improve the yield, but the reverse addition improved the yield to 76%.  
Using these optimized conditions, 1 g of 177 was synthesized. 
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Scheme 11.20.  Methyl ether deprotection and desilylation 
 
Table 11.6.  Deprotection conditions of 260 to 177 
Entry Scale Conditions Yield of 177 [%]  
1 50 mg BCl3, CH2Cl2 s.m. + decomp 
2 50 mg BCl3, Bu4NI, CH2Cl2 then TBAF, AcOH 22 
3 50 mg B-I-9-BBN,  ― 1 
4 430 mg BCl3, Bu4NI, CH2Cl2, then AcOH, TBAF 68 
5 1.7 g BCl3, Bu4NI, CH2Cl2, then AcOH, TBAF 76 
6 5 mg BBr3, then TBAF 18 
7 111 mg 2-Bromo-1,3,2-benzodioxaborole, then TBAF  8 
1 enone function was lost 
 
 The new synthesis provided 1.0 g of 177 from commercially available materials in 9 
steps and an overall yield of 26%.  This is a significant improvement from the original synthesis 
that was completed in 20 steps with a yield of 0.01%.  The last reaction needed for completion of 
this project was an esterification to the AIB prodrug 211.  This esterification was performed in 
four 250 mg batches.  The yield for the overall process was comparable to the yield observed on 
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the smaller scale.  A final BOC-deprotection utilizing 10% TFA in CH2Cl2 afforded 211 as the 
TFA salt. 
 
 
Scheme 11.21.  Synthesis of AIB prodrug 211 
11.7 PURSUIT OF 211 STARTING FROM 240 
Before the global deprotection of 260 to 177 was optimized (Scheme 11.21), there was concern 
about the scalability of the late stage removal of the methyl ether in 260.  The spiroketalization 
starting with 5-hydroxytetralone (240) was concurrently being investigated (Scheme 11.22).  
This modification would bypass the demethylation of the more acid sensitive spiroketal 260 to 
the more robust methoxytetralone 146.  With spiroketal 262 in hand, benzylic oxidation, enone 
introduction and a final deprotection would afford 177.  5-Methoxytetralone 146 was deprotected 
with HBr and AcOH to afford tetralone 240 in good yield.  The unoptimized spiroketalization 
afforded 262 in 20% overall yield.   
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Scheme 11.22.  Spiroketalization with free phenol 261 
 
With 262 in hand, the benzylic oxidation to 260 was investigated (Scheme 11.23).  In all 
the references found, phenols were protected prior to oxidation.  The first condition applied was 
catalytic bipyridinium chlorochromate with TBHP as the co-oxidant.  This reaction proceeded 
cleanly and 80% of a bright orange oil was isolated.  Characterization revealed that the product 
was in fact quinone 263 and not the desired tetralone.  Bipyridinium chlorochromate delivered 
trace amounts of the desired product according to 1H NMR analysis.  DDQ and mCPBA in the 
presence of air did not lead to any conversion.  Accordingly, the route described in Scheme 
11.20 was pursued. 
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Scheme 11.23.  Undesired oxidation of spiroketal to 263 
11.8 CONCLUSION 
An efficient second generation route to 177 was developed.  After much optimization, 177 was 
synthesized in 9 steps and 26% overall yield starting from commercially available material.  The 
original route required 20 steps and provided 0.01% overall yield (Scheme 11.24).  As discussed 
earlier, the original route was only scaleable to 100 mg of 177, but suffered from mediocre 
efficiency.  One of the primary problems encountered was the PIFA mediated oxidative 
cyclization of 193.  It was predicted it would be beneficial to construct the spiroketal in an 
alternative fashion when developing a synthesis amenable to the scaleup of 177 and subsequent 
prodrug synthesis.  Ultimately, spiroketalization between the naphthol and tetralone with 
catalytic amounts of acid reliably delivered the desired product and was amenable to further 
scaleup.   
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Scheme 11.24.  Original synthesis of 177 
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Scheme 11.25.  Final route for scaleup of 177 
 
The revised synthesis was scaleable and readily provided 1 g of 177 (Scheme 11.25).  
Conditions were developed for the selective monoprotection of the naphthalene triol and various 
protecting groups were screened until it was found that TBS protected 257 was robust enough for 
the spiroketalization conditions.  The spiroketalization was optimized to eliminate the side 
product formation and proceeded in good yield.  The addition of Bu4NI to BCl3 was discovered 
to effectively demethylate 260 in good yield.  This route delivered 177 in a rapid and concise 
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sequence.  Acylation with the AIB ester and BOC-deprotection afforded 1.1 g of 211 that was 
delivered to the laboratory of Dr. Garth Powis for animal studies. 
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12.0  PRODRUG SCALE UP EXPERIMENTAL PART 
General:  All moisture sensitive reactions were performed in flame-dried or oven-dried 
glassware under a nitrogen atmosphere.  THF and Et2O were distilled over Na/benzophenone, 
while pyridine and triethylamine were distilled over CaH2.  Hexanes and ethyl acetate were 
distilled prior to use.  All other reagents and solvents were used as received unless otherwise 
noted.  Analytical thin layer chromatography was performed on pre-coated silica gel 60 F-254 
plates available from Merck.  Flash chromatography was performed using silica gel (230-400 
mesh) available from Baker.  NMR spectra were recorded in CDCl3 (unless otherwise noted) at 
300 MHz for 1H NMR and 75 MHz for 13C NMR using a Bruker Avance 300 with XWIN-NMR 
software.  Chemical shifts (δ) are expressed relative to the NMR solvent peak.  IR spectra were 
obtained with a Nicolet Avator 360 FT-IR, ATR-IR spectra were measured with a Smiths 
IdentifyIR, optical rotations were measured with a Perkin-Elmer 241 polarimeter and mass 
spectra were obtained on a double focusing instrument.  EI mass spectra were obtained with VG 
Autospec and ESI mass spectra with Q-TOF API US. 
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4-Formyl-5-hydroxynaphthalen-1-yl 2-(tert-butoxycarbonylamino)-2-methylpropanoate 
(225).  A solution of naphthol 190 (Scheme 9.2, 100 mg, 0.532 mmol) in CH2Cl2 (44.3 mL) was 
treated with N-Boc AIB (209)316,317 (174 mg, 0.857 mmol) followed by DCC (171 mg, 0.829 
mmol) and DMAP (17 mg, 0.14 mmol) and stirred for 12 h.  The reaction mixture was 
concentrated under reduced pressure and purified by column chromatography on SiO2 (7:3, 
hexanes:EtOAc) to afford 172 mg (90%) of ester 225 as a bright yellow solid:  Rf 0.3 (7:3, 
hexanes:EtOAc); Mp 148.7-149.2 °C (EtOAc/hexanes);  IR (ATR) 3409, 2982, 1756, 1697, 
1666, 1517, 1500, 1470, 1452, 1387, 1270, 1150, 1213, 1149, 744 cm-1;  1H NMR δ 11.86 (s, 1 
H), 9.82 (s, 1 H), 8.07 (d, 1 H, J = 8.1 Hz), 7.62 (dd, 1 H, J = 1.2, 8.1 Hz), 7.55 (d, 1 H, J = 7.8 
Hz), 7.49 (d, 1 H, J = 8.1 Hz), 7.21 (dd, 1 H, J = 1.2, 7.5 Hz), 5.20 (bs, 1 H), 1.5 (s, 9H); 13C 
NMR δ 196.8, 172.5, 155.6, 154.8, 142.9, 130.0, 129.8, 129.5, 122.8, 116.6, 113.1, 80.5, 56.5, 
28.3, 25.6;  MS (ESI-Q-TOF) m/z (rel intensity) 396 ([M+23]+, 35), 189 (100);  HRMS (ESI-Q-
TOF) calculated for C20H23NO6Na 396.1525, found 396.1535.  
  
O
O
OBn
 
5-(Benzyloxy)naphthalene-1,4-dione (230).290  A solution of juglone (231) (1.70 g, 9.76 mmol) 
in CH2Cl2 (37 mL) was treated with Ag2O (9.14 g, 39.0 mmol) followed by benzyl bromide 
(3.79 mL, 31.3 mmol) and stirred at room temperature for 8 h.  The reaction mixture was filtered 
through celite, washed (CH2Cl2), concentrated under reduced pressure and purified by column 
chromatography on SiO2 (4:1, hexanes:EtOAc) to afford 2.57 g (86%) of 230 as a bright orange 
solid:  Rf 0.3 (7:3, hexanes:EtOAc);  1H NMR δ 7.74 (d, 1 H, J = 7.5 Hz), 7.64 (t, 1 H, J = 8.1 
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Hz), 7.58 (d, 2 H, J = 7.5 Hz), 7.42 (t, 2 H, J = 7.2 Hz), 7.53-7.33 (m, 2 H), 6.89 (s, 2 H), 5.30 (s, 
2 H); MS (EI) m/z (rel intensity)  264 (M+, 30), 246 (25), 174 (60), 160 (35), 105 (54), 91 (100), 
77 (71);  HRMS (EI) calculated for C17H12O3 264.0786, found 264.0786.   
   
OH
OH
OBn
 
5-(Benzyloxy)naphthalene-1,4-diol.  A suspension of benzyl juglone (230) (2.57 g, 9.72 mmol) 
in Et2O (406 mL) was treated with a solution of Na2S2O4 (22.01 g, 126.4 mmol) in H2O (256 
mL).  The biphasic mixture was transferred to a separatory funnel and shaken for 10 min and 
separated.  The organic extract was dried (Na2SO4), filtered, concentrated under reduced pressure 
to afford 2.30 g (89%) of the naphthalene diol as an off-white solid that was used without further 
purification:  Rf 0.4 (3:2, hexanes:EtOAc);  1H NMR (DMSO-d6) δ 9.36 (s, 1H), 8.89 (s, 1 H), 
7.67 (d, 1 H, J = 8.4 Hz), 7.56 (d, 2 H, J = 6.6 Hz), 7.46-7.40 (m, 3 H), 7.30 (t, 1 H, J = 8.3 Hz), 
7.07 (d, 1 H, J = 7.5 Hz), 6.73 (d, 1 H, J = 8.4 Hz), 6.57 (d, 1 H, J = 8.1 Hz), 5.38 (s, 2 H);  MS 
(EI) m/z (rel intensity)  266 (M+, 16), 175 (42), 91 (100), 69 (100);  HRMS (EI) calculated for 
C17H14O3 266.0943, found 266.0933,    
 
OH
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1-(Benzyloxy)-8-hydroxynaphthalen-5-yl acetate (232).375  A solution of 5-
(benzyloxy)naphthalene-1,4-diol (146 mg, 0.474 mmol) in CH2Cl2 (7.5 mL) and NEt3 (0.15 mL, 
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11 mmol) was treated with AcCl (0.05 mL, 0.7 mmol) and stirred at room temperature for 15 
min.  The reaction mixture was quenched with H2O, extracted with CH2Cl2 (2x), dried (Na2SO4), 
filtered, concentrated under reduced pressure and purified by column chromatography on SiO2 
(7:3, hexanes:EtOAc) to afford 0.140 g (82%) of acetate 232 as a bright orange solid:  Mp 154.3-
155.1 °C (EtOAc);  Rf 0.4 (7:3, hexanes:EtOAc);  1H NMR δ 9.35 (s, 1 H), 7.51-7.41 (m, 6 H), 
7.35 (dd, 1 H, J = 8.4, 7.2 Hz), 7.12 (d, 1 H, J = 8.4 Hz), 6.91 (dd, 1 H, J = 7.5, 1.2 Hz), 6.82 (d, 
1 H, J = 8.4 Hz), 5.29 (s, 2 H), 2.42 (s, 3 H);  MS (EI) m/z (rel intensity)  308 (M+, 41), 266 (33), 
175 (77), 174 (23), 91 (100);  HRMS (EI) calculated for C19H16O4 308.1049, found 308.1049.   
 
OH
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1,8-Dihydroxynaphthalen-5-yl acetate (229).  A solution of acetate 232 (140 mg, 0.452 mmol) 
in EtOAc (14 mL) was treated with 10% Pd/C (22.5 mg, 0.0212 mmol) followed by acetic acid 
(0.03 mL, 0.4 mmol) and purged twice with H2.  The reaction mixture was stirred under 
atmospheric H2 for 15 min, filtered through celite, washed (EtOAc), concentrated under reduced 
pressure and purified by column chromatography on SiO2 (7:3, hexanes:EtOAc) to deliver 0.114 
g (quant) of the diol as a light yellow oil:  Rf 0.1 (7:3, hexanes:EtOAc);  IR (neat) 3297 (bs), 
1731, 1612, 1590, 1411, 1370, 1229, 1205, 1031, 946, 809 cm-1;  1H NMR δ 8.26 (bs, 1 H), 8.20 
(bs, 1H),  7.19 (dd, 1 H, J = 8.4, 7.2 Hz), 7.14 (dd, 1 H, J = 8.4, 1.5 Hz) 6.92 (d, 1 H, J = 8.4 Hz), 
6.58 (dd, 1 H, J = 7.2, 1.2 Hz), 6.49 (d, 1 H, J = 8.4 Hz), 2.49 (s, 3 H);  13C NMR δ 172.1, 153.4, 
151.8, 139.0, 129.0, 127.7, 118.8, 115.3, 112.8, 110.3, 108.0, 21.1;  MS (EI) m/z (rel intensity) 
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218 (M+,11), 177 (11), 176 (100), 147 (17), 86 (32), 84 (48), 57 (44); HRMS (EI) calculated for 
C12H16O4 218.0579, found 218.0580. 
 
OH
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8-(Benzyloxy)-4-methoxynaphthalen-1-ol (233).290,334  A solution of 5-
(benzyloxy)naphthalene-1,4-diol (0.183 g, 0.691 mmol) in acetone (9 mL) was treated with 
K2CO3 (0.270 g, 1.95 mmol) followed by Me2SO4 (0.066 mL, 0.69 mmol) and stirred for 12 h.  
The reaction mixture was concentrated under reduced pressure and purified by column 
chromatography on SiO2 (1:4, EtOAc:hexanes) to deliver 0.19 g (98%) of 233 as an off white 
solid:  Rf 0.8 (7:3, hexanes:EtOAc); Mp 108.9-109.5 °C (EtOAc); IR (neat) 3394, 2920, 2851, 
1630, 1606, 1456, 1410, 1291, 1261, 1234, 1054, 982, 819, 802, 781, 752 cm-1;  1H NMR δ 9.09 
(s, 1 H), 7.87 (dd, 1 H, J = 8.6, 0.9 Hz), 7.51-7.40 (m, 4 H), 7.33 (t, 2 H, J = 8.4 Hz), 6.93 (d, 1 
H, J = 7.8 Hz), 6.77 (s, 2 H), 5.28 (s, 2 H), 3.94 (s, 3 H); 13C NMR δ 155.2, 148.2, 147.9, 135.3, 
129.0, 128.8, 128.0, 125.1, 116.2, 115.7, 109.2, 106.3, 71.7, 56.0;  MS (EI) m/z (rel intensity) 
280 (M+, 26), 190 (21), 189 (100), 91 (84), 69 (52);  HRMS (EI) calculated for C18H16O3 
280.1099, found 280.1108 
 
 
 8-(Benzyloxy)-4,4-dimethoxynaphthalen-1(4H)-one (228).376  A solution of methyl ether 233 
(0.208 g, 0.742 mmol) in MeOH (17.6 mL) was treated with DDQ (0.250 g, 1.08 mmol) 
  181
followed by K2CO3 (0.152 g, 1.10 mmol) and stirred at room temperature for 5 min.  The 
reaction mixture was quenched with 10% Na2S2O3 and extracted with EtOAc (2x).  The 
combined organic extracts were washed with H2O, dried (Na2SO4), filtered and concentrated 
under reduced pressure to afford 228 as a light yellow oil which was used without further 
purification:  Rf 0.4 (7:3, hexanes:EtOAc); 1H NMR δ 7.62-7.55 (m, 3 H), 7.43-7.28 (m, 4 H), 
7.08 (d, 1 H, J = 8.4 Hz), 6.76 (d, 1 H, J = 10.5 Hz), 6.53 (d, 1 H, J = 10.5 Hz), 5.27 (s, 2 H), 
3.17 (s, 6 H); MS (EI) m/z (rel intensity) 310 (M+, 10), 279 (20), 266 (21), 264 (22), 189 (6), 175 
(14), 91 (100); HRMS (EI) calculated for C19H18O4 310.1205, found 310.1189. 
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Naphthalene-1,4,5-triol (238).  A suspension of juglone (231) (0.500 g, 2.87 mmol) in Et2O (20 
mL) was transferred to a separatory funnel, treated with a freshly prepared solution of Na2S2O4 
(2.0 g, 12 mmol) in H2O (20 mL) and shaken for 10 min.  The organic extract was separated, 
washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure.  Further 
drying under high vacuum afforded 238 as a white solid (quant.) which was used without further 
purification:  1H NMR (DMSO-d6) δ 10.70 (s, 1 H), 10.34 (s, 1 H), 9.35 (s, 1 H), 7.50 (d, 1 H, J 
= 8.4 Hz), 7.21 (dd, 1 H, J = 8.4, 7.2 Hz), 6.71 (d, 1 H, J = 7.2 Hz), 6.65 (d, 1 H, J = 8.1 Hz), 
6.54 (d, 1 H, J = 8.1 Hz). 
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5-Hydroxy-3,4-dihydronaphthalen-1(2H)-one (240).  A solution of 5-methoxytetralone 146 
(0.100 g, 0.5675 mmol) in sat. HBr (9.0 mL) was treated with AcOH (1.0 mL, 17 mmol) and 
heated to 100 °C for 2 h.  The reaction mixture was cooled to room temperature, poured into 
H2O, extracted (EtOAc), dried (MgSO4), filtered and concentrated under reduced pressure.  
Purification by column chromatography on SiO2 (7:3, hexanes:EtOAc) afforded 66.3 mg (72%) 
of 240 as a yellow solid:  Rf 0.3 (7:3, EtOAc:hexanes);  1H NMR δ 7.67 (1H, d, J = 7.8 Hz), 7.19 
(1 H, t, J = 7.5 Hz), 6.97 (d, 1 H, J = 7.8 Hz), 2.90 (t, 2 H, J = 6.3 Hz), 2.65 (t, 2 H, J = 6.6 Hz), 
2.16 (app, 2 H, J = 6.3 Hz);  MS (EI) m/z (rel intensity) 162 (M+, 100), 134 (64), 106 (30);  
HRMS (EI) calculated for C10H10O2  162.0681, found 162.0685.     
 
 
1-(1,2-Dihydro-8-methoxynaphthalen-4-yl)pyrrolidine (244).  A solution of 5-
methoxytetralone (146) (0.100 g, 0.567 mmol) in Et2O (2.84 mL) was treated with pyrrolidine 
(0.16 mL, 1.9 mmol), cooled to 0 °C and treated with a freshly prepared solution of TiCl4 in 
Et2O (0.03 mL of TiCl4 in 0.5 mL of Et2O).  The reaction mixture was warmed to room 
temperature, stirred for 15 h and monitored by 1H NMR analysis of the crude reaction mixture.  
It was filtered through a plug of SiO2, washed (Et2O), concentrated under reduced pressure and 
244 was used without further purification:  Diagnostic 1H NMR signal δ 5.19 (t, 1 H, J = 4.5 Hz).  
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4-(1,2-Dihydro-8-methoxynaphthalen-4-yl)morpholine (243).  A solution of 5-methoxy 
tetralone (146) (0.100 g, 0.567 mmol) in Et2O (2.84 mL) was treated with morpholine (0.20 mL, 
2.3 mmol).  The reaction mixture was cooled to 0 °C, treated with a freshly prepared solution of 
TiCl4 in Et2O (0.03 mL of TiCl4 in 0.5 mL of Et2O), warmed to room temperature and stirred for 
15 h.  The reaction was monitored by 1H NMR and completion was established via the 
appearance of the enamine signal: 1H NMR δ 5.29 (t, 1 H, J = 4.5 Hz).  
 
 
1,2-Dihydro-4,8-dimethoxynaphthalene (242).  A solution of 5-methoxytetralone (146) (0.550 
g, 3.12 mmol) in MeOH (12 mL) was treated with TsOH (17.8 mg, 0.0935 mmol) followed by 
trimethylorthoformate (1.20 mL, 10.9 mmol) and stirred at room temperature for 6.5 h.  The 
mixture was monitored by TLC (7:3, hexanes:EtOAc) and used without further purification:  Rf 
0.5 (7:3, hexanes:EtOAc);  diagnostic 1H NMR δ 5.04 (t, 1 H, J = 4.7 Hz).  
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5-Acetyl-1,8-naphthosultone (246).377  A solution of 1,8-naphthosultone (245) (1.0 g, 4.8 
mmol) and acetyl chloride (0.6 mL, 0.66 g, 8.4 mmol) in MeNO2 (48 mL) was treated with AlCl3 
(2.6 g, 19.4 mmol) portionwise over 10 min, stirred at room temperature for 1 h and then heated 
to 60 °C for 9 h.  The reaction mixture was cooled to room temperature, poured into 2 M H3PO4 
(200 mL) and extracted with CH2Cl2 (2x).  The combined organic extracts were washed with 
H2O, dried (MgSO4), filtered and concentrated under reduced pressure.  Purification by column 
chromatography on SiO2 (7:3, hexanes:EtOAc) afforded 1.026 g (85%) of 246 as a white solid:  
Rf  0.25 (7:3, hexanes:EtOAc);  Mp 159.8-160.4 °C (CH2Cl2);  IR (ATR) 1668, 1577, 1482, 
1457, 1364, 1265, 1174, 1150, 1075, 1101, 833 cm-1;  1H NMR δ 9.31 (d, 1 H, J = 8.4 Hz), 8.32 
(d, 1 H, J = 8.1 Hz), 8.10 (d, 1 H, J = 7.2 Hz), 7.97 (dd, 1 H, J = 7.5, 8.4 Hz), 7.20 (d, 1 H, J = 
7.8 Hz), 2.77 (s, 3 H);  13C NMR (DMSO-d6)  199.0, 148.8, 135.6, 132.1, 131.7, 129.7, 128.3, 
127.2, 122.8, 120.8, 106.2, 28.6;  MS (EI) m/z (rel intensity) 248 (M+, 44), 233 (100), 206 (35), 
176 (12), 142 (27), 114 (22), 113 (35), 57 (100); HRMS (EI) calculated for C12H8O4S  248.0143, 
found 248.0141.    
 
O O
OH  
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2,2-Dimethylnaphtho[1,8-de][1,3]dioxin-6-ol (250).342  A solution of trihydroxynaphthalene 
238 (0.175 g) in acetone (30 mL) was treated with H2SO4 (0.4 mL).  The reaction mixture 
changed colors from orange to dark red over 12 h.  It was diluted with H2O, extracted with 
CH2Cl2, dried (MgSO4), filtered and concentrated under reduced pressure.  The mixture was 
purified by column chromatography on SiO2 (4:1, hexanes:EtOAc to 3:2, hexanes:EtOAc) to 
afford 0.186 g (87%) of 250 as a dark brown oil:  Rf 0.25 (3:2, hexanes:EtOAc);  1H NMR δ 
7.66 (d, 1 H, J = 8.4 Hz), 7.41 (t, 1 H, J = 8.4 Hz), 6.89 (d, 1 H, J = 7.5 Hz), 6.76 (d, 1 H, J = 8.1 
Hz), 6.69 (d, 1 H, J = 8.1 Hz), 1.64 (s, 6 H);  MS (EI) m/z (rel intensity) 216 (M+, 12), 176 (24), 
102 (70), 96 (100), 83 (87), 74 (100); HRMS (EI) calculated for C13H12O3 216.0786, found 
216.0868.  
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2,2-Dimethylnaphtho[1,8-de][1,3]dioxin-7-yl acetate (249).  A solution of acetal 250 (0.175 g, 
0.810 mmol) in CH2Cl2 (8.0 mL) was treated with acetic anhydride (0.15 mL, 1.6 mmol) and 
pyridine (0.15 mL, 1.9 mmol) and stirred at room temperature for 2 h.  Starting material 
remained according to TLC (7:3, hexanes:EtOAc) and additional Ac2O (0.05 mL, 0.5 mmol) was 
added.  After an additional 3 h, the reaction mixture was quenched with H2O, diluted with 
CH2Cl2, extracted, dried (MgSO4), filtered and concentrated under reduced pressure.  
Purification by column chromatography on SiO2 (9:1, hexanes:EtOAc) afforded 0.146 g (70%) 
of the desired acetate as a colorless oil:  Rf 0.6 (7:3, hexanes:EtOAc);  IR (ATR) 2993, 2917, 
1763, 1606, 1415, 1385, 1264, 1193, 1040 cm-1; 1H NMR δ 7.34-7.48 (m, 2 H), 7.15 (d, 1 H, J = 
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8.1 Hz), 6.89 (d, 1 H, J = 7.2 Hz), 6.82 (d, 1 H, J = 8.1 Hz), 2.44 (s, 3 H), 1.66 (s, 6 H); 13C 
NMR δ 169.5, 148.1, 145.7, 140.1, 127.9, 127.2, 119.4, 114.0, 109.5, 108.1, 101.9, 25.1, 20.8;  
MS (EI) m/z (rel intensity); 258 (M+, 22), 216 (100), 176 (38), 173 (29);  HRMS (EI) calculated 
for C15H14O4  258.0892, found 258.0897.    
 
 
Dimethoxydiphenylmethane (251).361  A suspension of montmorillonite K-10 (0.190 g) in 
anhydrous methanol (4.0 mL) was treated with trimethylorthoformate (3.0 mL, 0.027 mol) and 
p-TsOH (10 mg, 0.053 mmol) and stirred for 5 min before the addition of benzophenone (1.0 g, 
5.5 mmol).  The reaction mixture was stirred for 48 h, diluted with CH2Cl2, filtered over celite, 
washed with sat. Na2CO3, H2O, dried (MgSO4), filtered and concentrated under reduced 
pressure.  Purification by column chromatography on SiO2 (9:1, hexanes:EtOAc) delivered 17.1 
mg (2%) of 251 as a white solid:  1H NMR δ 7.53 (d, 2 H, J = 7.5 Hz), 7.32 (m, 2H), 7.26 (m, 1 
H), 3.15 (s, 3 H); MS (EI) m/z (rel intensity) 228 (M+, 3), 197 (100), 151 (58), 105 (100), 91 
(20), 77 (100), 51 (64); HRMS (EI) calculated for C15H16O2 228.1150, found 228.1149.  
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4-(tert-Butyldimethylsiloxy)-8-(benzyloxy)naphthalen-1-ol (256).  A suspension of 5-
(benzyloxy)naphthalene-1,4-diol (1.99 g, 7.47 mmol) in CH2Cl2 (110 mL) was treated with 
imidazole (0.763 g, 8.97 mmol) and stirred until all solids were dissolved.  The reaction mixture 
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was treated with TBSCl (1.37 g, 8.97 mmol), stirred at room temperature for 2.5 h, quenched 
with H2O and extracted with CH2Cl2 (2x).  The combined organic extracts were washed with 
H2O, dried (Na2SO4), filtered and concentrated under reduced pressure.  Purification by column 
chromatography on SiO2 (4:1, hexanes:EtOAc) afforded 2.84 g (99%) of the TBS ether 256 as a 
light yellow oil:  Rf  0.7 (7:3, hexanes:EtOAc);  IR (neat) 3428.1 (bs), 2954.8, 2930.0, 2886.4, 
2857.3, 1608.0, 1512.0, 1460.5, 1411.9, 1361.5, 1282.0, 1259.0, 1237.9, 1038.5, 1014.9, 835.3 
cm -1;  1H NMR δ 9.03 (s, 1 H), 7.78 (d ,1 H, J = 8.7 Hz), 7.51-7.40 (m, 5 H), 7.30 (t, 1 H, J = 
8.1 Hz), 6.90 (d, 1 H, J = 7.8 Hz), 6.79 (d, 1 H, J = 9.3 Hz), 6.70 (d, 1 H, J = 8.1 H), 5.27 (s, 2 
H), 1.14 (s, 9 H), 0.23 (s, 6 H);  13C NMR δ 155.2, 148.4, 143.7, 135.2, 130.1, 128.9, 128.7, 
127.9, 124.9, 116.8, 115.8, 114.6, 109.5, 105.7, 71.5, 26.2, 18.3, −4.3;  MS (ESI-Q-TOF) m/z 
(rel intensity) 403 ([M+Na]+, 100), 381 ([M+H]+,47), 380 (M+,10), 365 (25), 362 (27), 290 (88), 
289 (33);  HRMS (ESI- Q-TOF) calculated for C23H28O3SiNa 403.1705, found 403.1685.   
 
OH OH
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4-(tert-Butyldimethylsilyloxy)naphthalene-1,8-diol (257).  A solution of benzyl ether 256 
(1.00 g, 2.63 mmol) in EtOH (232 mL) was treated with 10% Pd/C (0.559 g, 0.526 mmol) and 
purged with H2 (2x).  The reaction mixture was stirred at room temperature under atmospheric 
H2 for 1 h, filtered through a plug of celite and washed with CH2Cl2.  It was concentrated under 
reduced pressure and purified by column chromatography on SiO2 (4:1, hexanes:EtOAc) to 
deliver 0.64 g (84%) of the 257 as a light yellow oil (this material decomposes when stored 
concentrated):  Rf  0.4 (7:3, hexanes:EtOAc);  IR (neat); 3249 (bs), 2955, 2931, 2892, 2858, 
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1612, 1520, 1467, 1412, 1282, 1259, 1029, 963, 842, 808, 780 cm-1;  1H NMR δ 8.39 (bs, 1 H), 
7.67 (d, 1 H, J = 8.4 Hz), 7.39 (bs, 1 H), 7.30 (t, 1 H, J = 8.0 Hz), 6.83 (d, 1 H, J = 7.2 Hz), 6.70 
(d, 1H, J = 8.1 Hz), 6.63 (d, 1 H, J = 8.1 Hz), 1.07 (s, 9H), 0.23 (s, 6 H);  13C NMR δ 152.8, 
146.4, 145.2, 130.5, 126.3, 115.3, 115.2, 113.2, 110.0, 108.5, 25.9, 18.4, −4.3;  MS (EI) m/z (rel 
intensity) 290 (M+, 59), 234 (29), 233 (100), 217 (15), 215 (12), 73 (30);  HRMS (EI) calculated 
for C16H22O3Si 290.1338, found 290.1339. 
 
 
tert-Butyl-(5-methoxy-3,4-dihydro-2H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-
6'-yloxy)dimethylsilane (258).  A solution of 5-methoxytetralone (146) (2.30 g, 13.1 mmol) in 
MeOH (54 mL) was treated with TsOH (77.0 mg, 0.447 mmol) and trimethyl orthoformate (5.4 
mL, 49.2 mmol) and stirred for 6 h.  The crude solution was treated with toluene (225 mL) in 4 
batches and concentrated down to ~50 mL.  The solution turned a deep purple.  The crude 
solution of the methyl enol ether was treated with a solution of the naphthalene diol 257 (2.60 g, 
8.95 mmol) in toluene (10 mL).  The reaction mixture was stirred at room temperature for 14 h, 
quenched with sat. NaHCO3, extracted with CH2Cl2, dried (Na2SO4), filtered, concentrated under 
reduced pressure and purified by column chromatography on SiO2 (4:1, hexanes:EtOAc) to 
afford 2.6 g (65%) of spiroketal 258 as a light green oil:   Rf 0.7 (7:3, hexanes:EtOAc);  IR 
(ATR) 1415, 1377, 1260, 1042, 971, 779, 760 cm-1; 1H NMR δ 7.72 (d, 1 H, J = 8.4 Hz), 7.49 (d, 
1 H, J = 7.8 Hz), 7.40 (t, 1 H, J = 8.1 Hz), 7.32 (t, 1 H, J = 8.1 Hz), 6.93 (d, 1 H, J = 7.5 Hz), 
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6.80 (d, 1 H, J = 8.1 Hz), 6.77 (d, 1 H, J = 7.8 Hz), 3.87 (s, 3 H), 2.81 (t, 2 H, J = 6.2), 2.12-2.10 
(m, 2 H), 1.99-1.88 (m, 2 H);  13C NMR δ 156.6, 148.3, 145.8, 142.6, 136.4, 128.1, 127.4, 127.0, 
126.5, 119.1, 115.7, 114.4, 113.7, 110.2, 109.8, 109.0, 100.4, 55.5, 30.2, 25.9, 23.0, 18.8, 18.4, 
−4.3, −4.4; MS (ESI-Q-TOF) m/z (rel intensity) 449 ([M+H]+, 100), 443 (23), 431 (19), 414 (11), 
413 (20), 301 (10), 149 (11);  HRMS (ESI-Q-TOF) calculated for C27H33O4Si 449.2148, found 
449.2148.   
 
 
6'-(tert-Butyldimethylsilyloxy)-5-methoxy-2H-spiro[naphthalene-1,2'-naphtho[1,8-
de][1,3]dioxin]-4(3H)-one (259).  A solution of spiroketal 258 (2.85g, 6.35 mmol) in benzene 
(29 mL) was treated with Celite® (2.3 g), PDC (1.14 g, 3.03 mmol) and TBHP (4.7 mL, 23.5 
mmol).  The reaction mixture was stirred at room temperature overnight, filtered over celite, 
rinsed (CH2Cl2) and concentrated under reduced pressure.  Purification by column 
chromatography on SiO2 (4:1, hexanes:EtOAc) afforded 1.78 g (61%) of 259 as a light yellow 
oil.  Rf 0.25 (4:1, hexanes:EtOAc); IR (neat) 2932.1, 2857.0, 1690.8, 1610.6, 1507.0, 1465.3, 
1379.6, 1321.6, 1267.7, 1189.7, 1136.3, 1066.7, 1047.2, 1022.0 cm -1;  1H NMR δ 7.75 (d, 1 H, J 
= 8.4 Hz), 7.66 (t, 1 H), 7.42 (t, 1 H, J = 8.0 Hz), 7.12 (d, 1 H, J = 8.1 Hz), 6.96 (d, 1 H, J = 7.5 
Hz), 6.81 (s, 2 H), 4.09 (s, 3 H), 2.75 (t, 2 H, J = 6.6 Hz), 2.44 (t, 2 H, J = 6.6 Hz), 1.09 (s, 9 H), 
0.27 (s, 6 H);  13C NMR δ 195.6, 147.6, 146.2, 142.9, 141.3, 134.9, 128.2, 126.6, 117.8, 116.3, 
114.2, 113.8, 113.5, 110.0, 109.2, 98.7, 56.3, 35.5, 29.3, 25.9, 18.4, −4.3;  MS (ESI-Q-TOF) m/z 
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(rel intensity) 485 ([M+Na]+, 100), 463 (8); HRMS (ESI-Q-TOF) calculated for C27H30O5NaSi 
485.1760, found 485.1720. 
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6'-(tert-Butyldimethylsilyloxy)-5-methoxy-4H-spiro[naphthalene-1,2'-naphtho[1,8-
de][1,3]dioxin]-4-one (260).   A solution of 259 (1.78 g, 3.66 mmol) in CH3CN (38 mL) was 
cooled to 0 °C, and treated with lutidine (0.76 mL, 6.5 mmol) followed by the dropwise addition 
of TMSOTf (0.76 mL, 4.2 mmol) over 30 min.  After 1 h, the reaction mixture was treated with 
additional lutidine (0.76 mL) and TMSOTf (0.76 mL), stirred for 30 min, and quenched with sat. 
NaHCO3.   The reaction mixture was extracted (CH2Cl2), dried (MgSO4), filtered, concentrated 
under reduced pressure and azeotroped with toluene (3x) to give the crude enol ether.  Rf 0.7 
(7:3, hexanes:EtOAc).  A solution of the crude enol ether in CH3CN (19.8 mL) was treated with 
Pd(OAc)2 (0.89 g, 3.9 mmol) stirred at room temperature for 12 h, filtered through celite and 
concentrated under reduced pressure.  Purification by column chromatography on SiO2 (4:1, 
hexanes:EtOAc) afforded 1.7 g (93%) of the desired product as a light yellow oil: Rf = 0.3 (4:1, 
hexanes:EtOAc);  IR (ATR) 1670, 1653, 1640, 1506, 1418, 1326, 1254, 1049, 1010 cm -1;  1H 
NMR δ 7.80 (dd, 1 H, J = 8.7, 0.6 Hz), 7.70 (t, 1 H, J = 8.1 Hz), 7.59 (dd, 1 H, J = 8.1 Hz), 7.44 
(t, 1 H, J = 8.0), 7.17 (d, 1H, J = 8.4 Hz), 6.98 (d, 1 H, J = 7.2 Hz), 6.87-6.81 (m, 3 H), 6.28 (d, 1 
H, J = 10.8 Hz), 4.01 (s, 3 H), 1.10 (s, 9 H), 0.29 (s, 3 H), 0.29 (s, 3 H); 13C NMR δ 183.1, 159.9, 
147.5, 146.6, 141.3, 141.1, 135.4, 134.9, 132.1, 128.1, 126.7, 120.2, 119.0, 116.7, 113.8, 110.4, 
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109.7, 93.3, 56.4, 25.9, 18.4, −4.2, −4.3;  MS (ESI-Q-TOF) m/z (rel intensity) 461 ([M+H]+, 
100), 443 (5), 365 (8), 169 (10);  HRMS (ESI-Q-TOF) calculated for C27H29O5Si 461.1784, 
found 461.1762.   
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5,6'-Dihydroxy-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxin]-4-one (177).  A 
solution of 260 (1.7 g, 3.7 mmol) in CH2Cl2 (100 mL) was treated with Bu4NI (3.08 g, 8.33 
mmol), cooled to −78 °C, treated with a 1.0 M solution of BCl3 in heptane (5.4 mL, 5.4 mmol) 
and stirred for 30 min at −78 °C.  The dry ice bath was removed and the reaction was quenched 
with ice after 30 min.  The solution was diluted with H2O and extracted with CH2Cl2 (2x).  The 
combined organic extracts were dried (MgSO4), filtered and concentrated under reduced pressure 
to afford a dark red oil.  The major spot by TLC correlated to TBS protected 177: Rf = 0.8 (7:3, 
hexanes:EtOAc).  A solution of the crude product in CH2Cl2 (100 mL) was cooled to 0 °C, 
treated with AcOH (0.10 mL, 1.7 mmol) and a 1.0 M solution of TBAF in THF (2.33 mL, 2.33 
mmol) and stirred for 30 min.  After 30 min, the starting material remained and additional AcOH 
(0.10 mL, 1.7 mmol) and a 1.0 M solution of TBAF in THF (2.33 mL, 2.33 mmol) were added to 
the reaction mixture.  After an additional 10 min, the reaction mixture was quenched with H2O, 
extracted with CH2Cl2 (2x), dried (MgSO4), filtered and concentrated under reduced pressure.  
Purification by column chromatography through a 3 cm plug of SiO2 (CH2Cl2) afforded 0.93 g 
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(76%) of 177 as an orange solid whose spectral and physical properties matched the previously 
synthesized material. 
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5-Hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-6'-yl 2-(tert-
butoxycarbonylamino)-2-methylpropanoate.  A suspension of 177 (0.208 g, 0.626 mmol) in 
CH2Cl2 (50 mL) was treated with 209 (0.208 g, 1.02 mmol), DCC (0.208 g, 1.01 mmol) and 
DMAP (0.021 g, 0.17 mmol), stirred for 45 min, treated with additional 209 (0.208 g, 1.02 
mmol), DCC (0.208 g, 1.01 mmol) and DMAP (0.021 g, 0.17 mmol) and stirred for 1 h.  The 
reaction mixture was quenched with H2O and extracted (CH2Cl2).  The organic extracts were 
dried (MgSO4), filtered, concentrated under reduced pressure and purified by column 
chromatography on SiO2 (7:3, hexanes:EtOAc) to afford 0.21 g (65%) of the AIB prodrug as a 
yellow oil whose physical and spectral properties matched the previously synthesized material.  
This reaction was run four times (with an average yield of 60%) in parallel to afford 1.07 g of the 
AIB prodrug whose spectral and physical properties matched the previously synthesized material 
(see chapter 9.6.1): 1H NMR δ 12.16 (s, 1 H), 7.69-7.62 (m, 2 H), 7.51 (d, 1 H, J = 7.6 Hz), 7.45 
(dd, 1 H, J = 7.6, 1.0 Hz), 7.23 (d, 1 H, J = 8.2 Hz), 7.14 (dd, 1 H, J = 8.4, 1.3 Hz), 7.03 (d, 1 H, 
J = 10.5 Hz), 7.01 (d, 1 H, J = 6.9 Hz), 6.95 (d, 1 H, J = 8.2 Hz), 6.38 (d, 1 H, J = 10.5 Hz), 5.15 
(s, 1 H), 1.76 (s, 6 H), 1.49 (s, 9 H);  13C NMR δ 188.7, 161.8, 154.8, 147.2, 144.8, 141.7, 138.6, 
  193
136.6, 129.8, 128.2, 127.5, 119.7, 119.6, 119.3, 113.7, 113.3, 110.6, 93.0, 56.4, 28.4, 25.7;  MS 
(EI) m/z (rel intensity) 517 (M+, 24), 458 (11), 444 (20), 443 (5), 417 (30), 401 (6), 373 (18), 334 
(22), 332 (81), 58 (100);  HRMS (EI) calculated for C29H27NO8 517.1737, found 517.1758.   
 
O O
OOH
O
O
NH3
O
CF3O
 
1-(5-Hydroxy-4-oxo-4H-spiro[naphthalene-1,2'-naphtho[1,8-de][1,3]dioxine]-6'-yloxy)-2-
methyl-1-oxopropan-2-aminium 2,2,2-trifluoroacetate (211).  A solution of the N-Boc AIB 
prodrug (1.07 g, 2.07 mmol) in CH2Cl2 (15 mL) was treated with TFA (0.5 mL), stirred 15 min 
treated with additional TFA (0.5 mL) and concentrated under reduced pressure.  Analysis of the 
1H NMR indicated that some of the starting material remained.  The mixture was dissolved in 
CH2Cl2 (15 mL), treated with TFA (1.5 mL), stirred 30 min and concentrated under reduced 
pressure.  Analysis of the 1H NMR indicated that trace amounts of starting material remained.  A 
solution of the mixture in CH2Cl2 (15 mL) was treated with TFA (1.5 mL), stirred 30 min and 
concentrated under reduced pressure to afford 1.09 g (quant) of 211.  Analysis of the 1H NMR 
spectrum indicated clean conversion to 211 and the physical and spectral properties matched the 
previously synthesized material (see chapter 9.6.1): 1H NMR (CD3CN) δ 12.07 (bs, 1 H), 8.16 
(bs, 3 H), 7.69 (t, 1 H, J = 8.0 Hz), 7.61-7.53 (m, 2 H), 7.45 (d, 1 H, J = 7.5 Hz), 7.35 (d, 1 H, J = 
8.3 Hz), 7.13 (d, 1 H, J = 8.3Hz), 7.08-7.04 (m, 2 H), 7.00 (d, 1 H, J = 8.2 Hz), 6.35 (d, 1 H, J = 
10.5 Hz), 1.89 (s, 6 H);  13C NMR (Acetone-d6) δ 189.8, 171.6, 162.6, 148.5, 146.6, 141.4, 
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140.5, 139.7, 137.8, 130.9, 130.1, 127.9, 121.0, 120.5, 120.4, 116.1, 114.7, 114.3, 111.9, 110.4, 
94.3, 59.1, 24.3;  MS (ESI) m/z (rel intensity) 441 ([M+Na]+, 32), 191 (42), 146 (87), 135 (100);  
HRMS (ESI) calculated for C24H20NO6Na 441.1179, found 441.1188. 
 
OH
OMe  
7,8-Dihydro-5-methoxynaphthalen-1-ol.  A suspension of 5-hydroxytetralone (0.09 g, 0.55 
mmol) in MeOH (2.16 mL) was treated with TsOH (3.2 mg, 0.017 mmol) followed by 
trimethylorthoformate (0.20 mL, 1.8 mmol) and stirred at room temperature for 6 h during which 
period the suspension turned to an orange solution.  The reaction was monitored by TLC: Rf 0.5 
(7:3, hexanes:EtOAc) and the product was used as a crude solution. 
 
 
6'-(tert-Butyldimethylsilyloxy)-3,4-dihydro-2H-spiro[naphthalene-1,2'-naphtho[1,8-
de][1,3]dioxin]-5-ol (262).  A solution of crude 7,8-dihydro-5-methoxynaphthalen-1-ol (97.7 
mg, 0.554 mmol) in MeOH (2.16 mL) containing TsOH (3.2 mg, 0.017 mmol) was treated with a 
solution of 257 (0.162 g, 0.558 mmol) in toluene (15 mL).  The reaction mixture was partially 
concentrated under reduced pressure (2x) and treated with additional toluene to keep the solvent 
level constant at ~15 mL.  The solution turned from light yellow to deep purple and was stirred 
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at room temperature for 20 h.  The reaction mixture was quenched with sat. NaHCO3, extracted 
with CH2Cl2, dried (Na2SO4), filtered and concentrated under reduced pressure.  Purification by 
column chromatography on SiO2 (9:1, hexanes:EtOAc) afforded 70 mg (29%) of 262 as a white 
foam:  Rf 0.5 (7:3, hexanes:EtOAc);  IR (ATR) 3400 (bs), 2928, 1608, 1461, 1415, 1377, 1327, 
1262, 1057, 837 cm-1; 1H NMR δ 7.75 (dd, 1 H, J = 8.4, 0.6 Hz), 7.50 (dd, 1 H, J = 7.8, 0.6 Hz), 
7.43 (t, 1 H, J = 8.4 Hz), 6.96 (d, 1 H, J = 7.2 Hz), 6.85-6.81 (m, 3 H), 5.30 (bs, 1 H), 2.80 (t, 2 
H, J = 6.3 Hz), 2.15-2.12 (m, 2 H), 1.99-1.93 (m, 2 H), 1.12 (s, 9 H), 0.30 (s, 3 H), 0.29 (s, 3 H);  
13C NMR δ 152.7, 148.2, 145.8, 141.9, 136.8, 128.1, 127.1, 126.5, 125.0, 119.6, 115.8, 115.3, 
114.4, 113.8, 114.4, 113.8, 109.9, 109.1, 100.2, 30.1, 25.9, 22.8, 18.7, 18.4, −4.3, −4.3;  MS 
(ESI-Q-TOF) m/z (rel intensity) 435 ([M+Na]+, 100);  HRMS (ESI-Q-TOF) calculated for 
C26H31O4Si 435.1992, found 435.1983  
 
 
6'-(tert-Butyldimethylsilyloxy)-3,4-dihydro-2H-spiro[naphthalene-1,2'-naphtho[1,8-
de][1,3]dioxine]-5,8-dione (263).    A solution of spiroketal 262 (24.0 mg, 5.52 mmol) in 
benzene (0.3 mL) was treated with celite (7 mg) followed by bipyridinium chlorochromate (1.3 
mg, 0.0044 mmol) and a solution of 5.0 M TBHP in nonane (0.05 mL, 0.03 mmol).  The reaction 
mixture was stirred at room temperature for 2 h, treated with additional 5.0 M TBHP in nonane 
(0.05 mL, 0.03 mmol) and heated to reflux for 20 h.  The mixture was cooled to room 
temperature, filtered through celite, washed (CH2Cl2), and purified by column chromatography 
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on SiO2 (9:1, hexanes:EtOAc to 4:1, hexanes:EtOAc) to afford 0.021 g (84%) of quinone 263 as 
a red oil: Rf 0.53 (7:3, hexanes:EtOAc);  IR (ATR) 2950, 2926, 2855, 1659, 1608, 1506, 1461, 
1377, 1290, 1221, 1113, 971 cm -1;  1H NMR δ 7.71 (d, 1 H, J = 8.4 Hz), 7.39 (t, 1 H, J = 8.1 
Hz), 6.89 (d, 1 H, J = 7.5 Hz), 6.82 (d, 1 H, J = 8.1 Hz), 6.79 (d, 1 H, J = 7.5 Hz), 6.77-6.72 (m, 
1 H), 6.73 (d, 1 H, J = 8.1 Hz), 2.60 (t, 1 H, J = 6.0), 2.08-2.03 (m, 2 H), 1.85-1.81 (m, 2 H), 
1.09 (s, 9 H), 0.26 (s, 3 H), 0.25 (s, 3 H); 13C NMR δ 187.5, 183.5, 146.9, 146.8, 140.5, 138.0, 
136.1, 135.0, 128.3, 126.4, 116.0, 113.8, 109.7, 109.0, 98.8, 31.5, 25.9, 23.6, 18.4, 17.7, -4.2, -
4.4;  MS (ESI-Q-TOF) m/z (rel intensity) 471 ([M+Na]+, 100);  HRMS (ESI-Q-TOF) calculated 
for C26H28O5SiNa 471.1604, found 471.1609.   
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13.0  SPIROXIN 
13.1 SPIROXIN ISOLATION AND CHARACTERIZATION 
The spiroxins are marine natural products isolated from non-sporulating fungi in Dixon Bay, off 
the coast of Vancouver Island, Canada (Figure 13.1).378,379  They are compact octacyclic 
compounds that primarily differ in their degree of oxidation and chlorination.  They showed 
activity as antibiotics against gram positive bacteria and marginal activity against gram negative 
bacteria, and displayed a mean IC50 value of 0.09 μG/mL in a 25 cell line cytotoxicity 
evaluation.126  This activity is competitive with the epoxyquinones terreic acid (264)380,381 and 
frenolicin (265, Figure 13.2).382   
 
 
Figure 13.1. Spiroxins 
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The spiroxins exhibited anti-tumor activity against ovarian carcinomas with 59% 
inhibition of tumor growth after 21 d in nude mice.  Their mode of action is postulated to involve 
single strand DNA cleavage.  In the presence of thiols, spiroxin A (156) exhibited a 
concentration dependent nicking of pBR322-DNA.  Quinones are known to be cytotoxic via a 
variety of mechanisms including oxidative stress, alkylation and DNA modification.383  The 
exact mode of cytotoxicity is not known, but any of these mechanisms might be responsible for 
the bioactivity of the spiroxins.   
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Figure 13.2.  Terreic acid (264) and frenolicin (265) 
  
 The structure of spiroxin A (156) was elucidated spectroscopically without the aid of X-
ray crystallography.  Negative MS indicated the presence of both acidic functionality and 
chlorine.  1H NMR and UV indicated an o-hydroxybenzoyl group and epoxide whereas IR 
supported the presence of the hydroxyl groups and a conjugated ketone.  DEPT, HMBC, HMQC, 
and NOESY were also consulted to elucidate spiroxin’s structure.  The pivotal HMBC signal 
between H-7 and C-4’ was the only signal that established the connectivity between the upper 
and lower naphthoquinone rings.  The NOE signal between epoxide proton and aromatic proton 
established the relative stereochemistry of the epoxide (Figure 13.3).126  
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Figure 13.3.  HMBC (left) and NOE (right) analyses of spiroxin A (156)126 
13.2 SPIROXIN BIOSYNTHESIS AND FIRST RETROSYNTHETIC ANALYSIS 
The proposed biosynthesis of the spiroxins bears similarities to the biosynthetic pathway of other 
bisnaphthospiroketals.384  As previously discussed, the proposed biosynthesis of type II 
bisnaphthospiroketals proceeds via the oxidation of type I bisnaphthospiroketals.  This 
hypothesis was validated as a possibility via organic synthesis (Figure 8.5).124  Two reports in 
2000 from the Zeeck lab further examined the interconnectivity and points of divergence in the 
biosyntheses of other bisnaphthospiroketals.  They proposed the biosynthesis of type III 
bisnaphthospiroketals proceeded via the introduction of a biaryl bond in type I 
bisnaphthospiroketals.384,385  Thus, the spiroxin core would result from an oxidative 
intramolecular carbon-carbon bond formation in palmarumycin CP1.  The early retrosynthetic 
analysis for the spiroxins drew inspiration from the proposed biosynthesis and pursued the late 
stage introduction of the biaryl bond into bisnaphthospiroketal 267 (Scheme 13.1). 
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Scheme 13.1.  Original retrosynthetic analysis of spiroxin (140) 
 
This retrosynthetic analysis aimed to exploit the methodology applied to the synthesis of 
the palmarumycin analogues and explore oxidative conditions on spiroketal 267 to arrive at the 
spiroxin core (Scheme 13.1).  Spiroxin B (140) would be the product from late stage chlorination 
and epoxidation of 266.  The key step in this retrosynthetic analysis would be the oxidative 
coupling of 267 to deliver the carbon-carbon bond in 266.  There are reports in the literature 
where PIFA386-390 or other oxidants391,392 mediate the oxidative biaryl coupling.  This 
transformation has been applied to natural product synthesis393,394 and proposed as a biosynthetic 
step in the production of several natural products.395  Typically, the intramolecular variant of this 
methodology is applied to aromatics tethered together with an aliphatic chain.   The early 
retrosynthetic analysis extended this methodology to the spiroketal bearing system.  The early 
steps in this retrosynthetic analysis closely mirrored well established work with the 
palmarumycin analogues.119  Spiroketal 267 would be synthesized via a PIFA or PIDA mediated 
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oxidative cyclization and an SNAr reaction between 269 and 270 would deliver the biaryl ether 
268.   
A model system was first explored for the key intramolecular phenolic oxidative 
coupling.  4’-Methoxypalmarumycin CP1 (174, Scheme 9.5) was synthesized utilizing chemistry 
previously applied to the palmarumycin analogue synthesis.  The problem that emerged was the 
realization of the key oxidation step.  Many oxidants were screened: PIFA, VOF3, VOCl3, Ag2O, 
FeCl3, Tl(OCOCF3)3 and a PIFA/H3[PMo12O40] mixture.  However, either the starting material 
hydrolyzed and oxidized into two equivalents of juglone related compounds or there was no 
reaction.  The spiroxin framework was never realized via this methodology.  Extensive work 
with this approach led to the conclusion that it was imperative to install the carbon-carbon bond 
prior to spiroketalization. 
13.3 MODIFIED RETROSYNTHETIC ANALYSIS OF SPIROXINS A & B  
The new retrosynthetic analysis of spiroxins A (156) and B (140) diverged with the final mono- 
and bis-chlorination, respectively, of the penultimate spiroketal 271 (Scheme 13.2).  The 
chlorination to arrive at spiroxin B (140), with two ortho phenol chlorines, is relatively 
straightforward.  The alternative selective mono-chlorination of spiroxin A (156) is difficult to 
predict due to the sterically and electronically related sites available for chlorination.  The 
organic toolbox is equipped with many alternatives for chlorinating reagents.396-400  The 
prediction was that with optimization and the strict use of a single equivalent of chlorinating 
reagent, the desired product could be obtained.  Oxidation of 272 with PIFA would install the 
needed naphthoquinone in a fashion similar to the palmarumycin syntheses.  The need for a 
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protecting group swap was anticipated to attenuate the electronics of the lower ring for the 
desired site specificity during oxidation.  Intermediate 273 could be derived from coupling of the 
highly oxygenated naphthyl iodide 274 which would be synthesized from 
dimethoxynaphthalene. 
 
 
Scheme 13.2.  Updated retrosynthetic analysis of spiroxins A (156) and B (140) 
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13.4 SYNTHESIS OF FUNCTIONALIZED BIARYL 284 
The synthesis of 278 commenced with the bis-methylation of 187 with Me2SO4.  This reaction 
was extremely exothermic and required slow addition when scaled to a 100 g scale.  Methylation 
was followed by mono-bromination with NBS,401 formylation with α,α-dichloromethylmethyl 
ether delivered naphthaldehyde 276, and a Dakin reaction with mCPBA and KOH to afford 277 
(Scheme 13.3).  Alternatively, 188 could be formylated with POCl3 to arrive at the same 
naphthaldehyde 189 utilized in the palmarumycin synthesis and brominated with NBS to afford 
276.  The advantage of this alternative route was the omittance of toxic α,α-
dichloromethylmethyl ether from the sequence and a comparable yield to the original sequence.  
The unmasked alcohol was readily methylated with MeI and NaH to deliver 278. 
 
 
Scheme 13.3.  Synthesis of bromonaphthalene 278 
 
The synthesis of sterically hindered biaryls is a well known challenge.402,403  Various 
coupling conditions were explored using bromide 278 (Scheme 13.4).  Suzuki coupling between 
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278 and 279 proceeded in low yield404 whereas the Stille reaction with this sterically hindered 
system led to preferential reduction.  The yield jumped from 27 to 53% for the Suzuki reaction 
when naphthyl bromide 278 was converted to the more reactive naphthyl iodide 280.  Although 
this Suzuki reaction provided an acceptable yield of biaryl 273, it required the synthesis of two 
separate reactants, 279 and 280.  A more straightforward approach to the synthesis of 273 would 
be the homocoupling of a single reactant.  During the 1970’s, Semmelhack investigated Ni(0) 
aryl halide homocouplings405  Various researchers since that initial report have altered the nickel 
catalyst and used additives to generate a more reactive catalyst.406-408  Ultimately, the most 
promising route for us involved the homodimerization of naphthyl iodide 280.  The reaction was 
optimized with Iyoda’s conditions of Zn, Ni(PPh3)2Cl2 and Et4NI.408 
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Scheme 13.4.  Synthesis of 273 by biaryl coupling  
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After much optimization, it was found that the reductive homocoupling of 280 with 40% 
Ni(PPh3)2Cl2, 2 equiv of zinc and 2 equiv of Et4NI delivered 273 in good yield.  The yield in this 
reaction was sensitive to the quality of zinc and the scale.  The best results were obtained with 
zinc purchased from Strem.  Additionally, when the reaction was performed with more than 20 g 
of naphthyl iodide 280, it was difficult to ensure rapid stirring of the suspension which resulted 
in inconsistent yields.  A single equivalent of PIFA oxidized 273 to 281 which was 
monodemethylated with lithium bromide.409  The free phenol was protected with MOMCl for 
ease of removal later in the synthesis.  Naphthoquinone 282 was epoxidized with hydrogen 
peroxide, and PIFA oxidation of 283 converted the remaining naphthalene to a naphthoquinone.  
Oxidative demethylation of para-dimethoxynaphthalenes with PIFA is a selective and mild 
procedure for demethylation.410  This naphthoquinone was reduced with Na2S2O4 and the 
resultant naphthalene diol was protected with acetic anhydride to afford 284.  It was important to 
protect the para-hydroxynaphthalene derived from 283 with an electron withdrawing group, such 
as an acetate, in order to prevent PIFA oxidation of the lower ring back to the quinone (Scheme 
13.5). 
.  
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Scheme 13.5.  Spiroxin core functionalization 
13.4.1 Alternative biaryl synthesis 
The first 10 steps of the synthesis to 282 proceeded in an overall yield of 2%.  The effect on the 
overall yield was investigated in the modified synthesis with the homocoupling moved to an 
earlier stage of the synthesis (Scheme 13.6).  275 was synthesized following the previously 
described protocol and the conversion to iodide 285 likewise mirrored the halogen exchange of 
278 and proceeded in good yield.  Gratifyingly, 285 readily underwent homocoupling in good 
yield, in fact in better yield than the homocoupling of 280.  The unoptimized yield for the bis-
formylation to 287 was 13%.  Naphthaldehyde 287 was highly insoluble and difficult to handle 
during both workup and purification, which could account for the low yield.  Disappointingly, 
none of 288 was recovered.  The mass recovery from the attempted Dakin reaction was poor and 
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although several conditions were tried, none of the diol was detected.  Accordingly, it was 
decided that handling diol 288 was not feasible and the original route was returned to.    
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Scheme 13.6.  Alternative biaryl synthesis via homocoupling of 285 
13.4.2 Studies toward the synthesis of the spiroxin core from 284 
Resuming the route from 284 (Scheme 13.4), the MOM group was deprotected and the PIFA 
oxidation of 289 was performed (Scheme 13.7).  The oxidation of 289 was particularly 
challenging.  Free phenols are substantially easier to oxidize, frequently reacting at room 
temperature or 0 °C.243  The most readily oxidized aryl methyl ethers are typically flanked with 
two or more methoxy groups.411-414  One example of PIFA oxidation on a lone methyl protected 
phenol needed to be heated to 60 °C415 and another example was ultimately optimized with the 
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aid of various coacids.416  The oxidation of the naphthalene was anticipated to require forcing 
conditions.  
A series of oxidative conditions of 289 were screened.  Oxidation with PIFA in CH3CN 
and H2O at either room temperature or 50 °C failed to give conversion and clean starting material 
was recovered.  Oxidation of 289 with CAN at room temperature proceeded quickly and, 
unfortunately, unselectively to deliver a mixture of unidentified products.  The yield of the PIFA 
oxidation in CH3CN and H2O at 80 °C proceeded in 36% yield.  While there was certainly room 
for improvement of the yield in the oxidation of 289, the synthesis was proceeded with. 
   
 
Scheme 13.7.  Oxidation of 289 
13.4.3 Model system for oxidation of 289 
Dimethoxynaphthalene 188 was selected as a model system of 289 for the oxidation condition 
screening due to its simplicity and availability (Scheme 13.8).  Naphthalene 188 was first 
oxidized with CAN and the reaction went cleanly.  Unfortunately, the 1H NMR of the product 
did not match the literature 1H NMR of the expected 5-methoxy naphthoquinone.417  Instead, 
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mass spectrometry confirmed that the oxidized compound was the result of naphthalene 
nitration, 291.  The oxidation in H2O with either THF or acetone as a co-solvent, different 
temperatures and various additives were explored, but consistently the same nitrated product was 
isolated.  Although initially unexpected, aromatic nitration with CAN has been reported 
previously in the literature.418-420  This led to the reevaluation of the applicability of the model 
system and the real system was proceeded with, 289. 
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Scheme 13.8.  CAN oxidation of model system 188 
 
13.4.4 Synthesis of spiroxin A core 
Acetate removal and spiroketalization on this late stage intermediate would lead to the spiroxin 
A core (Scheme 13.9).  There are many different methods to remove acetates.  Two common 
methods utilize NaOMe421 or LiOH422 under relatively mild conditions to unmask the phenol.  
The bis-acetate 290 was treated with LiOH in THF and water and 271 was isolated in 79% yield.  
These reaction conditions both globally removed the acetates and formed the spiroketal.  When 
the deprotection was performed with 12-crown-4 and LiOH there was no change in yield.  
K2CO3 in MeOH was also investigated, but the major product isolated was the tentatively 
  210
assigned mixed ketal 292 in 37% yield.  Treatment of mixed ketal 292 with PPTS in CH2Cl2 
quantitatively delivered the desired spiroketal as a 3:2 mixture of diastereomers. 
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Scheme 13.9.  Acetate deprotection of 290  
 
The oxidation of 289 formed diastereomers in the product mixture.  The resultant alcohol 
from the oxidation can either be cis or trans to the epoxide.  When the acetates were removed, 
the predicted mechanism involved the diol intermediates of A or B to arrive at spiroketal 271 and 
its epimer (Scheme 13.10).  These intermediates, presumably, form spiroketal 271 and epi-271 
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during the reaction workup and were never isolated.  Spiroketal 271 and epi-271 were isolated as 
a 3:2 mixture. 
  
 
Scheme 13.10.  Proposed intermediates enroute to 271 
 
 The proposed polyol intermediates of A and B were used to propose the conformation of 
271 and its epimer (Scheme 13.11).  Two possible conformations that A can rest in are either 
endo-A or exo-A.  There is no experimental proof for this system, but it is likely that there is a 
relatively free rotation around the C-C bond connecting the two ring systems.  When A adopts 
the conformation exo-A, the ketone component of the epoxyquinone is situated opposite of the 
tertiary alcohol making it sterically impossible to form a spiroketal.  The ketone could participate 
in the formation of a hemi-acetal with the phenolic oxygen, but this would be reversible and 
ultimately an unproductive pathway.  However, when A adopts the conformation of endo-A, the 
ketone is proximal to both the tertiary alcohol and the phenol and can participate in the formation 
of a spiroketal and ultimately form 271.  The stereochemistry depicted for 271 matches the 
relative stereochemistry found in the spiroxins.  The arguments used for the conformations of A 
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can likewise be applied to epimer B.  When B adopts the conformation of endo-B, it is free to 
form the spiroketal with the tertiary alcohol and phenol, and results in the formation of epi-271.     
 
 
Scheme 13.11.  Mechanistic pathway for formation of 271 
 
The next hurdle encountered was the epoxidation of 271 (Scheme 13.12).  The first 
condition explored was treatment with basic hydrogen peroxide, similar to the earlier used 
epoxidation conditions, but this material only decomposed.  The presence of the free phenol 
rendered the substrate more sensitive and prone to decomposition.  Several epoxidation 
conditions were screened with TBHP and DBU, but this only resulted in decomposition.  A 
report was later found where the researchers tried to epoxidize various 5-
hydroxynaphthoquinones with DBU and peroxide and found only decomposition.423  The yield 
improved for them with a simple base switch to NaOH.  Hence, a different base was likewise 
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explored for the epoxidation of 271.  TBHP, N-BCC and NaOH afforded the best yield of bis-
epoxide 293.125  It was also found that this epoxidation went diastereoselectively.   
 
 
Scheme 13.12.  Epoxidation conditions of 271 
 
A model helps in understanding the diastereoselectivity of this process (Figure 13.4).  
The MM2 energy minimized stereoviews of 271 and epi-271 were generated using Chem 3D.  
The predicted stereoselectivity of the epoxidation was based upon the cup-shaped structure of 
both 271 and epi-271.  This prediction was verified experimentally when the diastereomeric ratio 
before and after the epoxidation of 271 was the same according to 1H NMR analysis.  Non-
selective epoxidation would result in the formation of additional stereoisomers, which would be 
evident during 1H NMR analysis, but was not observed.  During the synthesis of spiroxin C 
(157), Imanishi observed a stereoselective epoxidation of enone 165 (Scheme 8.3) and likewise 
attributed it to the conformation of the core.130 
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Figure 13.4.  Stereoviews of 271 (top) and epi-271 (bottom) 
 
The product from the epoxidation, 293, was also modeled (Figure 13.5).  The 
stereochemistry corresponding to the natural diastereomer present in the spiroxin core was 
represented.129  A PM3 minimized model of dechloro-spiroxin 293 in CAChe clearly shows the 
retention of the cup-shaped structure after epoxidation.  The newly introduced epoxide on the 
lower ring of 293 resides on the convex face, the face sterically most accessible to 
epoxidation.424-426   
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Figure 13.5.  Model of spiroxin core 293 
13.4.5 Attempted chlorination of 293 
The final task was to either mono- or bis-chlorinate this core to finish either spiroxin A or B 
(Scheme 13.13).  A diverse set of chlorinating conditions were screened with the first focus 
being the bischlorination.427  N-chloromorpholine,428 NCS with silica and other additives 
397,429,430 NCS without additives,431,432 and sulfuryl chloride433,434 were all screened to no avail.  
Examples were found where the interaction of sulfuryl chloride with diphenyl sulfide afforded a 
very selective and active chlorinating agent, but this was not the case for 293.435,436  There are 
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also reports of  dichlorodimethylhydantoin as a chlorinating agent.437  These test reactions were 
typically run with 1-5 mg of the starting material and at least 2 equiv of chlorinating agent.   
With the small amount of material used, the conversion of 293 to the chloride was 
monitored using the negative detection mode in the LCMS, the same condition reported in the 
spiroxins isolation paper.126  Unfortunately, none of the desired bis-chloro spiroxin B 140 was 
detected.  Either unidentified decomposition products or unreacted starting material were 
isolated.   
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Scheme 13.13.  Failed chlorination of 293 
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13.5 CONCLUSION 
The synthesis of dechloro-spiroxin 293 proceeded in 19 steps and an overall yield of 0.15% 
(Scheme 13.14).  This synthesis addressed the difficult synthesis of the hindered biaryl 273 after 
much optimization via the reductive homocoupling of naphthyl iodide 280.  Although the PIFA 
mediated oxidation of 289 proceeded in low yield, it did allow access to a highly functionalized 
and oxygenated core that was readily deacetylated to 271.  Unfortunately, the final chlorination 
was never optimized to allow completion of the spiroxins’ synthesis.  This system either did not 
react or decomposed under more forcing conditions.  Ultimately, this route presents an extension 
of PIFA mediated oxidations, optimized yields for the epoxidation of 271 without the aid of a 
protecting group on the phenol and an unique approach to the spiroxin core.    
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Scheme 13.14.  Attempted synthesis of 140 
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14.0  SPIROXIN EXPERIMENTAL PART 
General:  All moisture sensitive reactions were performed in flame-dried or oven-dried 
glassware under a nitrogen atmosphere.  THF and Et2O were distilled over Na/benzophenone, 
while pyridine and triethylamine were distilled over CaH2.  Hexanes and ethyl acetate were 
distilled prior to use.  All other reagents and solvents were used as received unless otherwise 
noted.  Analytical thin layer chromatography was performed on pre-coated silica gel 60 F-254 
plates available from Merck.  Flash chromatography was performed using silica gel (230-400 
mesh) available from Baker.  NMR spectra were recorded in CDCl3 (unless otherwise noted) at 
300 MHz for 1H NMR and 75 MHz for 13C NMR using a Bruker Avance 300 with XWIN-NMR 
software.  Chemical shifts (δ) are expressed relative to the NMR solvent peak.  IR spectra were 
obtained with a Nicolet Avator 360 FT-IR, ATR-IR spectra were measured with a Smiths 
IdentifyIR, optical rotations were measured with a Perkin-Elmer 241 polarimeter and mass 
spectra were obtained on a double focusing instrument.  EI mass spectra were obtained with VG 
Autospec and ESI mass spectra with Q-TOF API US. 
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1,5-Dimethoxynaphthalene (188).313  The dark purple solution of dihydroxynaphthalene 187 
(100g, 0.63 moles) in 2.0 M NaOH (125 mL) was slowly treated with dimethyl sulfate (120 mL, 
1.26 moles) in two 60 mL batches over 10 minutes.  The addition was very exothermic and light 
beige solids precipitated out of solution.  Additional H2O (100 mL) was added to the thick 
suspension.  The reaction mixture was stirred for 2 h, quenched with 2.0 M NaOH (120 mL), 
diluted with water and extracted with CH2Cl2 (2x).  The combined organic extracts were dried 
(MgSO4), filtered, concentrated under reduced pressure and purified by chromatography on SiO2 
(CH2Cl2) to afford 64 g (55%) of 188 as a beige solid:  Rf = 0.64 (7:3, hexanes:EtOAc);  1H 
NMR δ 7.83 (d, 2 H, J = 8.4 Hz), 7.38 (t, 2 H, J = 8.1 Hz), 6.79 (d, 2 H, J = 8.1 Hz), 4.00 (s, 6 
H);  MS (EI) m/z (rel intensity) 188 (M+, 100), 173 (65), 115 (46); HRMS (EI) calculated for 
C12H12O2 188.0837, found 188.0833. 
 
 
4-Bromo-1,5-dimethoxynaphthalene (275).401  A solution of dimethoxynaphthalene 188 (64 g, 
0.34 mol) in CH3CN (1.7 L) was slowly treated with NBS (66 g, 0.37 mol) over 10 min and 
stirred for 2 h at room temperature.  The reaction mixture was concentrated under reduced 
pressure and the succinimide byproduct was triturated (CHCl3) out of solution and filtered.  The 
filtrate was concentrated under reduced pressure and purified by column chromatography on 
SiO2 (8:2, hexanes:EtOAc) to afford 100.53 g (69%) of 275 as a 1:0.3:0.3 mixture of 
bromonaphthalene 275, starting material 188 and di-brominated product as an inseparable 
mixture:  Rf 0.64 (7:3, hexanes:EtOAc);  1H NMR δ 7.91 (dd, 1 H, J = 8.6, 1.0 Hz), 7.66 (d, 1 H, 
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J = 8.4 Hz), 7.40 (app t, 1 H, J = 8.0 Hz), 6.97 (d, 1 H, J = 7.5 Hz), 6.64 (d, 1 H, J = 8.4 Hz), 
3.97 (s, 3 H), 3.95 (s, 3H);  MS (EI) m/z (rel intensity) 266 (M+, 100), 253 (61), 251 (82), 239 
(100), 236 (66), 211 (85); HRMS (EI) calculated for C12H11O2Br 265.9942, found 265.9936. 
 
 
5-Bromo-4,8-dimethoxynaphthalene-1-carbaldehyde (276).  A solution of α,α-
dichloromethylmethyl ether (29.45 mL, 0.3261 mol) in CH2Cl2 (736 mL) was cooled to 0 °C, 
treated with SnCl4 (37.85 mL, 0.3259 mol) and stirred at 0 °C for 30 min.  The reaction mixture 
was treated with a solution of bromonaphthalene 275 (57.84 g, 0.2174 mol) in CH2Cl2 (315 mL) 
over 5 min, warmed to room temperature, stirred for 4 h, poured into ice cold H2O and extracted 
with CH2Cl2 (2x).  The combined organic extracts were washed with H2O, dried (MgSO4), 
filtered and concentrated under reduced pressure.  The crude product was triturated with 
hexanes:EtOAc (7:3), and the solids were filtered and dried under high vacuum to afford 36.2 g 
(57%) of naphthaldehyde 276 as a beige solid:  Rf 0.5 (7:3, hexanes:EtOAc);  1H NMR δ 10.82 
(s, 1 H), 7.92 (d, 1 H, J = 8.3 Hz), 7.75 (d, 1H, J = 8.4 Hz), 6.97 (d, 1 H, J = 8.3 Hz), 6.80 (d, 1 
H, J = 8.4 Hz), 4.02 (s, 3 H), 3.98 (s, 3 H);  MS (EI) m/z (rel intensity) 294 (M+, 100), 281 (21), 
279 (27), 265 (25), 115 (25); HRMS (EI) calculated for C13H11O3Br 293.9892, found 293.9887. 
 
Unpublished spectral data (276):438  Mp 208-209 °C (EtOAc/hexanes);  IR (neat) 1668, 1570, 
1517, 1370, 1063 cm -1;  1H NMR δ 10.77 (s, 1 H), 7.85 (d, 1 H, J = 8.3 Hz), 7.69 (d, 1H, J = 8.4 
Hz), 6.91 (d, 1 H, J = 8.3 Hz), 6.75 ( d, 1 H, J = 8.4 Hz), 3.98 (s, 3 H), 3.95 (s, 3 H);  13C NMR δ 
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193.9, 159.3, 155.8, 133.5, 129.7, 128.5, 127.3, 124.4, 108.3, 108.0, 106.5, 56.2, 55.6;  MS (EI) 
m/z (rel intensity) 294 (M+, 100), 280 (25), 264 (26), 216 (12), 193 (14), 115 (27);  HRMS (EI) 
calculated for C13H11O3Br 293. 9892, found 293. 9897.   
 
Alternative synthesis of 276:  A solution of naphthaldehyde 189 (1.400 g, 6.475 mmol) in 
CH3CN (60 mL) was treated with NBS (1.164 g, 6.540 mmol) and stirred at room temperature 
for 12 h.  The reaction mixture was concentrated under reduced pressure and purified by column 
chromatography on SiO2 (7:3, hexanes:EtOAc).  Naphthaldehyde 276 and debromo starting 
material 189 co-elute on TLC and a trace amount of starting material was isolated from the 
column with 276.  Naphthaldehyde 276 was separated from 189 via trituration (Et2O) to afford 
0.774 g (41%) of 276 as a light yellow solid whose MS and 1H NMR matched previously 
synthesized 276.   
 
 
5-Bromo-4,8-dimethoxynaphthalen-1-ol (277).  A solution of naphthaldehyde 276 (36.2 g, 
0.186 mol) in CH2Cl2 (1.26 L) was treated with 70% mCPBA (45.27 g, 0.211 mol) and stirred 
for 6 h.  The reaction mixture was treated with a solution of 10% Na2S2O3 (1.26 L), stirred for 1 
h, the organic layer separated, and the aqueous extract washed with CH2Cl2.  The combined 
organic extracts were washed with sat. NaHCO3, dried (MgSO4), filtered and concentrated under 
reduced pressure.  A solution of the crude product in MeOH (450 mL) and THF (40 mL) was 
cooled to 0 °C, treated with a solution of KOH (19.9 g, 0.354 mol) in MeOH (90 mL) and stirred 
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for 20 min.  The reaction mixture was quenched dropwise with 1.0 M HCl until a maroon color 
persisted.  The reaction mixture was diluted with CH2Cl2, extracted with H2O, dried (MgSO4), 
filtered and concentrated under reduced pressure.  It was purified by column chromatography 
through a 3 cm pad of SiO2 (CH2Cl2) to provide 35 g (>100%) of 277 as an off-white solid:  Rf 
0.4 (7:3, hexanes:EtOAc);  1H NMR δ 9.29 (s, 1 H), 7.64 (d, 1 H, J = 8.4 Hz), 6.97 (d, 1 H, J = 
8.5 Hz), 6.85 (d, 1 H, J = 8.5 Hz), 6.63 (d, 1 H, J = 8.4 Hz), 4.04 (s, 3 H), 3.88 (s, 3 H);  MS (EI) 
m/z (rel intensity) 282 (M+, 85), 269 (93), 267 (100), 252 (34), 189 (20);  HRMS (EI) calculated 
for C12H11BrO3 281.9892, found 281.9890;  
 
Unpublished spectral data (277).438  Mp 142-143 °C (CH2Cl2);  IR (neat) 3370 (bs), 1625, 1602, 
1419, 1373, 1287, 1063 cm -1;  1H NMR δ 9.29 (s, 1 H), 7.63 (d, 1 H, J = 8.4 Hz), 6.97 (d, 1 H, J 
= 8.6 Hz), 6.85 (d, 1 H, J = 8.6 Hz), 6.62 (d, 1 H, J = 8.4 Hz), 4.04 (s, 3 H), 3.87 (s, 3 H);  13C 
NMR δ 155.8, 149.0, 148.6, 132.7, 125.5, 117.4, 112.5, 111.3, 108.9, 105.4, 57.7, 56.6;  MS (EI) 
m/z (rel intensity) 282 (M+, 100), 267 (93), 252 (31), 198 (9), 172 (7), 115 (9);  HRMS (EI) 
calculated for C12H11O3Br 281.9892, found 281.9896.   
 
 
 1-Bromo-4,5,8-trimethoxynaphthalene (278).  A solution of naphthol 277 (73.5 g, 0.260 mol) 
in DMF (675 mL) was cooled to 0 °C and treated with NaH (60% dispersion in mineral oil, 11.4 
g, 0.285 mol).  The reaction mixture was warmed to room temperature, stirred for 30 min, cooled 
to 0 °C, treated with MeI (24.3 mL, 0.39 mol), warmed to room temperature, stirred for 30 min, 
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cooled to 0 °C and quenched with H2O (1.35 L) which caused beige solids to precipitate out of 
solution.  The suspension was filtered through a coarse sintered glass filter and washed with 
H2O.  The solids were collected, dried under high vacuum, dissolved in CH2Cl2 and purified by 
column chromatography though a 3 cm pad of SiO2 (CH2Cl2) to afford 32.4 g (42%) of 
bromonaphthalene 278 as an off white solid:  Rf 0.3 (7:3, hexanes:EtOAc)  1H NMR δ 7.78 (d, 
1H, J = 8.5 Hz), 6.99 (d, 1 H, J = 8.6 Hz), 6.92 (d, 1 H, J = 8.6 Hz), 6.67 (d, 1H, J = 8.5 Hz), 
3.94 (s, 1H), 3.89 (s, 6H);  MS (EI) m/z (rel intensity), 296 (M+, 100), 283 (60), 282 (30), 267 
(22), 202 (12), 97 (39), 57 (63);  HRMS (EI) calculated for C13H13BrO3 296.0048, found 
296.0049.   
 
Unpublished spectral data (278):438  Mp 168-169 °C; Rf  0.3 (hexanes:EtOAc, 7:3);  IR (neat) 
1592, 1513, 1450, 1378, 1311, 1267, 1060 cm -1;  1H NMR δ 7.68 (d, 1 H, J = 8.5 Hz), 6.91 (d, 1 
H, J = 8.6 Hz), 6.84 (d, 1 H, J = 8.6 Hz), 6.67 (d, 1 H, J = 8.5 Hz), 3.92 (s, 3 H), 3.88 (s, 6 H);  
13C NMR δ  157.0, 151.8, 150.3, 133.8, 126.6, 121.3, 110.1, 109.4, 108.0, 107.5, 58.1, 57.2, 
56.9;  MS (EI) m/z (rel intensity) 296 (M+, 67),  281 (38), 218 (13), 203 (14), 111, (30), 97 (52), 
57 (100);  HRMS (EI) calculated for C13H13O3Br 296.0048, found 296.0047.   
 
 
1-Iodo-4,5,8-trimethoxynaphthalene (280).  A solution of bromonaphthalene 278 (32.3 g, 
0.109 mol) in THF (740 mL) was cooled to −78 °C and treated with a 1.6 M solution of n-BuLi 
in hexanes (77 mL, 0.12 mol).  The reaction mixture was stirred for 20 min, treated with a 
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solution of I2 (33 g, 0.13 mol) in THF (186 mL) over 5 min and warmed to room temperature, 
and stirred for 30 min.  It was quenched with water and extracted with EtOAc (2x).  The 
combined organic extracts were washed with 10% Na2S2O3, dried (MgSO4), filtered, 
concentrated under reduced pressure and purified by passing through a 3 cm pad of SiO2 
(CH2Cl2) to afford 33.6 g (90%) of iodonaphthalene 280 as a white solid:  Rf 0.3 (7:3, 
hexanes:EtOAc);  1H NMR δ 8.10 (d, 1H, J = 8.4 Hz), 6.90 (d, 1 H, J = 8.6 Hz), 6.85 (d, 1 H, J = 
8.6 Hz), 6.53 (d, 1 H, J = 8.4 Hz), 3.94 (s, 3 H), 3.89 (s, 3 H), 3.89 (s, 3 H);  MS (EI) m/z (rel 
intensity) 344 (M+,100), 329 (46), 301 (13), 171 (25); HRMS calculated for C13H13O3I 343.9910, 
found 343.9892. 
 
Unpublished spectral data (280):438  Mp 164-165 °C (CH2Cl2); IR (neat) 1588, 1449, 1378, 1308, 
1272, 1058 cm -1; 1H NMR δ 8.09 (d, 1 H, J = 8.4 Hz), 6.88 (d, 1 H, J = 8.6 Hz), 6.84 (d, 1 H, J 
= 8.6 Hz), 6.51 (d, 1 H, J = 8.4 Hz), 3.92 (s, 3 H), 3.88 (s, 3 H), 3.87 (s, 3 H); 13C NMR δ 157.8, 
151.5, 148.6, 141.8, 127.6, 120.6, 109.0, 108.8, 108.6, 74.2, 58.0, 56.7, 55.9; MS (EI) m/z (rel 
intensity) 344 (M+, 48), 329 (19), 218 (100), 203 (88), 115 (19); HRMS (EI) calculated for 
C13H13O3I 343.9909, found 343.9912.  
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1,4,5-Trimethoxy-8-(1,4,5-trimethoxynaphthalen-8-yl)naphthalene (273).  Zn (6.4 g, 98 
mmol), Et4NI (25.09 g, 97.60 mmol), and Ni(PPh3)2Cl2 (12.8 g, 19.6 mmol) were added to a 
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flame dried flask and purged with N2 (2x).  THF (12.8 mL) was added to the solid mixture and 
N2 was vigorously bubbled through the rapidly stirred suspension for 30 minutes as the color of 
the reaction mixture changed from maroon, to green, to a deep orange.  Iodonaphthalene 280 
(16.8 g, 48.9 mmol) was added to the reaction mixture in one batch and it was heated to 50 °C 
for 3 h.  The reaction mixture was cooled to room temperature, filtered through a pad of celite 
and washed with CH2Cl2.  The filtrate was washed with 1.0 M HCl and water, dried (MgSO4), 
filtered, concentrated under reduced pressure and purified by column chromatography on SiO2 
(CH2Cl2) to afford 9.04 g (85%) of biaryl 273 as a white solid:  Rf 0.16 (7:3, hexanes:EtOAc);  
1H NMR δ 7.08 (d, 1 H, J = 8.0 Hz), 6.88 (d, 1 H, J = 8.0 Hz), 6.78 (d, 1 H, J = 8.5 Hz), 6.63 (d, 
1 H, J = 8.5 Hz), 4.01 (s, 3 H), 3.95 (s, 3 H), 2.97 (s, 3 H);  MS (ESI-Q-TOF) m/z (rel intensity) 
457 ([M+Na]+, 48), 443 (100), 420 (50), 365 (20);  HRMS (ESI-Q-TOF) calculated for 
C25H22O8Na  457.1627, found 457.1630. 
 
Unpublished Spectral data (273):438  Mp 196-198 °C (hexanes/EtOAc), IR (neat) 1593, 1380, 
1270, 1070, 1032 cm -1, 1H NMR δ 7.09 (d, 2 H, J = 8.0 Hz), 6.89 (d, 2 H, J = 8.0 Hz), 6.81 (d, 2 
H, J = 8.5 Hz), 6.64 (d, 2 H, J = 8.5 Hz), 4.02 (s, 6 H), 3.96 (s, 6 H), 2.98 (s, 6 H), 13C NMR δ 
155.3, 152.0, 151.4, 135.4, 128.9, 127.2, 118.7, 107.6, 107.5, 106.2, 57.9, 56.8, 56.5; MS (EI) 
m/z (rel intensity) 434 (M+, 8), 246 (11), 234 (15), 218 (100), 203 (92), 175 (12), 115 (18); 
HRMS (EI) calculated for C26H26O6 434.1729, found 434.1709.  
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4-Iodo-1,5-dimethoxynaphthalene (285).  A solution of bromonaphthalene 275 (14.0 g, 52.6 
mmol) in THF (350 mL) was cooled to −78 °C and treated with a 1.6 M solution of n-BuLi in 
hexanes (36.8 mL, 57.9 mmol).  The reaction mixture was stirred for 20 min, treated dropwise 
with a solution of I2 (16.0 g, 63 mmol) in THF (89 mL), stirred for 5 min, warmed to room 
temperature, stirred for 1 h and quenched with H2O.  The reaction mixture was diluted with 
EtOAc, washed with H2O and 10% Na2S2O3, dried (MgSO4), filtered and concentrated under 
reduced pressure.  Purification by column chromatography on SiO2 (CH2Cl2) afforded 16.0 g 
(97%) of iodonaphthalene 285 as a beige solid:  Rf 0.63 (7:3, hexanes:EtOAc);  1H NMR δ 8.07 
(d, 1 H, J = 8.1), 7.92 (dd, 1 H, J = 8.4, 1.0 Hz), 7.41 (t, 1 H, J = 8.1 Hz), 6.95 (dd, 1 H, J = 8.4, 
1.0 Hz), 6.49 (d, 1 H, J = 8.1 Hz), 3.96 (s, 3 H), 3.94 (s, 3 H);  MS (EI) m/z (rel intensity) 314 
(M+, 100), 299 (17), 241 (17), 127 (80), 114 (65), 75 (49) HRMS (EI) calculated for C12H11O2I 
313.9804, found 313.9792. 
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1,5-Dimethoxy-4-(1,5-dimethoxynaphthalen-4-yl)naphthalene (286).  Zn (6.66 g, 101.9 
mmol), Et4NI (20.05 g, 76.40 mmol) and Ni(PPh3)2Cl2 (10.2 g, 15.3 mmol) were added to a 
flame dried flask followed by THF (160 mL).  N2 was vigorously bubbled through the rapidly 
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stirred suspension for 30 min as the color of the reaction mixture changed from green to maroon.  
Iodonaphthalene 285 (16.0 g, 50.9 mmol) was added in one portion and the mixture heated to 50 
°C for 3 h.  The reaction mixture was cooled to room temperature, filtered through celite, washed 
with CH2Cl2, concentrated under reduced pressure and triturated with EtOAc.  The solids were 
filtered, collected, and dried under high vacuum to afford 7.6 g (80%) of 286 as a light yellow 
solid.  An analytically pure sample was obtained by triturating the product with (1:1, 
EtOAc:hexanes):  Mp 218.9-216.4 °C (EtOAc);  Rf 0.5 (8:2, Hex: EtOAc);  IR (ATR) 1592, 
1508, 1459, 1467, 1319, 1262, 1247, 1068, 1055, 759 cm -1; 1H NMR δ 7.81 (d, 1 H, J = 8.1 Hz), 
7.35 (t, 1 H, J = 8.1 Hz), 6.98 (d, 1 H, J = 7.8 Hz), 6.96 (d, 1 H, J = 8.1 Hz), 6.77 (d, 1 H, J = 7.8 
Hz), 3.99 (s, 3 H), 3.33 (s, 3 H);  13C NMR δ156.8, 152.9, 134.0, 126.5, 125.9, 125.7, 124.8, 
113.7, 106.5, 103.5, 55.5, 55.1;  MS (EI) m/z relative intensity 374 (M+, 39), 278 (41), 277 (100), 
201 (14);  HRMS (EI) calculated for C24H22O4 274.1518, found 374.1526. 
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4,8 Dimethoxy-5-(4,8-dimethoxy-1-formyl-5-yl)-1-carbaldehyde (287).  A solution of biaryl 
286 (9.50 g, 25.4 mmol) in toluene (20 mL) and DMF (12 mL) was cooled to 0 °C, treated with 
POCl3 (6.02 mL, 63.9 mmol), warmed to room temperature and heated to reflux for 7h.  The 
reaction mixture was quenched with 2.0 M NaOH, extracted with EtOAc, dried (MgSO4), 
filtered and concentrated under reduced pressure.  Purification by column chromatography on 
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SiO2 (1:1, EtOAc:hexanes) afforded slightly impure 287 which was triturated with Et2O, filtered 
and dried under high vacuum to afford 1.3 g (12%) of 287 as an orange solid:  Rf 0.5 (1:1, 
EtOAc:hexanes); Mp 261.8 °C (Et2O, dec.);  IR (ATR) 2961, 1662, 1584, 1573, 1511, 1401, 
1310, 1128, 1059, 1025 cm -1; 1H NMR δ 11.03 (s, 2 H), 7.95 (d, 2 H, J = 8.1 Hz), 7.13 (d, 2 H, J 
= 8.1 Hz), 6.99 (d, 2 H, J = 8.1 Hz), 6.72 (d, 2 H, J = 8.1 Hz), 4.06 (s, 6 H), 3.11 (s, 6 H); 13C 
NMR δ 194.9, 160.8, 154.6, 135.2, 128.8, 128.2, 127.3, 126.3, 124.7, 106.3, 105.0, 55.7, 55.3; 
MS (EI) m/z (rel intensity) 430 (M+, 16), 278 (42), 277 (100), 201 (25), 77 (44);  HRMS (EI) 
calculated for C26H22O6 430.1416, found 430.1409.  
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5-Methoxy-8-(1,4,5-trimethoxynaphthalen-8-yl)naphthalene-1,4-dione (281).  A solution of 
biaryl 273 (7.56 g, 17.4 mmol) in CH2Cl2 (515 mL) was cooled to 0 °C and treated dropwise 
with a solution of PIFA (7.38 g, 17.2 mmol) in CH3CN (172 mL), and H2O (34 mL) over 5 min.  
The reaction mixture was stirred for 1 h, quenched with sat. NaHCO3, and extracted with 
CH2Cl2.  The combined organic extracts were dried (MgSO4), filtered, concentrated under 
reduced pressure and purified by column chromatography on SiO2 (7:3, hexanes:EtOAc) to 
afford 5.11 g (75%) of naphthoquinone 281 as a dark purple solid:  Rf 0.5 (7:3, hexanes:EtOAc);  
1H NMR δ 7.44 (d, 1 H, J = 8.7 H), 7.24 (d, masked), 6.99 (d, 1 H, J = 7.8 Hz), 6.90 (d, 1 H, J = 
8.1 Hz), 6.83 (d, 1 H, J = 8.1 Hz), 6.80 (d, 1 H, J = 9.9 Hz), 6.65 (d, 1 H, J = 8.7 Hz), 6.59 (d, 1 
H, J = 9.9 Hz), 4.06 (s, 3 H), 4.00 (s, 3 H), 3.94 (s, 3 H), 3.30 (s, 3 H);  MS (ESI-Q-TOF) m/z 
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(rel intensity) 427 ([M+Na]+, 100), 405 (10), 365 (32);  HRMS (ESI-Q-TOF) calculated for 
C24H20O6Na  427.1158, found 427.1138. 
 
Unpublished data (281):438  Mp 237-239 °C (EtOAc/hexanes); IR (neat) 1266,1590, 1288, 1275, 
1247, 1108 cm -1; 1H NMR δ 7.43 (d, 1H, J = 8.7 Hz), 7.24 (d, 1 H, J = 8.7 Hz), 6.98 (d, 1 H, J = 
8.0 Hz), 6.89 (d, 1 H, J = 8.0 Hz), 6.82 (d, 1 H, J = 8.5 Hz), 6.79 (d, 1 H, J = 10.1 Hz), 6.64 (d, 1 
H, J = 8.5 Hz), 6.58 (d, 1H, J = 10.1 Hz), 4.04 (s, 3H), 4.00 (s, 3 H), 3.93 (s, 3 H), 3.29 (s, 3H); 
13C NMR δ 185.8, 185.7, 158.3, 156.5, 152.0, 150.7, 139.6, 139.3, 137.5, 137.4, 130.9, 127.1, 
127.0, 119.6, 119.4, 116.1, 108.4, 107.0, 106.7, 58.1, 56.7, 56.6, 56.1; MS (EI) m/z (rel intensity) 
404 (M+, 100), 389 (6); HRMS (EI) calculated for C24H20O6 404.1260, found 404.1270  
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5-Hydroxy-8-(1,4,5-trimethoxynaphthalen-8-yl)naphthalene-1,4-dione.  A solution of 
naphthoquinone 281 (9.28 g, 23.0 mmol) in DMF (464 mL) was treated with LiBr (99.3 g, 1.15 
mol), heated to 130 °C for 3h, cooled to room temperature, poured into 1.0 M HCl and extracted 
with EtOAc (2x).  The combined organic extracts were washed with H2O (3x), dried (MgSO4), 
filtered, concentrated under reduced pressure and purified by column chromatography on SiO2 
(4:1, EtOAc:hexanes) to afford 3.93 g (45%) of the demethylated product as a dark red solid:  1H 
NMR δ 12.56 (s, 1 H), 7.43 (d, 1 H, J = 8.7 Hz), 7.21 (d, 1 H, J = 8.7 Hz), 6.99 (d, 1 H, J = 8.1 
Hz), 6.89 (d, 1 H, J = 8.1 Hz), 6.89 (d, 1 H, J = 10.3 Hz), 6.84 (d, 1 H, J = 8.7 Hz), 6.67 (d, 1 H, 
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J = 10.2 Hz), 6.66 (d, 1 H, J = 8.6 Hz), 4.00 (s, 3 H), 3.93 (s, 3 H), 3.24 (s, 3 H);  MS (ESI-Q-
TOF) m/z (rel intensity) 413 ([M+Na]+, 100);  HRMS (ESI-Q-TOF) calculated for C23H18O6Na 
413.1001, found 413.1001. 
 
Unpublished Spectral data:438  Mp 179-180 °C (EtOAc/Hex), IR (neat) 3431 (br), 1664, 1641, 
1590, 1466, 1381, 1275 cm -1; 1H NMR δ 12.57 (s, 1 H), 7.43 (d, 1 H, J = 8.7 Hz), 7.21 (d, 1 H, J 
= 8.7 Hz), 6.98 (d, 1 H, J = 8.1 Hz), 6.89 (d, 1H, J = 8.1 Hz), 6.88 (d, 1 H, J = 10.3 Hz), 6.83 (d, 
1 H, J = 8.6 Hz), 6.66 (d, 1H, J = 10.3 Hz), 6.65 (d, 1 H, J = 8.6 Hz), 4.00 (s, 3 H), 3.94 (s, 3 H), 
3.32 (s, 3 H), 13C NMR δ 191.5, 184.6, 160.8, 156.7, 152.1, 150.7, 140.8, 140.2, 140.0, 137.2, 
129.6, 127.6, 126.9, 122.5, 119.5, 114.4, 108.3, 107.0, 106.6, 58.1, 56.7, 56.1; MS (EI) m/z (rel 
intensity) 390 (M+, 100), 375 (11), 347 (7), 217 (13), 201 (34); HRMS (EI) calculated for 
C23H18O6 390.1103, found 390.1103  
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5-(Methoxymethoxy)-8-(1,4,5-trimethoxynaphthalen-8-yl)naphthalene-1,4-dione (282).  A 
solution of 5-hydroxy-8-(1,4,5-trimethoxynaphthalen-8-yl)naphthalene-1,4-dione (3.93 g, 0.101 
mol) in DMF (98.6 mL) was treated with NaH (60% dispersion in mineral oil, 0.493 g, 12.3 
mmol), stirred for 30 min, treated with chloromethylmethyl ether (1.33 mL, 0.018 mol), stirred 
for 30 min, quenched with H2O and extracted with EtOAc (3x).  The combined organic extracts 
were washed with H2O (3x), dried (MgSO4), filtered, concentrated under reduced pressure and 
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purified by column chromatography on SiO2 (4:1, EtOAc:hexanes) to afford 2.49 g (57%) of 
naphthoquinone 282 as a red solid:  1H NMR δ 7.46 (d, 1 H, J = 8.7 Hz), 7.41 (d, 1 H, J = 8.7 
Hz), 6.99 (d, 1 H, J = 8.1 Hz), 6.90 (d, 1 H, J = 8.1 Hz), 6.83 (d, 1 H, J = 8.6 Hz), 6.80 (d, 1 H, J 
= 10.2 Hz), 6.65 (d, 1 H, J = 8.6 Hz), 6.60 (d, 1 H, J = 10.2 Hz), 5.43, 5.36 (dAB, 1 H, J = 6.9 
Hz), 4.01 (s, 3 H), 3.94 (s, 3 H), 3.60 (s, 3 H), 3.30 (s, 3 H);  MS (ESI-Q-TOF) m/z (rel intensity) 
457 ([M+Na]+, 100);  HRMS (ESI-Q-TOF) calculated for C25H22O7Na 457.1263, found 
457.1268.  
 
Unpublished spectral data (282):438  Mp 145-147 °C (EtOAc/hexanes); IR (neat) 1659, 1590, 
1389, 1268, 1255, 1106, 1075 cm -1;  1H NMR δ 7.45 (d, 1 H, J = 8.7 Hz), 7.40 (d, 1 H, J = 8.7 
Hz), 6.99 (d, 1 H, J = 8.1 Hz), 6.90 (d, 1 H, J = 8.1 Hz), 6.83 (d, 1 H, J = 8.6 Hz), 6.79 (d, 1 H, J 
= 10.2 Hz), 6.65 (d, 1 H, J = 8.6 Hz), 6.60 (d, 1 H, J = 10.2 Hz), 5.43, 5.37 (dAB, 2H, J = 6.9 Hz), 
4.01 (s, 3 H), 3.94 (s, 3 H), 3.60 (s, 3 H), 3.30 (s, 3 H); 13C NMR δ 185.6, 185.5, 156.6, 155.7, 
152.0, 150.7, 141.2, 139.2, 137.7, 137.3, 130.8, 130.3, 127.0, 120.8, 119.4, 108.4, 107.1, 106.6, 
105.3, 95.6, 58.1, 56.8, 56.7; MS (ESI-Q-TOF) m/z (rel intensity) 457 ([M+Na]+. 100), HRMS 
(ESI-Q-TOF), calculated for C25H22O7Na 457.1263, found 457.1267.  
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3-(Methoxymethoxy)-6-(1,4,5-trimethoxynaphthalen-8-yl)naphtho[2,3-b]oxirene-
2,7(1aH,7aH)-dione (283).  A solution of biaryl 282 (0.459 g, 1.06 mmol) in CHCl3 (30.2 mL) 
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was treated with LiOH (0.447 g, 18.7 mol), N-benzylcinchonidinium chloride (48.4 mg, 0.114 
mmol) and 30% H2O2 (6.04 mL), and the biphasic solution was stirred rapidly for 10 h.  The 
reaction mixture was quenched with 1.0 M HCl, extracted with CH2Cl2, dried (MgSO4), filtered, 
concentrated under reduced pressure and purified by column chromatography on SiO2 (4:1, 
EtOAc:hexanes) to afford 0.395 g (83%) of epoxide 283 as a yellow foam and 1:1 mixture of 
atropisomers:  Rf 0.6 (4:1, EtOAc:hexanes); IR (ATR) 2945 (bs), 1698, 1589, 1523, 1457, 1387, 
1262, 1064 cm-1;  1H NMR δ 7.41-7.40 (m, 2 H), 7.09 (d, 0.5 H, J = 8.1 Hz), 6.96 (d, 0.5 H, J = 
8.1 Hz), 6.91 (d, 0.5 H, J = 8.0 Hz), 6.88-6.80 (m, 1.5 H), 6.72 (d, 0.5 H, J = 8.6 Hz), 6.67 (d, 0.5 
H, J = 8.6 Hz), 5.38 (d, 0.5 H, J = 6.9 Hz), 5.35 (d, 0.5 H, J = 6.9 Hz), 5.31 (d, 0.5 H, J = 6.9 
Hz), 5.30 (d, 0.5 H, J = 6.9 Hz), 4.04 (s, 1.5 H), 3.99 (s, 1.5 H), 3.98 (d, 0.5 H, J = 4.4 Hz), 3.94 
(s, 1.5 Hz), 3.92 (s, 1.5 Hz), 3.82 (d, 0.5 H, J = 4.4 Hz), 3.75 (d, 0.5 H, J = 4.4 Hz) 3.65 (d, 0.5 
H, J = 4.4 Hz), 3.59 (s, 1.5 H), 3.57 (s, 1.5 H), 3.49 (s, 1.5 H), 3.28 (s, 1.5 H); 13C NMR δ 192.2, 
191.8, 191.7, 191.6, 156.6, 155.0, 154.3, 154.2, 151.7, 151.5, 154.2, 151.7, 150.7, 150.0, 140.4, 
139.5, 137.0, 136.1, 135.1, 131.7, 130.1, 129.8, 128.7, 128.3, 125.3, 120.9, 120.8, 119.5, 119.2, 
118.4, 108.3, 108.2, 107.6, 107.4, 107.3, 106.5, 106.0, 105.9, 105.7, 95.4, 95.3, 57.9, 57.8, 57.6, 
56.5, 56.4, 56.2, 55.6, 55.5, 55.4, 54.8;  MS (ESI-Q-TOF) m/z (rel intensity) 473 ([M+Na]+, 
100), 457 (8);  HRMS (ESI-Q-TOF) calculated for C25H22O8Na  473.1212, found 473.1180.   
 
Unpublished spectral data (283):438  1H NMR δ 7.43-7.41 (m, 2H), 7.09 (d, 0.5 H, J = 8.1 Hz), 
6.95 (d, 0.5 H, J = 8.1 Hz), 6.91 (d, 0.5 H, J = 8.0 Hz), 6.87-6.80 (m, 1.5 H), 6.72 (d, 0.5 H, J = 
8.6 Hz), 6.67 (d, 0.5 H, J = 8.6 Hz), 5.39-5.28 (m, 2 H), 4.01 (s, 1.5 H), 3.98 (s, 1.5 H), 3.96 (d, 1 
H, J = 4.7 Hz), 3.94 (s, 1.5 H), 3.92 (s, 1.5 H), 3.81 (d, 0.5 H, J = 4.4 Hz), 3.75 (d, 0.5 H, J = 4.4 
Hz), 3.59 (s, 1.5 H), 3.57 (s, 1.5 H), 3.49 (s, 1.5 H), 3.28 (s, 1.5 H);  MS (EI) mz (rel intensity) 
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450 (M+, 31), 406 (26), 309 (18), 176 (52), 91 (100);  HRMS (EI) calculated for C25H22O8 
450.1315, found 450.1315  
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3-(1,4-Dihydro-5-methoxy-1,4-dioxonaphthalen-8-yl)-6-(methoxymethoxy)naphtho[2,3-
b]oxirene-2,7(1aH,7aH)-dione.  A solution of epoxide 283 (0.274 g, 0.611 mmol) in CH2Cl2 
(14.1 mL) was cooled to 0 °C and treated dropwise with a solution of PIFA (0.260 g, 0.610 
mmol) in CH3CN (3.5 mL) and H2O (0.70 mL) over 5 min.  The reaction mixture was stirred for 
30 min, treated with additional PIFA (0.078 g, 0.18 mmol) in CH3CN (1.05 mL) and H2O (0.21 
mL), stirred 10 minutes, quenched with sat. NaHCO3, diluted with water and extracted with 
CH2Cl2 (2x).  The combined organic extracts were dried (MgSO4), filtered, concentrated under 
reduced pressure and purified by column chromatography on SiO2 (4:1, EtOAc:hexanes) to 
afford 0.3321 g (90%) of the oxidized product as a red oil:  Rf = 0.3 (4:1, EtOAc:hexanes);  IR 
(neat) 2939, 1700, 1658, 1618, 1584, 1560, 1465, 1279, 1248, 1150, 1084, 1025, 975 cm -1;  1H 
NMR δ 7.56 (d, 0.5 H, J = 8.5 Hz), 7.49 (d, 0.5 H, J = 8.5 Hz), 7.44 (d, 0.5 H, J = 8.8 Hz), 7.40 
(d, 0.5 H, J = 8.8 Hz), 7.32 (d, 1 H, J = 8.7 Hz), 7.25 (d, 1 H, J = 8.5 Hz), 6.87 (d, 0.5 H, J = 10.2 
Hz), 6.82 (d, 0.5 H, J = 10.2 Hz), 6.66 (d, 1 H, J = 10.2 Hz), 5.38 (dAB, 1 H, J = 6.9 Hz), 5.31 
(dAB, 1 H, J = 6.9 Hz), 4.06 (s, 3 H), 4.03 (s, 3 H), 4.02 (d, 1 H, J = 4.3 Hz), 3.98 (d, 1 H, J = 4.3 
Hz), 3.83 (d, 1 H, J = 4.3 Hz), 3.80 (d, 1 H, J = 4.3 Hz);  13C NMR δ 192.4, 192.0, 191.0, 190.3, 
186.0, 185.5, 184.5, 184.3, 159.3, 159.2, 155.5, 139.6, 138.5, 137.0, 136.9, 136.2, 136.1, 135.8, 
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135.5, 134.1, 133.1, 132.9, 132.0, 129.6, 121.1, 120.2, 117.6, 116.8, 95.2, 95.1, 56.6, 56.4, 55.3, 
55.2, 55.1, 54.7;  MS (ESI-Q-TOF) m/z (rel intensity) 443 ([M+Na]+, 100), 427 (20), 421 (15), 
365 (11);  HRMS (ESI-Q-TOF) calculated for C23H16O8Na  443.0743, found 443.0757.   
 
 
3-(1,4-Diacetoxy-5-methoxynaphthalen-8-yl)-6-(methoxymethoxy)naphtho[2,3-b]oxirene-
2,7(1aH,7aH)-dione (284).  A solution of 3-(1,4-dihydro-5-methoxy-1,4-dioxonaphthalen-8-yl)-
6-(methoxymethoxy)naphtho[2,3-b]oxirene-2,7(1aH,7aH)-dione (0.332 g, 0.790 mmol) in 
CHCl3 (20.1 mL) and THF (10.1 mL) was treated with sat. Na2S2O3 and stirred rapidly for 30 
min.  The reaction mixture was diluted with H2O, extracted with CH2Cl2, dried (MgSO4), filtered 
and concentrated under reduced pressure.  The reaction mixture was carried directly onto the 
acetylation sequence.  The crude mixture was dissolved in CH2Cl2 (20.2 mL) treated with 
pyridine (2.02 mL, 24.9 mmol), Ac2O (0.749 mL, 7.9 mmol) and DMAP (0.020 g, 0.164 mmol) 
and stirred at room temperature for 3 h.  The reaction mixture was concentrated under reduced 
pressure and directly submitted to purification by column chromatography on SiO2 (4:1 EtOAc: 
hexanes) to afford 0.3182 g (80%) of acetate 284 as an orange foam contaminated with some of 
the MOM deprotected product 289:  Rf  0.6 (4:1, hexanes:EtOAc);  crude 1H NMR δ 7.13-7.03 
(m), 6.93 (d, 1 H, J = 7.8 Hz), 6.91 (d, 1 H, J = 8.1 Hz), 6.78 (d, 1 H, J = 8.1 Hz), 5.35-5.19 (m, 
2 H), 3.94 (s, 3 H), 3.99 (d, 1 H, J = 4.5 Hz), 3.92 (s, 3 H), 3.82 (d, 1 H, J = 4.5 Hz), 3.54 (s, 3 
H), 3.53 (s, 3 H), 2.37 (s, 6 H);  MS (ESI-Q-TOF) m/z (rel intensity) 529 ([M+Na]+, 100), 527 
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(50), 443 (73), 365 (22);  HRMS (ESI-Q-TOF) calculated for C27H22O10Na 529.1111, found 
529.1101.   
  
 
3-(1,4-Diacetoxy-5-methoxynaphthalen-8-yl)-6-hydroxynaphtho[2,3-b]oxirene-
2,7(1aH,7aH)-dione (289).  A solution of acetate 284 (0.318 g, 0.628 mmol) in CH2Cl2 (18 mL) 
was cooled to 0 °C, treated with TFA (0.91 mL, 12 mmol) and stirred for 1 h.  The reaction 
mixture was concentrated under reduced pressure without any aqueous workup and purified by 
column chromatography on SiO2 (4:1, EtOAc:hexanes) to afford 0.265 g (91%) of 289 as a red 
foam:  Rf 0.6 (4:1, EtOAc:hexanes); IR (neat) 3584, 2936, 2360, 1761, 1699, 1653, 1520, 1457, 
1389, 1366, 1308, 1273, 1027 cm -1; 1H NMR δ 11.35 (s, 1 H), 11.32 (s, 1 H), 7.52 (d, 1 H, J = 
8.7 Hz), 7.48 (d, 1 H, J = 8.7 Hz), 7.28 (d, 1 H, J = 9.3 Hz), 7.25 (d, 1 H, J = 8.8 Hz), 7.12-7.12 
(m, 5 H), 6.93 (d, 1 H, J = 8.1 Hz), 6.92 (d, 1 H, J =8.1 Hz), 6.79 (d, 1 H, J = 8.1 Hz), 4.00 (d, 1 
H, J = 3.9 Hz), 3.99 (d, 1 H, J = 3.9 Hz), 3.98 (s, 3 H), 3.94 (s, 3 H), 3.88 (d, ,1 H, J = 3.9 Hz), 
3.86 (d, 1 H, J = 3.9 Hz), 2.39 (s, 3 H), 2.39 (s, 3 H); 13C NMR 196.8, 196.7, 190.7, 190.4, 
170.5, 170.4, 169.6, 169.0, 160.5, 160.5, 155.3, 155.3, 145.0, 144.7, 144.2, 144.0, 140.6, 140.5, 
137.2, 136.2, 131.0, 129.7, 129.2, 129.0, 128.5, 126.8, 126.8, 122.5, 122.4, 120.5, 120.4, 120.2, 
119.3, 119.2, 114.2, 114.0, 106.1, 105.7, 60.6, 56.2, 55.4, 55.3, 55.1, 53.4, 20.9, 20.2, 19.9, 14.1;  
MS (ESI-Q-TOF) m/z (rel intensity) 485 ([M+Na]+, 100), 469 (5), 443 (4), 422 (4); HRMS (EI) 
calculated for C25H18O9Na 485.0849, 485.0866.  
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1,5-Dimethoxy-4-nitronaphthalene (291).439  A solution of dimethoxynaphthalene 188 (0.01 g, 
0.05 mmol) in acetone (0.23 mL) and H2O (0.08 mL) was treated dropwise with a solution of 
CAN (73 mg, 0.13 mmol) in H2O (0.3 mL) at 0 °C.  The mixture was stirred for 10 min at 0 °C, 
diluted with H2O and EtOAc and extracted.  The organic extract with dried (MgSO4), filtered 
and concentrated under reduced pressure.  Analysis of the 1H NMR indicated the presence of 
starting material and nitro 291 (14%):  Representative signals:  1H NMR δ 7.91 (dd, 1 H, J = 8.5, 
0.9 Hz), 7.51 (dd, 1 H, J = 8.3, 1.6 Hz), 7.49 (d, 1 H, J = 8.4 Hz), 7.02 (d, 1 H, J = 8.3 Hz), 6.75 
(d, 1 H, J = 8.3 Hz), 4.03 (s, 3 H), 3.92 (s, 3H);  MS (EI) m/z (relative intensity) 233 (M+, 100), 
203 (5), 188 (10), 172 (13), 127 (35);  HRMS (EI) calculated for C12H11O4N 233.0688, found 
233.0686. 
 
O
O
OH
OAc
O
OH
O
AcO
 
3-(1,4-Dihydro-5-hydroxy-4,8-diacetoxy-1-oxonaphthalen-4-yl)-6-hydroxynaphtho[2,3-
b]oxirene-2,7(1aH,7aH)-dione.  A solution of 289 (0.139 g, 0.300 mol) in CH3CN (6.88 mL) 
and H2O (1.11 mL) was treated with PIFA (0.140 g, 0.325 mol) and heated to 80 °C for 2 h.  One 
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additional equivalent of PIFA (0.140 g, 0.325 mol) was added, the reaction mixture stirred for an 
additional h, cooled to room temperature, diluted with CH2Cl2, washed with water, dried 
(MgSO4), filtered, and concentrated under reduced pressured.  The reaction mixture was purified 
by column chromatography on SiO2 (1:1, EtOAc:hexanes) to afford ~49.8 mg (36%) of the 
oxidized product as an orange film and a mixture of several coeluting deacetylated compounds:  
Representative 1H NMR δ 11.49 (s, 1 H), 9.32 (s, 1 H),  6.27 (d, 1 H, J = 10.3 Hz). 
 
 
De-epoxy,de-chlorospiroxin A (271).  A solution of impure 3-(1,4-dihydro-5-hydroxy-4,8-
diacetoxy-1-oxonaphthalen-4-yl)-6-hydroxynaphtho[2,3-b]oxirene-2,7(1aH,7aH)-dione (41.5 
mg, 0.0894 mmol) in THF (0.5 mL) and H2O (0.5 mL) was treated with LiOH (5.6 mg, 0.23 
mmol) and stirred at room temperature for 45 minutes.  The reaction mixture was treated with 
additional LiOH (5.6 mg, 0.23 mmol) and quenched with 1.0 M HCl after an additional 5 min.  It 
was extracted with CH2Cl2, dried (MgSO4) filtered and concentrated under reduced pressure.  
Purification by column chromatography on SiO2 (7:3, hexanes:EtOAc) afforded 25.5 mg (79%) 
of deacetylated 271 as a dark orange foam and 1.5:1 inseparable mixture of epimers:  Rf  0.3 
(7:3, hexanes:EtOAc);  IR (ATR) 2956 (bs), 2850, 1685, 1640, 1603, 1526, 1454, 1254, 1224, 
1008 cm -1;  1H NMR δ 12.57 (s, 0.5 H), 12.50 (s, 1 H), 11.49 (s, 1 H), 11.29 (s, 0.5 H), 7.37 (s, 2 
H), 7.30-7.25 (m, 5 H), 7.21 (d, 1.5 H, J = 8.7 Hz), 6.96 (d, 1 H, J = 10.2 Hz), 6.92 (d, 0.5 H, J = 
10.2 Hz), 6.77 (d, 1.5 H, J = 10.2 Hz), 4.00 (d, 0.5 H, J = 3.9 Hz), 3.86 (d, 0.5 H, J = 3.9 Hz), 
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3.85 (d, 1.5 H, J = 3.9 Hz);  13C NMR δ 196.7, 196.7, 191.3, 190.8, 190.6, 184.9, 184.6, 161.9, 
161.7, 161.4, 161.0, 140.6, 140.3, 140.3, 139.3, 138.7, 138.5, 138.2, 137.8, 137.6, 134.9, 131.0, 
129.6, 128.1, 124.5, 124.1, 123.9, 123.4, 115.2, 114.6, 55.5, 55.5, 55.3, 54.8;  MS (EI) m/z (rel 
intensity) 362 (M+, 34), 305 (56), 292 (51), 291 (48), 264 (100), 236 (46);  HRMS (EI) C20H10O7 
calculated for 362.0427, found 362.0448.   
 
O OH
OOH
O
O
OO
 
Dechlorospiroxin A (293).   A solution of N-benzylcinchonidinium chloride (0.6 mg, 
0.001 mmol), a 4.0 M solution of TBHP in isooctane (0.1 mL) and H2O (0.1 mL) was treated 
with a suspension of 271 (5.0 mg, 0.014 mmol) in toluene (0.14 mL) and CHCl3 (0.42 mL).  The 
reaction mixture was treated with a 0.2 M solution of NaOH (0.06 mL) and stirred for 2 h.  
Added an additional amount of H2O (0.5 mL) and TBHP (0.5 mL) and worked up 1 h later.  The 
reaction mixture was quenched with sat. NH4Cl and extracted with CH2Cl2, dried (MgSO4), 
filtered and concentrated under reduced pressure.  Purification by column chromatography on 
SiO2 (1:1, EtOAc:hexanes) afforded 1.8 mg (35%) of dechlorospiroxin 293 as a dark red foam 
and 1.5:1 mixture of epimers:  Rf  0.6 (1:1, hexanes:EtOAc);  IR (ATR) 2917, 2848, 1653, 1579, 
1472, 1442, 1347, 1220, 1088, 1010 cm -1;  1H NMR δ 11.52 (s, 1 H), 11.39 (s, 1 H), 11.37 (s, 
0.5 H), 11.24 (s, 0.5 H), 7.47 (d, 0.5 H, J = 8.8 Hz), 7.44 (d, 1 H, J = 8.8 Hz), 7.36 (d, 1.5 H, J = 
8.8 Hz), 7.33 (d, 0.5 H, J = 8.8 Hz), 7.32-7.28 (m, 4 H), 4.07 (d, 0.5 H, J = 3.9 Hz), 4.04 (d, 1 H, 
J = 3.9 Hz), 3.99 (d, 0.5 H, J = 3.9 Hz), 3.96 (d, 0.5 H, J = 3.9 Hz), 3.91 (d, 1 H, J = 3.9 Hz), 
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3.94-3.92 (m, 3.5 H);  MS (EI) m/z (rel intensity) 378 (M+, 63), 379 (16), 293 (20), 280 (35), 252 
(27), 81 
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